

**Funding Opportunities Monthly Edition
Feb 2025 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Feb 2025.

The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 below for assistance or questions.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128420	Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R01 Clinical Trial Optional)	Fogarty International Center/NIH/DHHS	PAR-25-213	08-Jan-2025 [Optional][LOI/Pre-App]	Not Specified

Contact Name	Brad Newsome, Ph.D.
Contact Telephone	301-480-8389
Contact Email	brad.newsome@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-May-2025 , 06-Oct-2025 [Optional][LOI/Pre-App], 05-Nov-2025 , 07-Jan-2026
Synopsis	The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.

128421	Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R61/R33 Clinical Trial Required)	Fogarty International Center/NIH/DHHS	PAR-25-223	08-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	--	---------------------------------------	------------	-------------------------------------	---------------

Contact Name	Brad Newsome, Ph.D.
Contact Telephone	301-480-8389
Contact Email	brad.newsome@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-May-2025 , 06-Oct-2025 [Optional][LOI/Pre-App], 05-Nov-2025 , 07-Jan-2026</p> <p>Synopsis The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. This NOFO uses the bi-phasic, milestone driven R61/R33 grant mechanism. Awards made under this NOFO will initially support a one-year milestone-driven initiation (R61) phase, with possible transition to an implementation (R33) phase of up to four additional years. Only projects that meet the scientific milestones and award requirements of the R61 phase may transition to the R33 phase. Applications submitted in response to this NOFO must address both the R61 and R33 phases. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.</p>				
111859	<p>Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	PAR-22-198	05-Feb-2025	Not Specified
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-5609</p> <p>Contact Email SP@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110471	Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-131	05-Feb-2025	Not Specified
	<p>Contact Name Sudhir Srivastava, Ph.D., MPH</p> <p>Contact Telephone 240-276-7028</p> <p>Contact Email srivasts@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>				
112619	Biology of Bladder Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-218	05-Feb-2025	Not Specified
	<p>Contact Name Ron Johnson, Ph. D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.

112622	Biology of Bladder Cancer (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-219	16-Feb-2025	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Ron Johnson, Ph. D.
 Contact Telephone | 240-276-6250
 Contact Email | rjohnso2@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2025 , 16-Jun-2025

Synopsis | This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.

122437	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	PAR-23-288	14-Feb-2025	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Sergey Radaev, PhD
 Contact Telephone | 240-276-5630
 Contact Email | sradaev@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>					
122436	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)		National Cancer Institute/NIH/DHHS	PAR-23-287	14-Feb-2025	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).</p>				
122435	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-286	14-Feb-2025	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).</p>				
111860	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-199	16-Feb-2025	275,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D. Contact Telephone 240-276-5609 Contact Email SP@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
125423	Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-24-153	19-Feb-2025	Not Specified
	<p>Contact Name Yansong Bian, MD, PhD Contact Telephone 240-276-5630 Contact Email yansong.bian@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 19-Feb-2025 , 18-Jun-2025 , 18-Feb-2026 , 18-Jun-2026 , 18-Feb-2027 Synopsis The purpose of the NCI Wortz McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12) is to support the training of clinical scientists in community cancer prevention, screening, intervention, control, and treatment research. Special emphasis is placed on training clinical scientists whose career goal is to improve the care and outcomes of minority health populations and populations with health disparities that are underrepresented in clinical research by increasing their access to and representation as human subjects in cancer clinical trials using an equity</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

lens. This Notice of Funding Opportunity (NOFO) allows the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; proposing to increase the integration of cancer health disparities research questions into clinical trials; or proposing a separate ancillary study to an existing prevention, screening, intervention, control or treatment trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of minority health populations and populations with health disparities that are underrepresented as human subjects in cancer clinical trials, as part of their research and career development.

113746	Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	05-Jan-2025	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Matthew Young, Ph.D.
Contact Telephone	240-276-5846
Contact Email	matthew.young@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 13-Feb-2025 , 01-Mar-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Jul-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI.

115117	Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-23-030	07-Jan-2025	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Eric M. Johnson Chavarria, Ph.D.
Contact Telephone	240-276-7416
Contact Email	eric.johnsonchavarria@nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.</p>				
117714	Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-23-060	07-Jan-2025	Not Specified
	<p>Contact Name Stefan Maas, Ph.D.</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email stefan.maas@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.</p>				
110931	Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-22-085	07-Jan-2025	Not Specified
	<p>Contact Name Ron Johnson, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.</p>				
121826	<p>Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)</p> <p>Contact Name Sumana Dey, Ph.D.</p> <p>Contact Telephone 240-276-5748</p> <p>Contact Email sumana.dey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025 , 11-Jul-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jul-2026 , 14-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this NOFO encourage multidisciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.</p>	National Cancer Institute/NIH/DHHS	PAR-24-304	14-Feb-2025	450,000 USD
128227	<p>RFA-CA-24-033--NCI National Clinical Trials Network - Network Lead</p>	National Cancer	RFA-CA-	24-Jan-2025	10,200,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Academic Participating Sites (UG1 Clinical Trial Not Allowed)	Institute/NIH/DHHS	24-033 [Optional][LOI/Pre-App]	USD	
	<p>Contact Name Margaret Mooney, MD</p> <p>Contact Telephone 240-276-6006</p> <p>Contact Email NCINCTNRFA@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jan-2025 [Optional][LOI/Pre-App], 24-Feb-2025</p> <p>Synopsis National Cancer Institute (NCI) invites applications from from institutions/organizations that propose to maintain or establish Network Lead Academic Participating Sites (LAPS) for the NCI National Clinical Trials Network (NCTN). The NCTN Network LAPS will provide scientific leadership by helping to develop and conduct clinical trials in association with one or more adult Network Groups and will contribute substantial accrual to clinical trials conducted across the entire NCTN. This program will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.</p>				
128228	RFA-CA-24-035-- NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 24-Jan-2025 24-035 [Optional][LOI/Pre-App]	USD	5,100,000
	<p>Contact Name Margaret Mooney, MD</p> <p>Contact Telephone 240-276-6006</p> <p>Contact Email NCINCTNRFA@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jan-2025 [Optional][LOI/Pre-App], 24-Feb-2025</p> <p>Synopsis National Cancer Institute (NCI) invites applications from institutions/organizations that propose to maintain or establish Network Group Integrated Translational Science Centers for the NCI National Clinical Trials Network (NCTN). The NCTN Network Group Integrated Translational Science Centers will provide support for leadership and expertise to facilitate incorporating translational science into Network Group clinical trials, including the conduct of pilot projects to collect preliminary data.This program will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.</p>				
122281	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25- 14-Feb-2025 074		Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Tracy G. Lively, Ph.D. 240-276-5944 livelyt@mail.nih.gov Link to program URL 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026 Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.
--	---

122288	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-075	14-Feb-2025	750,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name Contact Telephone	Sumana Dey, Ph.D. 240-276-5748
-----------------------------------	-----------------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sumana.dey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>				
127772	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-043	06-Jan-2025 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email edward.sauter@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 ,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027 Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.			
127774	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-044	16-Jan-2025 [Optional][LOI/Pre-App]	550,000 USD
	Contact Name	Edward R. Sauter, M.D., Ph.D.			
	Contact Telephone	240-276-7657			
	Contact Email	edward.sauter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027			
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.			
108550	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-25-123	16-Feb-2025	275,000 USD
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	Tram.Lam@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
114326	Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (UH2 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-118	15-Jan-2025 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Kristine Willis, Ph.D. Contact Telephone 301-792-1338 Contact Email Kristine.Willis@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025 , 23-Sep-2025 [Optional][LOI/Pre-App], 23-Oct-2025 Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) requests applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. For this announcement, unpublished preliminary data are limited to one figure, comprising no more than one-half page, to facilitate the entry of qualified new investigators to the field.</p>				
114325	Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-119	15-Jan-2025 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Kristine Willis, Ph.D. Contact Telephone 301-792-1338 Contact Email Kristine.Willis@nih.gov Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025 , 23-Sep-2025 [Optional][LOI/Pre-App], 23-Oct-2025</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO) the National Cancer Institute (NCI) requests applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.</p>				
128547	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-143	16-Feb-2025	275,000 USD
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115306	Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-23-018	07-Jan-2025	Not Specified
	<p>Contact Name Gary Della'Zanna</p> <p>Contact Telephone 240-276-7042</p> <p>Contact Email Gary.DellaZanna@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications directed toward identifying, characterizing, and mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.</p>				
114678	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-082	05-Feb-2025	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
114550	NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-078	07-Jan-2025	100,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email wolfreyc@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 24-Feb-2025 , 07-May-2025 , 20-Jun-2025 , 07-Sep-2025 , 17-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
128497	Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-144	05-Feb-2025	Not Specified
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
120726	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-079	05-Feb-2025	2,499,995 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Darrell Tata, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-5894</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>Darrell.Tata@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.</td> </tr> </table>					Contact Name	Darrell Tata, Ph.D.	Contact Telephone	240-276-5894	Contact Email	Darrell.Tata@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Oct-2026	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.
Contact Name	Darrell Tata, Ph.D.																		
Contact Telephone	240-276-5894																		
Contact Email	Darrell.Tata@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Oct-2026																		
Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.																		
113232	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-242	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Rao Divi, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6913</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>divir@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences</td> </tr> </table>					Contact Name	Rao Divi, Ph.D.	Contact Telephone	240-276-6913	Contact Email	divir@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025	Synopsis	The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences
Contact Name	Rao Divi, Ph.D.																		
Contact Telephone	240-276-6913																		
Contact Email	divir@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025																		
Synopsis	The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

113233	Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-243	07-Jan-2025	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Rao Divi, Ph.D.
Contact Telephone	240-276-6913
Contact Email	divir@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025
Synopsis	The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production.

112442	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-139	13-Feb-2025	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Morgan O'Hayre, Ph.D.
Contact Telephone	240-276-7482

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email ohayrem@mail.nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 13-Feb-2025 , 01-Mar-2025 , 12-Jun-2025 , 01-Jul-2025

Synopsis This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

128595	Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-25-103	25-Feb-2025	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.
 Contact Telephone 240-276-7048
 Contact Email heckmanbm@mail.nih.gov
 Sponsor Website

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Feb-2025 , 25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128597	<p>Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)</p>	National Cancer Institute/NIH/DHHS	PAR-25-104	25-Feb-2025	Not Specified
	<p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7048</p> <p>Contact Email heckmanbm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Feb-2025 , 25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128619	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-311	06-Jan-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	Contact Name	Charles Lin , Ph.D.			
	Contact Telephone	240-276-6108			
	Contact Email	linp3@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027			
	Synopsis	<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily on in vitro and ex vivo methods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions.</p>			
128629	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-145	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128723	Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-241	16-Feb-2025	275,000 USD

Contact Name	Kelly Filipski PhD, MPH
Contact Telephone	240-276-6841
Contact Email	Kelly.Filipski@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

Contact Name	Margaret Mayer, PhD, MPH
Contact Telephone	202-815-5515
Contact Email	margaret.mayer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

120897	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-306	05-Feb-2025	2,495,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Joanna Watson, Ph.D.
Contact Telephone	240-276-6206
Contact Email	Joanna.Watson@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026

Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO, encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

128621	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-175	06-Jan-2025 [Optional][LOI/Pre-App]	499,999 USD
--------	---	------------------------------------	------------	-------------------------------------	-------------

Contact Name	Shane Woodward
Contact Telephone	240-276-6624

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email woodwars@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027 , 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 07-May-2027 , 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
128676	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-253	16-Feb-2025	275,000 USD
	<p>Contact Name Mukesh Verma, Ph.D.</p> <p>Contact Telephone 240-276-6889</p> <p>Contact Email vermam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028 , 16-Feb-2028 , 07-May-2028 , 16-Jun-2028 , 07-Sep-2028</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123053	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-081	07-Jan-2025	2,499,995 USD
	<p>Contact Name Lori A. Henderson, Ph.D.</p> <p>Contact Telephone 240-276-5930</p> <p>Contact Email hendersonlori@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.</p>				
123051	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-167	07-Jan-2025	Not Specified
	<p>Contact Name Jessica Faupel-Badger, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7296</p> <p>Contact Email badgerje@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 05-Jan-2027</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

128654	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-172	05-Feb-2025	1,250,000 USD
--------	--	------------------------------------	-----------	-------------	---------------

	Contact Name	Scott Rogers, MPH
	Contact Telephone	240-276-6932
	Contact Email	rogerssc@mail.nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027
	Synopsis	This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.

109173	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-108	16-Feb-2025	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

	Contact Name	Avi Rasooly, PhD
	Contact Telephone	240-276-6196
	Contact Email	rasoolya@mail.nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	16-Feb-2025
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</p>				
121246	Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-237	05-Feb-2025	Not Specified
	<p>Contact Name David Dean Jr., Ph.D., M.S. Contact Telephone 240-276-8703 Contact Email chipper.dean@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.</p>				
128724	Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-240	05-Feb-2025	2,500,000 USD
	<p>Contact Name Margaret Mayer Sutherland, PhD, MPH Contact Telephone 202-815-5515 Contact Email margaret.mayer@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
120755	Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-153	05-Feb-2025	Not Specified
	<p>Contact Name Suzanne Forry, Ph.D.</p> <p>Contact Telephone 240-276-5922</p> <p>Contact Email forryscs@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
109172	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-107	05-Feb-2025	Not Specified
	<p>Contact Name Avi Rasooly, PhD</p> <p>Contact Telephone 240-276-6196</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rasoolya@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</p>				
109910	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-25-173	16-Feb-2025	275,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-7619</p> <p>Contact Email SP@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>				
128810	Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-244	16-Feb-2025	400,000 USD
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sharmananu@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.</p>				
128848	NCI Pathway to Independence Award (K99/R00 – Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-135	13-Feb-2025	Not Specified
	<p>Contact Name Michael Schmidt, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email mschmidt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Feb-2025 , 17-Jun-2025 , 15-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026 , 17-Feb-2027 , 15-Jun-2027 , 14-Oct-2027</p> <p>Synopsis The goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128883	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-248	10-Feb-2025	Not Specified
	<p>Contact Name Claire Zhu, Ph.D.</p> <p>Contact Telephone 240-276-7013</p> <p>Contact Email zhucla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025 , 10-Jun-2025 , 10-Oct-2025 , 10-Feb-2026 , 10-Jun-2026 , 09-Oct-2026 , 10-Feb-2027 , 10-Jun-2027 , 08-Oct-2027</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.</p>				
108551	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-171	06-Jan-2025 [Optional][LOI/Pre-App]	2,000,000 USD
	<p>Contact Name Steven Becker, Ph.D.</p> <p>Contact Telephone 240-276-6210</p> <p>Contact Email steven.becker@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				
114360	<p>Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)</p>	National Cancer Institute/NIH/DHHS	PAR-25-072	14-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Wynne E. Norton, PhD</p> <p>240-276-6875</p> <p>wynne.norton@nih.gov</p> <p></p> <p>Link to program URL</p> <p>14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025</p> <p>Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.</p>			
114679	<p>Co-infection and Cancer (R21 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-25-083	16-Feb-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Tram Kim Lam, Ph.D., MPH</p> <p>240-276-6967</p> <p>lamt@mail.nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
120756	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-254	05-Feb-2025	Not Specified
	<p>Contact Name Rebecca Ferrer</p> <p>Contact Telephone 240-276-6914</p> <p>Contact Email ferrerra@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one’s response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.</p>				
111848	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-295	16-Feb-2025	275,000 USD
	<p>Contact Name Kelly D. Blake, ScD</p> <p>Contact Telephone 240-281-5934</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kelly.blake@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111847	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-294	05-Feb-2025	2,500,000 USD
	<p>Contact Name Kelly D. Blake, ScD</p> <p>Contact Telephone 240-281-5934</p> <p>Contact Email kelly.blake@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
117334	Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-094	05-Feb-2025	Not Specified
	Contact Name Curt DellaValle, Ph.D., MPH				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-7225</p> <p>Contact Email curt.dellavalle@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
128809	Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-243	05-Feb-2025	Not Specified
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email sharmananu@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
121014	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-070	16-Feb-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Edward R. Sauter, MD, PhD</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email edward.sauter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.</p>				
117338	Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-152	16-Feb-2025	275,000 USD
	<p>Contact Name Curt DellaValle, Ph.D., MPH</p> <p>Contact Telephone 240-276-7225</p> <p>Contact Email curt.dellavalle@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
109909	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-25-174	05-Feb-2025	2,500,000 USD
	<p>Contact Name Yisong Wang, Ph.D.</p> <p>Contact Telephone 240-620-0690</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Yisong.wang@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>				
128801	<p>NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-24-316	12-Feb-2025	Not Specified
	<p>Contact Name Shahrooz Vahedi., Ph.D.</p> <p>Contact Telephone 240-276-7754</p> <p>Contact Email vahedis@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 26-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Notice of Funding Opportunity Announcement (NOFO), NCI Mentored Research Scientist Development Award to Promote Diversity (K01), is intended to support individuals from diverse backgrounds, including those who bring unique perspectives shaped by their life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that contribute to a diverse and inclusive research workforce supports individuals from diverse backgrounds, including individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences (NOT-OD-20-031), by providing salary and research support for a period of three to five years of "protected time," dedicated to intensive research career development under the guidance of an experienced advisor. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates seeking support through this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					315).
120973	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-069	05-Feb-2025	Not Specified
	<p>Contact Name Edward R. Sauter, MD, PhD</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email edward.sauter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose?dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.</p>				
110473	Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-275	28-Feb-2025	Not Specified
	<p>Contact Name Somdat Mahabir, PhD, MPH</p> <p>Contact Telephone 240-276-6914</p> <p>Contact Email mahabir@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.

123155	Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-276	20-Feb-2025	500,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Elizabeth Ginexi, Ph.D.
Contact Telephone	301-827-0160
Contact Email	elizabeth.ginexi@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026

Synopsis This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating data coordinating center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under companion PAR-24-275. The DCC application must be specific to the companion clinical coordinating center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (<https://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate Scientific/Research Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

128271	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-275	21-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	------------	-------------------------------------	---------------

Contact Name	Elizabeth Ginexi, Ph.D.
Contact Telephone	301-827-0160

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email elizabeth.ginexi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jan-2025 [Optional][LOI/Pre-App], 20-Feb-2025 , 10-Mar-2025 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 14-Jul-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 17-Mar-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026 , 14-Jul-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages applications for investigator-initiated multisite clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH-designated areas of high research priority. Clinical coordinating centers (CCC) should develop and implement the proposed fully powered multisite clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCC applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying data coordinating center (DCC) application (U24), submitted under PAR-24-087 and proposing a data analysis and data management plan for the clinical project, is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Research Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
123858	Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-313	20-Feb-2025	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 20-Feb-2025 , 10-Mar-2025 , 23-Jun-2025 , 15-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-24-312. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
123153	<p>Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-268	20-Feb-2025	Not Specified
	<p>Contact Name Beda Jean-Francois, Ph.D.</p> <p>Contact Telephone 202-313-2144</p> <p>Contact Email beda.jean-francois@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 17-Nov-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

123147	NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-267	20-Feb-2025	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Pete Murray, Ph.D.
Contact Telephone	301-496-4054
Contact Email	peter.murray@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Feb-2025 , 20-Jun-2025 , 15-Jul-2025 , 20-Oct-2025 , 18-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026
Synopsis	<p>This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH’s mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

123152	Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-274	20-Feb-2025	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Jennifer N. Baumgartner, Ph.D.
Contact Telephone	301-402-4084
Contact Email	jennifer.baumgartner@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 17-Nov-2026
Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH’s mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

119560	NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-23-200	16-Feb-2025	Not Specified
--------	--	---------------------------------	------------	-------------	---------------

Contact Name Tony Gover, Ph.D.
 Contact Telephone 301-529-7320
 Contact Email tony.gover@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 16-Feb-2025

Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.

119565	NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-23-205	16-Feb-2025	3,000,000 USD
--------	--	---------------------------------	------------	-------------	---------------

Contact Name Tony Gover, Ph.D.
 Contact Telephone 301-529-7320
 Contact Email tony.gover@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Feb-2025</p> <p>Synopsis The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PAR-23-200.</p>				
109678	NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-135	07-Jan-2025	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.</p>				
109824	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-141	07-Jan-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p>				
109530	<p>NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</p>	National Eye Institute/NIH/DHHS	PAR-22-128	07-Jan-2025	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

117409	Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research	National Eye Institute/NIH/DHHS	NOT-EY-23-005	05-Jan-2025	Not Specified
--------	--	---------------------------------	---------------	-------------	---------------

Contact Name	James Gao, Ph.D.
Contact Telephone	301-594-6074
Contact Email	james.gao@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.

125580	RFA-HL-26-003 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-003	20-Jan-2025 [Optional][LOI/Pre-App]	4,900,000 USD
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Narasimhan Danthi, Ph.D.
Contact Telephone	301-451-5170
Contact Email	NHLBI_R35@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025 , 28-Apr-2025 , 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026 , 28-Apr-2026 , 20-Jan-2027 [Optional][LOI/Pre-App], 19-Feb-2027 , 28-Apr-2027

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125579	RFA-HL-26-002 -- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-002	20-Jan-2025 [Optional][LOI/Pre-App]	4,900,000 USD

Synopsis The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission. It is anticipated that the EIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service

Contact Name Narasimhan Danthi, Ph.D.
 Contact Telephone 301-451-5170
 Contact Email NHLBI_R35@mail.nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025 , 28-Apr-2025 , 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026 , 28-Apr-2026 , 20-Jan-2027 [Optional][LOI/Pre-App], 19-Feb-2027 , 28-Apr-2027

Synopsis The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards or an NHLBI R35 award in the 6th or 7th year of funding and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support an investigator's research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years and will provide investigators with freedom to conduct

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research that breaks new ground or extends previous discoveries in new directions. It will also allow PDs/PIs to take greater risks and to pursue research that requires a longer time frame. Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.</p>			
125805	RFA-HL-25-009 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-009	07-Jan-2025	Not Specified
	Contact Name	Karin F. Lidman, Ph.D.			
	Contact Telephone	301-435-0535			
	Contact Email	karin.fredriksson@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 11-Feb-2025 , 07-May-2025 , 15-Oct-2025 , 07-Jan-2026 , 11-Feb-2026 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) invites applications to provide career development activities for a diverse pool of highly trained investigators in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This NOFO is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial to support the lead investigator should apply to the companion NOFO (RFA-HL-25-008).</p>			
125802	RFA-HL-25-008 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-008	07-Jan-2025	Not Specified
	Contact Name	Karin F. Lidman, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-0535</p> <p>Contact Email karin.fredriksson@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 11-Feb-2025 , 07-May-2025 , 15-Oct-2025 , 07-Jan-2026 , 11-Feb-2026 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications to provide career development opportunities for a diverse pool of highly trained investigators by providing eligible faculty members with the opportunity to undertake special study and supervised research under an accomplished investigator in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This NOFO is designed to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutes to apply to companion NOFO (RFA-HL-25-009).</p>				
124964	RFA-HL-26-001 -- Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 26-001	28-Feb-2025 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name Lisbeth Welniak, PhD</p> <p>Contact Telephone 301-435-0050</p> <p>Contact Email welniakla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025 [Optional][LOI/Pre-App], 28-Mar-2025</p> <p>Synopsis The purpose of the Limited Competition: NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This is a limited competition Notice of Funding Opportunity (NOFO) offering the opportunity for current RFA-HL-20-001 or RFA-HL-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

20-002 K99 recipients to apply for the independent phase (R00) of the program. In the R00 phase, successful blood science physician scientist scholars will receive up to three years of funding to continue their research activity with support from this NOFO, which will require updated research plans and a limited competition review.

108068	Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-024	05-Feb-2025	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Bishow Adhikari, Ph.D.
Contact Telephone	301-594-2791
Contact Email	adhikarb@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025
Synopsis	The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically disadvantaged, rural or have few health care resources. Please see NOT-OD-20-031 for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation.

112260	Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-030	07-Jan-2025	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Qing Lu, Ph.D.
Contact Telephone	301-480-9158
Contact Email	qing.lu@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this NOSI is to promote research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics) to better understand specific pathobiological processes in systems of interacting cell types.			
114141	Notice of Special Interest (NOSI): Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-052	07-Jan-2025	Not Specified
	Contact Name	Lijuan Liu, PhD			
	Contact Telephone	301-435-0582			
	Contact Email	lliu@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD.			
125098	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-173	04-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Sumita Khatri, MD			
	Contact Telephone	301-402-9673			
	Contact Email	sumita.khatri@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 03-Feb-2025 , 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.</p>				
125065	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-172	04-Jan-2025 [Optional][LOI/Pre-App]	4,545,000 USD
	<p>Contact Name: Sumita Khatri, MD Contact Telephone: 301-402-9673 Contact Email: sumita.khatri@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 04-Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025, 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025, 04-Jun-2025, 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025, 02-Oct-2025, 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026, 03-Feb-2026, 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026, 04-Jun-2026, 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026, 02-Oct-2026, 07-Jan-2027 Synopsis: The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO PAR-24-173, which utilizes an R61/R33 phased approach.</p>				
106202	Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-Jan-2025	Not Specified
	<p>Contact Name: Alison G.M. Brown, PhD, MS, RDN</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-0583</p> <p>Contact Email Alison.brown@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.</p>				
113286	Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-043	07-Jan-2025	Not Specified
	<p>Contact Name Ravi Balijepalli, Ph.D.</p> <p>Contact Telephone 301-435-0504</p> <p>Contact Email ravi.balijepalli@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.
113729	RFA-HL-24-005 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-24-005	07-Jan-2025	150,000 USD
	Contact Name	Qing Lu, Ph.D.			
	Contact Telephone	301-480-9158			
	Contact Email	Qing.Lu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 13-Oct-2025 , 07-Jan-2026			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.</p>			
116586	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

067

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	James Luo, Ph.D. 301-435-0533 luoja@nih.gov Link to program URL 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.
--	--

122332	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-049	07-Jan-2025	450,000 USD
--------	--	--	------------	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website	Patrice Desvigne-Nickens, MD 301-435-0504 desvignp@mail.nih.gov
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. - Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
107287	Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused	National Heart, Lung, and Blood	NOT-	07-Jan-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Ancillary Studies to Large Ongoing Clinical Studies (Revised)	Institute/NIH/DHHS	HL-21-030		Specified
	<p>Contact Name Jue Chen, Ph.D.</p> <p>Contact Telephone 301-435-0550</p> <p>Contact Email jue.chen@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).</p>				
108064	Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-003	07-Jan-2025	Not Specified
	<p>Contact Name Jining Lu</p> <p>Contact Telephone 301-827-2807</p> <p>Contact Email jining.lu@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPSC cell and lung progenitor/organoid culture systems, advanced single cell-and “-omic” technologies, and lung cell biology is encouraged. We encourage investigators to Utilization of lung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.</p>				
115585	Notice of Special Interest (NOSI): Development of Functional Assay Sites to	National Heart, Lung, and Blood	NOT-	05-Jan-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)	Institute/NIH/DHHS	HL-23-066		Specified

Contact Name	Charlene Schramm, Ph.D.
Contact Telephone	301-402-3793
Contact Email	schrammc@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 , 07-Sep-2026
Synopsis	The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships between genotypes and phenotypes Development and validation of functionally informed risk predictions

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127015	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-209	12-Feb-2025	Not Specified

Contact Name	Kristen Z. Morgan, Ph.D.
Contact Telephone	301-827-5163
Contact Email	direducation@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027
Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA, PAR-24-211 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".</p>				
127019	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-211	12-Feb-2025	Not Specified
	<p>Contact Name: Kristen Z. Morgan, Ph.D. Contact Telephone: 301-827-5163 Contact Email: direducation@nhlbi.nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p>				
	<p>Synopsis: The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Notice of Funding Opportunity Announcement (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion NOFO, PAR-24-209.</p>				
112358	Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-193	10-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Nancy DiFronzo, PhD 301-435-0065 difronzon@nhlbi.nih.gov Link to program URL 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025 <p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>
--	--

112357	Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-192	10-Jan-2025	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Nancy DiFronzo, PhD 301-435-0065 difronzon@nhlbi.nih.gov Link to program URL 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025 This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

111425	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	11-Jan-2025	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Nahed El Kassar, MD
Contact Telephone	301-435-0065
Contact Email	nahed.elkassar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025

Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP),.</p>				
112356	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	11-Jan-2025	Not Specified
	<p>Contact Name Nahed El Kassar, MD Contact Telephone 301-435-0065 Contact Email nahed.elkassar@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).</p>				
126331	T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-199	29-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Wayne Wang, PhD Contact Telephone 301-435-0535</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email wayne.wang2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jan-2025 [Optional][LOI/Pre-App], 28-Feb-2025 , 16-Aug-2025 [Optional][LOI/Pre-App], 15-Sep-2025 , 28-Jan-2026 [Optional][LOI/Pre-App], 27-Feb-2026 , 15-Aug-2026 [Optional][LOI/Pre-App], 14-Sep-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to enhance training opportunities at institutions that have a documented historical institutional mission of educating underrepresented students from across the career development continuum. The NHLBI T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research Service Award Program intended to support training of predoctoral, health professional students, and individuals in postdoctoral training at institutions with a documented historical institutional mission focused on educating underrepresented students and/or institutions that provide clinical services to populations that experience health disparities, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to educate and train students from diverse backgrounds, including those from underrepresented groups, in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for populations experiencing health disparities. Please note that institution eligibility is outlined in Section III, and funding decisions are based on the outcome of the peer review process and scientific priorities of the NHLBI. This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
114386	Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-23-036	07-Jan-2025	150,000 USD
	<p>Contact Name Ruth Kirby, RN, BS</p> <p>Contact Telephone 301-435-0401</p> <p>Contact Email kirbyr@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 28-Feb-2025 , 07-May-2025 , 28-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| biobehavioral research. Generation of new primary data is not allowed.

128899	RFA-HL-26-016 -- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-016	11-Feb-2025	700,000 USD
--------	---	--	---------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Mike Pieck, Ph.D.</p> <p>301-827-7986</p> <p>nhlbi_catalyze@nih.gov</p> <p></p> <p>Link to program URL</p> <p>11-Feb-2025 , 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.</p>
---	--

128905	RFA-HL-26-019 -- Catalyze Product Definition – Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-019	11-Feb-2025	900,000 USD
--------	---	--	---------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Mike Pieck, Ph.D.</p> <p>301-827-7986</p> <p>nhlbi_catalyze@nih.gov</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 , 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
128906	RFA-HL-26-020 -- Catalyze: Product Definition – Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-020	11-Feb-2025	600,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 , 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
128904	RFA-HL-26-018 -- Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-018	11-Feb-2025	800,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Not Allowed					
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 , 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
128901	<p>RFA-HL-26-017 -- Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-017	11-Feb-2025	1,200,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 , 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep (HLBS)</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
119382	RFA-HG-23-026--Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-23-026	03-Feb-2025 [Optional][LOI/Pre-App]	1,200,000 USD
	<p>Contact Name Adam L. Felsenfeld, Ph.D. Contact Telephone 301-496-7531 Contact Email Adam_felsenfeld@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 03-Feb-2025 [Optional][LOI/Pre-App], 03-Mar-2025 Synopsis This NOFO seeks applications for the development of informatics tools to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). Emphasis for this RFA will be on development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. These tools will use pangenome datasets and build on systems developed by the Human Pangenome Coordinating Center (see below), which will support general computational infrastructure for pangenome use. This informatics tools RFA will fund one component of an overall HGRP, which will also include two other components: High Quality Reference Genomes (herein called "Genomes Center"), and a Human Pangenome Coordinating Center (Herein called "Coordinating Center"). (See Companion Funding Opportunities). Awardees under all three RFAs will work collaboratively within a consortium towards production and community adoption of the human pangenome reference.</p>				
121563	Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	PAR-25-255	05-Feb-2025	Not Specified
	<p>Contact Name Alexander Arguello, Ph.D. Contact Telephone 240-731-3753 Contact Email alexander.arguello@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128803	RFA-HG-25-005 -- Enhancing Reuse of NHGRI Data Assets (R03 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-25-005	13-Feb-2025	250,000 USD
	<p>Contact Name Shurjo K. Sen, Ph.D.</p> <p>Contact Telephone 301-827-7028</p> <p>Contact Email sensh@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Feb-2025 , 13-Feb-2026</p> <p>Synopsis The purpose of this concept is to encourage the genomics research community to leverage data sets available through NHGRI's AnVIL platform for innovative research and secondary analysis projects. As the NHGRI-designated data repository specified in NOT-HG-24-020, AnVIL makes available large amounts of data, tools and resources generated primarily by NHGRI-funded programs and initiatives.</p>				
122382	RFA-HG-25-004 -- Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-25-004	11-Feb-2025	100,000 USD
	<p>Contact Name Christine Chang, MPH</p> <p>Contact Telephone 240-552-1208</p> <p>Contact Email changcq@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis This NOFO solicits proposals that stimulate innovation and advance understanding of when, where, and how best to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122378	RFA-HG-25-002 -- Advancing Genomic Medicine Research (R01 Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-25-002	11-Feb-2025	2,500,000 USD
	<p>Contact Name Christine Chang, MPH</p> <p>Contact Telephone 240-552-1208</p> <p>Contact Email changcq@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis This NOFO solicits proposals that stimulate innovation and advance understanding of when, where, and how best to implement the use and sharing of genomic information and technologies in clinical care provided to all persons irrespective of racial/ethnic background or socioeconomic status. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
114026	Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-033	13-Feb-2025 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Sujata Vijh, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-761-7713</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">sujata.vijh@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">13-Feb-2025 [Optional][LOI/Pre-App], 14-Mar-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.</p> </td> </tr> </table>					Contact Name	Sujata Vijh, Ph.D.	Contact Telephone	301-761-7713	Contact Email	sujata.vijh@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	13-Feb-2025 [Optional][LOI/Pre-App], 14-Mar-2025	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.</p>
Contact Name	Sujata Vijh, Ph.D.																		
Contact Telephone	301-761-7713																		
Contact Email	sujata.vijh@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	13-Feb-2025 [Optional][LOI/Pre-App], 14-Mar-2025																		
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.</p>																		
123681	Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-112	05-Feb-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Ari Joffe, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">240-669-5084</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">ari.joffe@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p> </td> </tr> </table>					Contact Name	Ari Joffe, Ph.D.	Contact Telephone	240-669-5084	Contact Email	ari.joffe@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p>
Contact Name	Ari Joffe, Ph.D.																		
Contact Telephone	240-669-5084																		
Contact Email	ari.joffe@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026																		
Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p>																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
115065	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-070	07-Jan-2025	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-5945</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>AITrainingHelpDesk@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)</td> </tr> </table>					Contact Name		Contact Telephone	301-594-5945	Contact Email	AITrainingHelpDesk@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026	Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)
Contact Name																			
Contact Telephone	301-594-5945																		
Contact Email	AITrainingHelpDesk@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026																		
Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)																		
123682	Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-111	16-Feb-2025	275,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ari Joffe, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-669-5084</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ari.joffe@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3)</td> </tr> </table>					Contact Name	Ari Joffe, Ph.D.	Contact Telephone	240-669-5084	Contact Email	ari.joffe@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3)
Contact Name	Ari Joffe, Ph.D.																		
Contact Telephone	240-669-5084																		
Contact Email	ari.joffe@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3)																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.				
115066	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-071	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-594-5945</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).</p>				
113565	Notice of Special Interest (NOSI): argeting the Pathogen within the Arthropod Vector	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-074	07-Jan-2025	Not Specified
	<p>Contact Name Adriana Costero-Saint Denis, Ph.D.</p> <p>Contact Telephone 240-292-4184</p> <p>Contact Email acostero@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right;">Synopsis</p> <p>This Notice of Special Interest (NOSI) invites applications to stimulate multidisciplinary research to better understand pathogen/vector interactions to identify approaches to prevent pathogen transmission to the vertebrate host.</p>				
116360	Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-031	05-Jan-2025	Not Specified
	<p>Contact Name: Dona C. Love, Ph.D.</p> <p>Contact Telephone: 301-761-7788</p> <p>Contact Email: Dona.Love@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p style="text-align: right;">Synopsis</p> <p>The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.</p>				
109336	Notice of Special Interest (NOSI): Optimizing Vascularized Composite Allograft Survival	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-023	07-Jan-2025	Not Specified
	<p>Contact Name: Patricia Kehn, Ph.D.</p> <p>Contact Telephone: 240-627-3547</p> <p>Contact Email: pkehr@NIAID.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p style="text-align: right;">Synopsis</p> <p>The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	immunosuppression required for long-term VCA acceptance.				
114374	Notice of Special Interest (NOSI): Complement in Fundamental Immunology	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-012	07-Jan-2025	Not Specified
	Contact Name	Ari Joffe, PhD			
	Contact Telephone	240-669-5084			
	Contact Email	ari.joffe@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.			
128173	RFA-AI-24-067 -- Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-067	07-Jan-2025 [Optional][LOI/Pre-App]	1,750,000 USD
	Contact Name	Anjali Singh, Ph.D.			
	Contact Telephone	240-507-4924			
	Contact Email	anjalisingh@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 [Optional][LOI/Pre-App], 06-Feb-2025			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support early to mid-stage research focused on development of alternative human models of acute and/or delayed radiation-induced injuries (extracorporeal systems) to elucidate mechanisms of injury and to test medical countermeasures to treat and/or mitigate these injuries.			
127897	RFA-AI-24-023 -- U.S.-South Africa Program for Collaborative Biomedical Research - Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-023	10-Feb-2025 [Optional][LOI/Pre-App]	400,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
App]					
	<p>Contact Name Brian Remortel, M.P.H.</p> <p>Contact Telephone 240-292-4816</p> <p>Contact Email remortelbg@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025 [Optional][LOI/Pre-App], 12-Mar-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.</p>				
113395	NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-Jan-2025	Not Specified
	<p>Contact Name Diane Adger-Johnson, MPH</p> <p>Contact Telephone </p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.</p>				
128586	RFA-AI-24-074 -- Combating Antibiotic-Resistant Bacteria	National Institute of Allergy and	RFA-AI-	24-Feb-2025	7,500,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Interdisciplinary Units (CARBIRUs) (P01 Clinical Trial Not Allowed)	Infectious Diseases/NIH/DHHS	24-074	[Optional][LOI/Pre-App]	USD
	<p>Contact Name Nancy Lewis Ernst, Ph.D.</p> <p>Contact Telephone 240-669-5076</p> <p>Contact Email nancy.ernst@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2025 [Optional][LOI/Pre-App], 26-Mar-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections. Funding Opportunity Goal(s) To assist public and private nonprofit institutions and individuals to establish, expand and improve biomedical research and research training in infectious diseases and related areas; to conduct developmental research, to produce and test research materials. To assist public, private and commercial institutions to conduct developmental research, to produce and test research materials, to provide research services as required by the agency for programs in infectious diseases, and controlling disease caused by infectious or parasitic agents, allergic and immunologic diseases and related areas. Projects range from studies of microbial physiology and antigenic structure to collaborative trials of experimental drugs and vaccines, mechanisms of resistance to antibiotics as well as research dealing with epidemiological observations in hospitalized patients or community populations and progress in allergic and immunologic diseases. Because of this dual focus, the program encompasses both basic research and clinical research.</p>				
128907	RFA-AI-24-076 -- Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LAsT) (R61/R33 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-076	11-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Kristen A. Porter, Ph.D.</p> <p>Contact Telephone 301-761-7022</p> <p>Contact Email kristen.porter@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support preclinical activities for the development of safe and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to ultimately advance these products toward submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Solicited LA/SR products will have demonstrated strong rationale, competitive advantage, and effectiveness in appropriate non-clinical or animal models at intermittent dosing from either a single administration (injection, topical, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.).</p>			
117716	Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-006	06-Dec-2024	Not Specified
	<p>Contact Name Jana Eisenstein</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email jana.eisenstein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.</p>				
114290	Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-004	06-Dec-2024	Not Specified
	<p>Contact Name Heiyoung Park, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email parkh1@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>				
128167	Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-25-093	16-Feb-2025	450,000 USD
	<p>Contact Name Peter J Koch, PhD</p> <p>Contact Telephone</p> <p>Contact Email Peter.Koch@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) intends to support fundamental research that will contribute to basic understanding of skin injuries caused by chemicals that have been identified as public health threats, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for medical countermeasure development.</p>				
109528	Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22-119	19-Feb-2025	100,000 USD
	<p>Contact Name Su-Yau Mao, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email maos2@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025</p> <p>Synopsis The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$100,000 direct costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability of its scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide support, in addition to the career development award, for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>				
117677	Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-23-002	08-Jan-2025	Not Specified
	<p>Contact Name Hye-Sook Kim, Ph.D.</p> <p>Contact Telephone 301-827-6910</p> <p>Contact Email hye-sook.kim@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.</p>				
113756	NCMRR Early Career Research Award (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-029	16-Feb-2025	200,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Maria Nurminskaya, PhD</p> <p>Contact Telephone 240-591-9986</p> <p>Contact Email Maria.nurminskaya@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
113468	<p>Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies (Reissue)</p>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-22-049	07-Jan-2025	Not Specified
	<p>Contact Name John V. Ilekis, PhD</p> <p>Contact Telephone 301-435-6895</p> <p>Contact Email ilekisj@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025</p> <p>Synopsis Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	help address a number of major gaps in knowledge.				
128527	Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-185	06-Jan-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	Contact Name	Reiko Toyama, Ph.D.			
	Contact Telephone	301-435-2723			
	Contact Email	ToyamaR@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027			
	Synopsis	Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural congenital anomalies (SCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest			
112833	Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-146	05-Feb-2025	2,499,995 USD
	Contact Name	Reiko Toyama, Ph.D.			
	Contact Telephone	301-435-2723			
	Contact Email	toyamar@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.</p>				
126985	<p>Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)</p>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-092	16-Feb-2025	100,000 USD
	<p>Contact Name Susan M. Jekielek, PhD</p> <p>Contact Telephone</p> <p>Contact Email susan.jekielek@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p>				
114857	<p>Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</p>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-109	16-Feb-2025	200,000 USD
	<p>Contact Name Marcia Fournier, PhD</p> <p>Contact Telephone 240-328-8308</p> <p>Contact Email marcia.fournier@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.</p>				
128792	<p>NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)</p>	National Institute of Child Health and Human Development/NIH/DHHS	PA-25-126	16-Feb-2025	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis</p> <p>The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA.</p>				
128791	<p>NICHD Small Research Grant Program (R03 Clinical Trial Required)</p>	National Institute of Child Health and Human Development/NIH/DHHS	PA-25-125	16-Feb-2025	100,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
126762	Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-112	05-Feb-2025	Not Specified
	<p>Contact Name Virginia Salo</p> <p>Contact Telephone 301-402-3682</p> <p>Contact Email virginia.salo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Mar-2025 , 05-Jun-2025 , 05-Jul-2025 , 05-Oct-2025 , 05-Nov-2025 , 05-Feb-2026 , 05-Mar-2026 , 05-Jun-2026 , 05-Jul-2026 , 05-Oct-2026 , 05-Nov-2026 , 05-Feb-2027 , 05-Mar-2027 , 05-Jun-2027 , 05-Jul-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children’s language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children’s language development and/or impairment, and predictors thereof. This NOFO requires a Community Engagement (CE) Plan, which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a CE Plan will be considered incomplete and will be withdrawn. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Diverse Perspectives (PEDP).				
126760	Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-113	16-Feb-2025	275,000 USD
	Contact Name	Virginia Salo			
	Contact Telephone	301-402-3682			
	Contact Email	virginia.salo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026 , 16-Feb-2027 , 16-Mar-2027 , 16-Jun-2027 , 16-Jul-2027			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children’s language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children’s language development and/or impairment, and predictors thereof. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).			
116699	Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-23-004	07-Jan-2025	Not Specified
	Contact Name	Amanda Melillo, Ph.D.			
	Contact Telephone	301-529-7217			
	Contact Email	amanda.melillo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026			
	Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is reissuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
CoV-2 and/or Coronavirus Disease 2019 (COVID-19).					
110993	Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-121	07-Jan-2025	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025</p> <p>Synopsis The goal of the NIDCR Career Enhancement Award (K18) is to support mentored research experiences for established investigators who either wish to expand or augment their dental, oral, or craniofacial (DOC) research program, or to redirect their research by incorporating DOC research into their research program to advance fundamental knowledge about dental, oral, and craniofacial health and disease. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
110754	Notice of Special Interest (NOSI): Achieving Tissue Robustness Through Harnessing Immune System Plasticity	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-22-005	07-Jan-2025	Not Specified
	<p>Contact Name Preethi Chander, PhD</p> <p>Contact Telephone 301-827-4620</p> <p>Contact Email preethi.chander@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.</p>				
117461	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-162	07-Jan-2025	Not Specified
	<p>Contact Name: Lorena Baccaglini, DDS, MS, PhD Contact Telephone: 301-435-7908 Contact Email: lorena.baccaglini@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 Synopsis: This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.</p>				
127032	NIDCR Mentored Career Development Award to Promote Broad Participation in Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-022	12-Feb-2025	Not Specified
	<p>Contact Name: Shoba Thirumangalathu, Ph.D. Contact Telephone: 301-594-0652 Contact Email: nidcrtraining@nidcr.nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028 Synopsis: The purpose of the NIDCR Mentored Career Development Award to Promote Broad Participation in Research is to strengthen the dental, oral, and craniofacial research workforce by expanding the pool of well-trained postdoctoral fellows and early</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

career faculty engaged in these areas of research This Notice of Funding Opportunity (NOFO) provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

102596	NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-057	08-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	------------	-------------------------------------	---------------

Contact Name	Dena Fischer, DDS, MSD, MS
Contact Telephone	301-594-4876
Contact Email	dena.fischer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-May-2025 [Optional][LOI/Pre-App], 08-May-2025 , 06-Jun-2025 , 04-Sep-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 06-Jan-2026 , 10-Jan-2026 [Optional][LOI/Pre-App], 09-Feb-2026 , 08-May-2026 , 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026 , 08-Sep-2026 [Optional][LOI/Pre-App], 09-Sep-2026 , 08-Oct-2026 , 08-Jan-2027 , 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027 , 06-May-2027 , 08-May-2027 [Optional][LOI/Pre-App], 07-Jun-2027 , 07-Sep-2027 [Optional][LOI/Pre-App], 08-Sep-2027 , 07-Oct-2027 , 06-Jan-2028
Synopsis	This Notice of Funding Opportunity (NOFO) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this NOFO are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this NOFO will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical trial including detail about the study population, intervention(s), and outcome(s) described in the application, following the instructions described in this NOFO. The UG3 planning phase permits both scientific and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy or assess the study's primary outcome. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	be supported by this NOFO.				
128366	RFA-RM-24-009 -- Human Virome Program: Developing Novel and Innovative Tools To Interrogate and Annotate the Human Virome (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-24-009	27-Jan-2025 [Optional][LOI/Pre-App]	1,400,000 USD
	Contact Name	Amanda Melillo, PhD			
	Contact Telephone	301-529-7217			
	Contact Email	amanda.melillo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Jan-2025 [Optional][LOI/Pre-App], 27-Feb-2025			
	Synopsis	<p>The Common Fund Human Virome Program aims to extensively characterize the human virome and create tools, models, and methods that will enable an in-depth study of its variation in relation to host factors and its influence on health and disease. The purpose of this NOFO is to address the technological challenges that are currently hindering robust interrogation of the constituents and functionality of the human virome. Despite major advances in sequencing technology and computational analysis of large sequence data sets, challenges remain in examining viruses. This NOFO solicits applications to develop innovative and novel tools, models, and methods to overcome the major challenges in identifying and characterizing viruses, as well as the development of computational and bioinformatics tools to enhance the analysis of the human virome. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. This notice of funding opportunity (NOFO) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination. All NIH Institutes and Centers participate in Common Fund initiatives. The NOFO will be administered by the National Institute of Dental and Craniofacial Research (NIDCR) (http://www.nidcr.nih.gov).</p>			
128678	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-027	12-Feb-2025	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentist scientists from NIH Intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).</p>				
117231	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-166	07-Jan-2025	200,000 USD
	<p>Contact Name Noffisat Oki</p> <p>Contact Telephone 301-402-6778</p> <p>Contact Email noffisat.oki@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
117230	NIDCR Research Grants for Analyses of Existing Genomics Data (R01)	National Institute of Dental and	PAR-25-	07-Jan-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(Clinical Trial Not Allowed)	Craniofacial Research/NIH/DHHS	164		Specified
	<p>Contact Name Noffisat Oki</p> <p>Contact Telephone 301-402-6778</p> <p>Contact Email noffisat.oki@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
128813	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-105	16-Feb-2025	200,000 USD
	<p>Contact Name Preethi Chander, PhD</p> <p>Contact Telephone 301-827-4620</p> <p>Contact Email preethi.chander@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This NIDCR Small Grant Program for New Investigators supports basic and clinical research, behavioral, and population</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

science conducted by scientists who are establishing an independent research career in dental, oral and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator-initiated Research Project Grant (R01) or equivalent application.

122206	Notice of Special Interest (NOSI): Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases (Defunct)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-21-022	06-Feb-2025	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Hanyu Liang, MD/PhD
Contact Telephone	301-443- 8737
Contact Email	hanyu.liang@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Feb-2025
Synopsis	The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.

107685	Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-074	05-Feb-2025	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Julie Barthold, MD
Contact Telephone	301-594-9655
Contact Email	julia.barthold@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.</p>			
123312	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-103	05-Feb-2025	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.			
	Contact Telephone	301-594-4748			
	Contact Email	rankint@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	<p>This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material located at: https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp attached to "PEDP guidance material".</p>			
123309	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-102	05-Feb-2025	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research Staff strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material. (with link to https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp for "PEDP guidance material").</p>				
116589	<p>Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23-086	07-Jan-2025	600,000 USD
	<p>Contact Name Aynur Unalp-Arida, M.D., M.Sc., Ph.D.</p> <p>Contact Telephone 301-594-8879</p> <p>Contact Email aynur.unalp-arida@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	transformative research.																		
128623	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-25-205	05-Feb-2025	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Shilpa Hattangadi, M.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-7726</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>shilpam.hattangadi@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</td> </tr> </table>					Contact Name	Shilpa Hattangadi, M.D.	Contact Telephone	301-594-7726	Contact Email	shilpam.hattangadi@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027	Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
Contact Name	Shilpa Hattangadi, M.D.																		
Contact Telephone	301-594-7726																		
Contact Email	shilpam.hattangadi@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027																		
Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).																		
113279	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-129	07-Jan-2025	150,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Lisa M. Spain, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-9871</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>SpainL@niddk.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025</td> </tr> </table>					Contact Name	Lisa M. Spain, Ph.D.	Contact Telephone	301-451-9871	Contact Email	SpainL@niddk.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025		
Contact Name	Lisa M. Spain, Ph.D.																		
Contact Telephone	301-451-9871																		
Contact Email	SpainL@niddk.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>				
113566	Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-23-002	07-Jan-2025	Not Specified
	<p>Contact Name: Lingamanaidu V. Ravichandran, Ph.D Contact Telephone: 984-287-3309 Contact Email: lingamanaidu.ravichandran@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 Synopsis: The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).</p>				
128750	RFA-ES-25-002 -- Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-25-002	17-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Claudia Thompson, Ph.D Contact Telephone: 984-287-3330 Contact Email: thomps14@niehs.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2025 [Optional][LOI/Pre-App], 18-Mar-2025 , 30-Jan-2026 , 29-Jan-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites grant applications for Environmental Health Sciences Core Centers (EHSCC). As intellectual hubs for environmental health science research, the EHSCC are expected to be the thought leaders for the field and advance the goals of the 2025-2029 NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHSCC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHSCC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHSCC supports community engagement and translational research as key approaches to improving public health. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128752	<p>RFA-ES-25-001 -- Epitranscriptomics Crosstalks and Toxicants (EPCOT) (R01 Clinical Trials Not Allowed)</p>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-25-001	06-Jan-2025 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name Frederick L. Tyson, Ph.D.</p> <p>Contact Telephone 984-287-3334</p> <p>Contact Email tyson2@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 06-Feb-2025</p> <p>Synopsis The purpose of this initiative is to solicit new R01 applications that propose innovative studies to explore how exposures to environmental toxicants may inhibit, create new or otherwise impact epitranscriptomic crosstalks and provide mechanistic insights into how these interactions play a role in initiation, progression, and/or exacerbation of adverse health outcomes. Epitranscriptomic crosstalks are defined as interactions between epitranscriptomic marks and associated Readers Writers and Erasers (RWEs) and epigenomic marks and/or epigenomic RWEs, and genomic structures.</p>				
127138	<p>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-225	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Kenneth D. Gibbs, Jr., Ph.D. kenneth.gibbs@nih.gov Link to program URL 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH’s efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should work with their institutions to apply to the companion NOFO PAR-24-226.
--	---

125765	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-152	07-Jan-2025	375,000 USD
--------	---	---	------------	-------------	-------------

Contact Name Contact Telephone	Charles Ansong, Ph.D.
-----------------------------------	-------------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email charles.ansong@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.</p>				
117879	Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-23-145	03-Feb-2025	1,375,000 USD
	<p>Contact Name Sailaja Koduri, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email sailaja.koduri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025 , 03-Oct-2025 , 03-Feb-2026</p> <p>Synopsis The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.</p>			
128628	Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-117	05-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Laurie Stepanek, Ph.D.</p> <p>laurie.stepanek@nih.gov</p> <p>Link to program URL</p> <p>05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			
125769	Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-148	25-Feb-2025	375,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Mahua Mukhopadhyay, PhD</p> <p>301-435-6886</p> <p>mukhopam@mail.nih.gov</p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 25-Feb-2025 , 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027 , 25-Jun-2027 , 07-Sep-2027 , 25-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials such as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm, and which address the mission and research interests of the participating NIH institutes.</p>				
128746	Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-202	16-Feb-2025	275,000 USD
	<p>Contact Name Alvin T. Yeh</p> <p>Contact Telephone</p> <p>Contact Email NIGMS_techdev@nigms.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. This NOFO does not support technology development that is narrowly focused on addressing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>specific biological questions or that re-purposes existing technologies for new uses. Rather, applications should propose development of new tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this NOFO and will be administratively withdrawn without review.</p>				
128748	Focused Technology Research and Development (R01 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-203	05-Feb-2025	Not Specified
	Contact Name	Alvin T. Yeh			
	Contact Telephone				
	Contact Email	NIGMS_techdev@nigms.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.</p>			
128806	Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-084	07-Jan-2025	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email laurie.stepanek@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 10-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027 , 11-Jun-2027 , 07-Sep-2027 , 08-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of the Advancing Research Careers (ARC) program is to support cohorts of promising, late-stage graduate students from diverse backgrounds pursuing research training in NIH mission areas. The program has two components: an individual predoctoral-to-postdoctoral transition award (F99/K00) and a research education cooperative agreement (UE5) awarded to organizations to provide F99/K00 fellows with additional mentoring, networking and professional development activities to support their transition to and success in mentored postdoctoral research positions. The ARC program supports NIH’s efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The ARC Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) is a two-phase award that will provide support for promising late-stage graduate students from diverse backgrounds pursuing research related to the mission areas of participating NIH Institutes, Centers and Offices (ICOs), to complete their doctoral research training (F99 phase) and transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). The program also is designed to support predoctoral researchers who have, appropriate to their career stage, demonstrated contributions and propose meaningful plans to promote broad participation in the biomedical research workforce. It is anticipated that completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (for example, academic research and teaching at a range of organization types, industry, or government research). This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
128517	Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-268	19-Feb-2025	2,500,000 USD
	<p>Contact Name Sydella A. Blatch Alexander, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIGMSBRE-SPAD@nigms.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025 , 27-Jan-2026 , 27-Jan-2027</p> <p>Synopsis The Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program aims to promote broad participation in biomedical research by supporting resource-limited institutions to conduct research, enhance their research environments, and increase sponsored programs administration capacity. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
115209	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-23-105	16-Feb-2025	450,000 USD
	<p>Contact Name Susan T. Azrin, Ph.D.</p> <p>Contact Telephone 301-443-3267</p> <p>Contact Email azrinst@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>				
117822	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)	National Institute of Mental Health/NIH/DHHS	PA-23-150	12-Feb-2025	Not Specified
	<p>Contact Name Ashlee Van't Veer</p> <p>Contact Telephone 301-443-3107</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-23-149.</p>				
117821	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-23-149	12-Feb-2025	Not Specified
	<p>Contact Name Ashlee Van't Veer</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PAR-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				23-150.	
118003	Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-235	07-Jan-2025	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email mgrabb@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration’s (FDA’s) guidance on natural history studies for rare disorders).</p>				
118004	Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-236	07-Jan-2025	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email NIMHgenetherapies@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.				
108834	Notice of Special Interest (NOSI): Neuro-Glia Mechanisms Governing Complex Behaviors (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-090	07-Jan-2025	Not Specified
	<p>Contact Name Michele Ferrante, Ph.D.</p> <p>Contact Telephone 301-435-6782</p> <p>Contact Email michele.ferrante@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.</p>				
112309	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-170	07-Jan-2025	Not Specified
	<p>Contact Name Jamie Driscoll</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email jdrisco1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.

128025	RFA-MH-26-120 --BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-26-120	15-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Douglas S. Kim, Ph.D.
Contact Telephone	301-827-6463
Contact Email	douglas.kim@nih.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025 , 03-Jan-2026 [Optional][LOI/Pre-App], 02-Feb-2026 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027
Synopsis	<p>This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support facilities at Resource-Limited Institutions (RLIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access reagents. The reagents to be distributed will first be developed in separately supported reagent design and development projects for brain cell type-specific access across vertebrate species in the BRAIN Initiative Armamentarium project. Recipients of awards under this NOFO will then work with these Armamentarium projects to manufacture and distribute the reagents for use throughout the neuroscience community. It is envisioned that the recipients will work both with Armamentarium researchers as well as with the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users. This NOFO is part of the BRAIN Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor brain cell</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	types across multiple vertebrate species. This NOFO will foster close interaction between technologists, disseminators, and neurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				
128553	Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-206	06-Jan-2025 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This notice of funding opportunity (NOFO) supports pilot research to evaluate the feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of post-acute phase intervention approaches, to generate the preliminary data needed as a prerequisite to well powered effectiveness trials, and to inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 NOFO, PAR-25-207.</p>				
128559	Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-207	06-Jan-2025 [Optional][LOI/Pre-	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

App]

Contact Name	Adam Haim, Ph.D.
Contact Telephone	301-435-3593
Contact Email	haima@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027
Synopsis	NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This notice of funding opportunity (NOFO) encourages clinical trials to establish the effectiveness and test hypotheses regarding mechanisms of action, mediators, and predictors and moderators of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This NOFO is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R01 NOFO,PAR-25-206 .

128677	Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-201	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	------------	-------------------------------------	---------------

Contact Name	Vidya Vedham, Ph.D.
Contact Telephone	
Contact Email	vidya.vedham@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>[Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis This notice of funding opportunity (NOFO) seeks implementation research projects focused on the integrating mental health services with chronic health care (for both communicable and non-communicable conditions) across various healthcare and non-healthcare settings (such as schools, places of worship, and community centers) in low and middle-income countries (LMICs). The objective is to develop, refine, and evaluate innovative strategies to facilitate the integration of mental health care with other services. This NOFO aims to support research geared towards implementing, scaling up, and ensuring the financial sustainability of integrated mental health care models, with the overarching goal of enhancing the availability, accessibility, utilization, and quality of mental health care services in both healthcare and non-healthcare settings. In addition, this NOFO seeks to strengthen sustainable mental health research capacity in LMICs.</p>				
117550	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-036	07-Jan-2025	Not Specified
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIA.</p>				
117750	Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-063	05-Feb-2025	Not Specified
	<p>Contact Name Enrique Michelotti, PhD</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
128661	Laboratories to Optimize Digital Health (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-136	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email Haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| particularly in populations who experience health disparities and vulnerable populations.

119255	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-064	16-Feb-2025	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	laura.rowland@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-25-065 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.

119254	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-065	05-Feb-2025	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	laura.rowland@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026
Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both bio behavioral

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-25-064 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism .</p>				
115199	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-034	21-Feb-2025	Not Specified
	<p>Contact Name Jamie Driscoll Contact Telephone 301-443-5288 Contact Email jdrisco1@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 21-Feb-2025 , 20-Jun-2025</p>				
	<p>Synopsis The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to pharmacologic manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.</p>				
128913	Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-282	16-Feb-2025	275,000 USD
	<p>Contact Name Laura M. Rowland, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-792-3242</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This NOFO uses the R21 mechanism, while the companion NOFO PAR-25-281 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				
128914	<p>Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-25-291	16-Feb-2025	275,000 USD
	<p>Contact Name Jessica Tilghman, Ph.D.</p> <p>Contact Telephone 301-827-0439</p> <p>Contact Email jessica.tilghman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This NOFO aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>modalities that have high translational potential. Intervention-development clinical trials of therapeutic devices are outside the scope of this NOFO, though development of novel tools/methods to enable relevant mental health studies is encouraged. This NOFO uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-25-290, seeks R01 grant applications.</p>				
119702	Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-038	05-Feb-2025	Not Specified
	<p>Contact Name David Panchision</p> <p>Contact Telephone 301-402-3969</p> <p>Contact Email panchisiond@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p>				
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO PAR-25-037.</p>			
119664	Schizophrenia and Related Disorders During mid- to Late-Life (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-040	16-Feb-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov Link to program URL 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R21 grant mechanism, while the companion NOFO (PAR-25-039) uses the R01 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.
--	--

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

128886	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-287	05-Feb-2025	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Jessica Tilghman, PhD 301-827-0439 jessica.tilghman@nih.gov Link to program URL 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.

123916	Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-278	17-Jan-2025 [Optional][LOI/Pre-App]	450,000 USD
--------	--	--	------------	-------------------------------------	-------------

Contact Name	Michael Freed, Ph.D.
Contact Telephone	301-443-3747
Contact Email	michael.freed@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025
Synopsis	This Notice of Funding Announcement (NOFO) solicits exploratory/developmental research applications within the learning health care framework to support adoption, implementation, sustainability, and continuous improvement of evidence-based practices in outpatient mental health and substance use treatment systems. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) expansion grant program and CCBHCs participating in their states' Section 223 CCBHC Medicaid demonstration program, or as a part of independent state programs where the CCBHCs are meeting the federal CCBHC certification criteria. This NOFO requires active collaboration between behavioral health researchers and community behavioral health partners across all phases of the research process. Studies that are co-designed between community clinic staff/service users and health services researchers may focus on (1) identifying subgroups within the population of individuals served by CCBHCs with unique needs, including health disparities experienced by people from racial and ethnic minority groups or underserved communities; (2) workforce development strategies, including new approaches to train providers who vary in terms of prior experience, expertise and skills; (3) developing and testing tools to promote measurement-based

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	treatment; (4) hybrid effectiveness-implementation trials aimed at implementing and improving evidence-based prevention, treatment, or services delivery approaches in real-world settings; and (5) research to establish and/or expand 988 crisis response services within CCBHC settings.				
119320	RFA-MH-26-170 -- BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-26-170	08-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Eunyoung Kim, Ph.D.</p> <p>Contact Telephone 301-827-3420</p> <p>Contact Email eunyoung.kim@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026 , 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027</p> <p>Synopsis The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
119705	Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-037	16-Feb-2025	275,000 USD
	<p>Contact Name David Panchision</p> <p>Contact Telephone 301-402-3969</p> <p>Contact Email panchisiond@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO PAR-25-038.</p>				
119663	Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-039	05-Feb-2025	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	the R01 grant mechanism, while the companion NOFO (PAR-25-040), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.																		
115030	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-035	05-Feb-2025	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jamie Driscoll</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-5288</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>jdrisco1@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p> </td> </tr> </table>					Contact Name	Jamie Driscoll	Contact Telephone	301-443-5288	Contact Email	jdrisco1@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025	Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>
Contact Name	Jamie Driscoll																		
Contact Telephone	301-443-5288																		
Contact Email	jdrisco1@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025																		
Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>																		
128885	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-286	16-Feb-2025	275,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jessica Tilghman, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-0439</td> </tr> </table>					Contact Name	Jessica Tilghman, PhD	Contact Telephone	301-827-0439										
Contact Name	Jessica Tilghman, PhD																		
Contact Telephone	301-827-0439																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	jessica.tilghman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited, non-clinical trial human testing necessary to demonstrate initial proof of concept is allowable. This NOFO uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity PAR-25-287 seeks R01 grant applications.

128915	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-290	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	------------	-------------------------------------	---------------

Contact Name	Jessica Tilghman, Ph.D.
Contact Telephone	301-827-0439
Contact Email	jessica.tilghman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This NOFO uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 NOFO, PAR-25-291, seeks grant applications encouraging shorter, higher-risk studies with little (or no) preliminary data.</p>				
128878	RFA-MH-26-111--Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-26-111	18-Feb-2025 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Jeymohan Joseph, Ph.D. Contact Telephone 240-627-3869 Contact Email jjeymoha@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 18-Feb-2025 [Optional][LOI/Pre-App], 18-Mar-2025 Synopsis The goal of this NOFO is to encourage research to define the mechanisms and roles of T-cells in HIV/CNS (central nervous system) reservoir seeding, persistence and neuropathogenesis. Strategies to develop therapeutic approaches to target T-cell neuro-invasion, reservoir maintenance, and neuropathogenesis is also an area of high priority. State-of-the-art CNS cell systems, organoid models, post-mortem tissue, animal models, clinical samples and single-cell technologies can be used as potential tools to address this research area. Basic and Translational research in domestic and international settings are also of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data are most appropriate for this R21 mechanism, RFA-MH-26-111, while applicants with preliminary data should apply to the R01 mechanism RFA-MH-26-110.</p>				
128877	RFA-MH-26-110--Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-26-110	18-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Jeymohan Joseph, Ph.D. Contact Telephone 240-627-3869</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email jjeymoha@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2025 [Optional][LOI/Pre-App], 18-Mar-2025</p> <p>Synopsis The goal of this NOFO is to encourage research to define the mechanisms and roles of T-cells in HIV/CNS (central nervous system) reservoir seeding, persistence and neuropathogenesis. Strategies to develop therapeutic approaches to target T-cell neuro-invasion, reservoir maintenance, and neuropathogenesis is also an area of high priority. State-of-the-art CNS cell systems, organoid models, post-mortem tissue, animal models, clinical samples and single-cell technologies can be used as potential tools to address this research area. Basic and translational research in domestic and international settings are also of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 NOFO, RFA-MH-26-111, while applicants with preliminary data may wish to apply using this R01 mechanism.</p>				
128912	Mood and Psychosis Symptoms During the Menopause Transition (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-281	05-Feb-2025	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This NOFO uses the R01 grant mechanism, while the companion NOFO PAR-25-282 uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120155	RFA-NS-24-014 -- NIH Blueprint and BRAIN Initiative Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences (BP BRAIN-ENDURE) (R25 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-014	11-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Michelle D. Jones-London, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email jonesmiche@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jan-2025 [Optional][LOI/Pre-App], 10-Feb-2025</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences, to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation (NSF), see http://www.nsf.gov/statistics/wmpd/ (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in a historically documented contribution by the institution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated curriculum/academic enhancement and research experience activities designed to increase participants' preparation to enter doctoral programs in the neurosciences; and d) well-described plans to provide early communication and interaction between participating students and graduate neuroscience programs across the country.</p>				
123614	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-098	21-Feb-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Carol Taylor-Burds, PhD</p> <p>301-496-1779</p> <p>carol.taylor-burds@nih.gov</p> <p></p> <p>Link to program URL</p> <p>21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026</p> <p>The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."</p>
---	--

123611	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-096	21-Feb-2025	Not Specified
--------	--	--	------------	-------------	---------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Carol Taylor-Burds, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email carol.taylor-burds@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."</p>				
126698	NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-212	12-Feb-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Diversity \(K99/R00 Independent Clinical Trial Not Allowed\)](#)

	<p>Contact Name Amelie Gubitz, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email ADRDK99@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</p>				
--	--	--	--	--	--

126699	NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-213	12-Feb-2025	Not Specified
--------	---	--	------------	-------------	---------------

	<p>Contact Name Amber McCartney, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email amber.mccartney@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00) program is to support a cohort of new and talented, independent investigators conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.

126542	Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-204	19-Feb-2025 [Optional][LOI/Pre-App]	625,000 USD
--------	---	--	------------	-------------------------------------	-------------

Contact Name	Marguerite Matthews, Ph.D.
Contact Telephone	301-496-3272
Contact Email	laura.kwako@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	19-Feb-2025 [Optional][LOI/Pre-App], 18-Mar-2025 , 07-May-2025 , 18-Feb-2026 [Optional][LOI/Pre-App], 17-Mar-2026 , 07-May-2026 , 18-Feb-2027 [Optional][LOI/Pre-App], 17-Mar-2027 , 07-May-2027
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences for high school students, undergraduate students, and/or science teachers during the summer academic break.

126685	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-228	07-Jan-2025	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Michelle Jones-London, Ph.D.
Contact Telephone	301-451-7966
Contact Email	NINDSDiversityTraining@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-229).</p>			
126690	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-229	07-Jan-2025	Not Specified
	Contact Name	Michelle Jones-London			
	Contact Telephone	301-451-7966			
	Contact Email	NINDSDiversityTraining@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027			
	Synopsis	<p>The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-228).</p>			
109940	Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-076	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email adam.hartman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 19-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
127141	<p>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-227	07-Jan-2025	Not Specified
	<p>Contact Name Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email lanay.mudd@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

111323	Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-003	07-Jan-2025	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Jill Morris, Ph.D.
Contact Telephone	301-496-5754
Contact Email	jill.morris@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025
Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.			
111360	Notice of Special Interest (NOSI): Disease Mechanisms of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-004	07-Jan-2025	Not Specified
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.</p>				
120789	RFA-NS-25-020 -- HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-020	06-Feb-2025	3,250,000 USD
	<p>Contact Name D.P. Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Feb-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.</p>				
128250	RFA-NS-24-038 -- Human Brain Single-cell Genomics Explorer (U24 - Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-038	14-Jan-2025 [Optional][LOI/Pre-App]	3,000,000 USD
	<p>Contact Name Daniel Miller Contact Telephone 301-496-1853 Contact Email daniel.miller@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 14-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025 Synopsis The NIH Blueprint for neuroscience is soliciting applications to pilot the establishment of an integrated resource for users to explore, analyze, and download processed deidentified human brain single-cell transcriptomics and epigenomics data that is harmonized across reference and disease datasets. The resource will generate a unified cell type taxonomy and provide users with a draft annotatable cell-type nomenclature and the ability to map community generated single cell omics data to the taxonomy. This pilot will lay the groundwork for an expanded and sustained effort to increase utility and accessibility of human cell-type classification data across multiple NIH consortia.</p>				
123610	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-050	22-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Carol Taylor-Burds, PhD Contact Telephone 301-496-1779 Contact Email carol.taylor-burds@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 22-Jan-2025 [Optional][LOI/Pre-App], 21-Feb-2025 , 20-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>[Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators.</p>				
--	--	--	--	--	--

123613	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-055	22-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	------------	--	---------------

Contact Name	Carol Taylor-Burds, PhD
Contact Telephone	301-496-1779
Contact Email	carol.taylor-burds@nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2025 [Optional][LOI/Pre-App], 21-Feb-2025 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.</p>				
128305	Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-115	17-Jan-2025 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name William Daley, Ph.D.</p> <p>Contact Telephone 301-496-1431</p> <p>Contact Email william.daley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 16-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		must propose such studies in the context of a post-infectious etiology.			
128304	Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-116	06-Jan-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	Contact Name	William Daley, Ph.D.			
	Contact Telephone	301-496-1431			
	Contact Email	william.daley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025			
	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.</p>			
128339	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-060	18-Feb-2025	750,000 USD
	Contact Name	Becky Roof, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	rebecca.roof@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2025 , 18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this NOFO is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Models proposed for this NOFO would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128451	<p>Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-024	22-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Carol Taylor-Burds Ph.D</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email carol.taylor-burds@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2025 [Optional][LOI/Pre-App], 21-Feb-2025 , 07-May-2025 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 07-Sep-2025 , 20-Sep-2025 [Optional][LOI/Pre-App], 20-Oct-2025 , 07-Jan-2026 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 07-May-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026 , 07-Sep-2026 , 20-Sep-2026 [Optional][LOI/Pre-App], 20-Oct-2026 , 07-Jan-2027 , 23-Jan-2027 [Optional][LOI/Pre-App], 22-Feb-2027 , 07-May-2027 , 22-May-2027 [Optional][LOI/Pre-App], 21-Jun-2027 , 07-Sep-2027 , 20-Sep-2027 [Optional][LOI/Pre-App], 20-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarker(s) or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for one or two defined Context(s) of Use. In the first phase, applicants are expected to demonstrate that the biomarker</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

128722	Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-170	22-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	------------	-------------------------------------	---------------

Contact Name	Scott Janis, Ph.D.
Contact Telephone	301-496-9135
Contact Email	moyc@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Jan-2025 [Optional][LOI/Pre-App], 21-Feb-2025 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. To increase standardization and improve clinical adoption, applicants must propose to develop and evaluate the DHT enabled biomarkers or COAs in three or more diseases or conditions. Applicants must also propose to conduct development studies that are informed by people with lived experience (PWLE) and patient advocacy organizations. The first phase of this funding mechanism is to evaluate the technical performance of the proposed DHTs with PWLE input; the second phase is to support a prospective longitudinal clinical study in representative populations to validate the DHT. Research outcomes should include demonstrating how a meaningful change in the biomarkers or COAs derived from the DHT(s) can be statistically measured and quantified at the individual participant level.

128336	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-225	18-Feb-2025	750,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	Becky Roof, PhD
Contact Telephone	301-496-1779
Contact Email	rebecca.roof@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 18-Feb-2025 , 18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027 Synopsis This Notice of Funding Opportunity (NOFO) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents include small molecules or biologics. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE).				
126781	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-220	12-Feb-2025	Not Specified
	Contact Name Laura D. Wandner Contact Telephone Contact Email Laura.Wandner@nih.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027 Synopsis The purpose of the NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23) (Clinical Trial Required) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion NOFO.				
126790	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-219	12-Feb-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Laura D. Wandner</p> <p></p> <p>Laura.Wandner@nih.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p> <p>The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion NOFO. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>
---	---

126806	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-217	12-Feb-2025	Not Specified
--------	---	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Laura D. Wandner</p> <p></p> <p>Laura.Wandner@nih.gov</p>
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p> <p>Synopsis The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Required) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to a companion NOFO.</p>				
115920	NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-049	08-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Jeremy Brown, MD</p> <p>Contact Telephone 301-594-4481</p> <p>Contact Email jeremy.brown@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-May-2025 [Optional][LOI/Pre-App], 06-Jun-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 07-Jan-2026 [Optional][LOI/Pre-App], 06-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this NOFO. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.				
128662	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-234	10-Feb-2025	Not Specified
	<p>Contact Name Tish Weigand, Ph.D.</p> <p>Contact Telephone 301-496-4188</p> <p>Contact Email letitia.weigand@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 09-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 09-Jun-2026 , 07-Sep-2026 , 09-Oct-2026 , 07-Jan-2027 , 09-Feb-2027 , 07-May-2027 , 09-Jun-2027 , 07-Sep-2027 , 08-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months (or 18 months for resubmissions) after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
110549	NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-054	11-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Jeremy Brown MD</p> <p>Contact Telephone </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email jeremy.brown@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jan-2025 [Optional][LOI/Pre-App], 10-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism.</p>				
128725	<p>RFA-NS-25-025--Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-025	03-Feb-2025 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name William Daley, Ph.D.</p> <p>Contact Telephone 301-496-1431</p> <p>Contact Email william.daley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025 [Optional][LOI/Pre-App], 03-Mar-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 03-Oct-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) solicits applications for support of exploratory/developmental studies aimed at accelerating progress toward understanding, preventing or treating Guillain Barre Syndrome (GBS) and/or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Innovative studies of disease mechanisms, susceptibility factors, model systems, biomarkers and treatments are encouraged.</p>				
128004	<p>Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-23-189: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-24-085	15-Feb-2025	Not Specified
	<p>Contact Name Eric M. Hudak, PhD</p> <p>Contact Telephone 301-496-1779</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email eric.hudak@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2025 , 15-Apr-2025 , 15-Nov-2025 , 15-Feb-2026 , 15-Apr-2026 , 15-Nov-2026 , 15-Feb-2027 , 15-Apr-2027 , 15-Nov-2027 , 15-Feb-2028 , 15-Apr-2028</p> <p>Synopsis The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031). Research shows that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogenous teams. Scientists and trainees from diverse backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems. There are many benefits that flow from a diverse NIH-supported scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved or health disparity populations participate in, and benefit from health research, and enhancing public trust. NIH encourages institutions to use legally available means to create a diverse and inclusive scientific workforce. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-23-189 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed).</p>				
123196	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-052	19-Feb-2025	Not Specified
	<p>Contact Name Scott Janis, Ph.D.</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email moyc@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025 , 20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026</p> <p>Synopsis This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.</p>				
128884	RFA-NS-25-027 -- Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-027	23-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Marguerite Matthews, Ph.D.</p> <p>marguerite.matthews@nih.gov</p> <p>Link to program URL</p> <p>23-Feb-2025 [Optional][LOI/Pre-App], 25-Mar-2025</p> <p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. This Neuroscience Doctoral Readiness Program (DR Program) expects that the proposed research education programs will incorporate extensive research</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>experiences within the participating NIH Institutes missions and well-designed courses for skills development and education to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous, research-focused doctoral degree programs (e.g., Ph.D., M.D./Ph.D., or D.D.S./Ph.D.) in biomedical fields. This is a limited competition funding opportunity announcement to support postbaccalaureate programs that will be affiliated with a funded NIH T32 program. Eligibility is limited to PD(s)/PI(s) or MPI teams that include at least one PD/PI of a grant supported by the following T32 NOFOs: Jointly Sponsored Institutional Predoctoral Training Program (JSPTPN), PAR-22-265; NINDS Advanced Institutional Research Training Program, PAR-21-149; NINDS Institutional Translational Research Training Program, PAR-19-228 and PAR-24-108; NINDS Institutional AD/ADRD Research Training Program, PAR-23-113; or Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant, PA-23-048. In all cases, a PD/PI of the T32 grant from a NOFO cited above must be the PD/PI or an MPI of this R25. These postbaccalaureate programs are intended to exclusively support participants from institutions that do not offer undergraduates access to substantive research opportunities. This NOFO does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
128868	Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-25-190	05-Feb-2025	Not Specified
	<p>Contact Name Lauren Ullrich, Ph.D. Contact Telephone 301-451-7966 Contact Email NINDSDiversityTraining@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 Synopsis This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that would support independent research projects within the scientific mission areas of the participating NIH Institutes or Centers from a diverse cohort of New Investigators and At-Risk Investigators.</p>				
125561	RFA-NR-24-006 -- Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health Disparities: The Axes Initiative (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	RFA-NR-24-006	15-Jan-2025 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Shalanda A. Bynum, PhD, MPH Contact Telephone 301-755-4355</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email shalanda.bynum@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025 , 10-Mar-2025</p> <p>Synopsis Research shows that intersecting systems of privilege and oppression produce and sustain wide and unjust variations in health. The Axes Initiative will support research to understand health at the intersections of social statuses such as race, ethnicity, socioeconomic status, sexual orientation, and ability, by examining contributions of social and other determinants of health. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
113257	NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-230	07-Jan-2025	Not Specified
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p> <p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025</p> <p>Synopsis This funding announcement solicits R01 grant applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
113258	NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-231	07-Jan-2025	200,000 USD
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025</p> <p>Synopsis This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
120843	<p>Analytical and Clinical Validation of Biomarkers for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	PAR-23-258	05-Feb-2025	Not Specified
	<p>Contact Name Yuan Luo, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email Yuan.Luo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer's disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.</p>				
124752	<p>New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	PAR-24-160	05-Feb-2025	Not Specified
	<p>Contact Name Elizabeth Newman, Ph.D.</p> <p>Contact Telephone 301-480-7937</p> <p>Contact Email elizabeth.newman@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</p> <p>Synopsis The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
126708	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-24-223	06-Jan-2025 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Lorenzo M. Refolo, Ph.D.</p> <p>Contact Telephone 301-594-7576</p> <p>Contact Email refolol@nia.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 05-Mar-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Jun-2025 [Optional][LOI/Pre-App], 05-Jul-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Oct-2025 [Optional][LOI/Pre-App], 05-Nov-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 03-Feb-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 05-Mar-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Jul-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Oct-2026 [Optional][LOI/Pre-App], 05-Nov-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 03-Feb-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 05-Mar-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Jun-2027 [Optional][LOI/Pre-App], 05-Jul-2027 , 05-Sep-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>[Optional][LOI/Pre-App], 05-Oct-2027 , 06-Oct-2027 [Optional][LOI/Pre-App], 05-Nov-2027</p> <p>This Notice of Funding Opportunity (NOFO) invites applications proposing pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Grant recipients will receive funding for therapy development activities, such as the following: Medicinal chemistry; Pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); Efficacy in animal models; Development of biomarkers for target engagement; Formulation development chemical synthesis under Good Manufacturing Practices (GMP) ; Investigational New Drug (IND) enabling studies; Initial Phase I clinical testing.</p>			
124754	<p>New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	PAR-24-161	16-Feb-2025	400,000 USD

	<p>Contact Name Elizabeth Newman, Ph.D.</p> <p>Contact Telephone 301-480-7937</p> <p>Contact Email elizabeth.newman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027</p>
Synopsis	<p>The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
108048	NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-077	14-Feb-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Suzana Petanceska, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-594-7754</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">petanceskas@nia.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">14-Feb-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer’s and Related Dementias.</p> </td> </tr> </table>					Contact Name	Suzana Petanceska, Ph.D.	Contact Telephone	301-594-7754	Contact Email	petanceskas@nia.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	14-Feb-2025	Synopsis	<p>This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer’s and Related Dementias.</p>
Contact Name	Suzana Petanceska, Ph.D.																		
Contact Telephone	301-594-7754																		
Contact Email	petanceskas@nia.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	14-Feb-2025																		
Synopsis	<p>This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer’s and Related Dementias.</p>																		
127749	NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-271	12-Feb-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Yuan Luo, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-9350</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">yuan.luo@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including frontotemporal dementia, Lewy body dementia, and vascular dementia. This pathway to independence award will support early career investigators from diverse backgrounds, including those from groups underrepresented in the biomedical sciences, to gain critical translational research skills that they can apply to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This program will support highly trained</p> </td> </tr> </table>					Contact Name	Yuan Luo, Ph.D.	Contact Telephone	301-496-9350	Contact Email	yuan.luo@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including frontotemporal dementia, Lewy body dementia, and vascular dementia. This pathway to independence award will support early career investigators from diverse backgrounds, including those from groups underrepresented in the biomedical sciences, to gain critical translational research skills that they can apply to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This program will support highly trained</p>
Contact Name	Yuan Luo, Ph.D.																		
Contact Telephone	301-496-9350																		
Contact Email	yuan.luo@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027																		
Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including frontotemporal dementia, Lewy body dementia, and vascular dementia. This pathway to independence award will support early career investigators from diverse backgrounds, including those from groups underrepresented in the biomedical sciences, to gain critical translational research skills that they can apply to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This program will support highly trained</p>																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

translational researchers as they transition to research independence in the field of AD/ADRD. The long-term goal of this program is to expand the pool of translational researchers who can effectively participate in and/or lead a team-science, interdisciplinary approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This NOFO is designed for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

115099	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23-082	21-Feb-2025	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Nandini Arunkumar, Ph.D.
Contact Telephone	301-451-2313
Contact Email	nandini.arunkumar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Feb-2025
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.

112937	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-228	21-Feb-2025	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Nandini Arunkumar, Ph.D.
Contact Telephone	301-451-2313
Contact Email	nandini.arunkumar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Feb-2025

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right;">Synopsis</p> <p>This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.</p>				
113465	Notice of Special Interest (NOSI): Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	07-Jan-2025	Not Specified
	<p style="text-align: right;">Contact Name</p> <p>Lorenzo M. Refolo, Ph.D.</p> <p style="text-align: right;">Contact Telephone</p> <p>301-594-7576</p> <p style="text-align: right;">Contact Email</p> <p>refolol@nia.nih.gov</p> <p style="text-align: right;">Sponsor Website</p> <p></p> <p style="text-align: right;">Program URL</p> <p>Link to program URL</p> <p style="text-align: right;">Deadline Dates (ALL)</p> <p>07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025</p> <p style="text-align: right;">Synopsis</p> <p>This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration.</p>				
114123	Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25-199	16-Feb-2025	275,000 USD
	<p style="text-align: right;">Contact Name</p> <p>Amanda DiBattista, Ph.D.</p> <p style="text-align: right;">Contact Telephone</p> <p>301-496-9350</p> <p style="text-align: right;">Contact Email</p> <p>amanda.dibattista@nih.gov</p> <p style="text-align: right;">Sponsor Website</p> <p></p> <p style="text-align: right;">Program URL</p> <p>Link to program URL</p> <p style="text-align: right;">Deadline Dates (ALL)</p> <p>16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p style="text-align: right;">Synopsis</p> <p>This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this NOFO. Applicants with preliminary data may instead wish to apply to the companion R01 NOFO, which is identified above under the "Companion Funding Opportunity" heading.</p>				
123977	NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-120	12-Feb-2025	Not Specified
	<p>Contact Name Jamie Lahvic, Ph.D. Contact Telephone Contact Email NIATraining@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 Synopsis The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
127791	RFA-AG-25-031--Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-25-031	14-Feb-2025	200,000 USD
	<p>Contact Name Maryam Ghaleh, Ph.D. Contact Telephone Contact Email maryam.ghaleh@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-Feb-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites R03 applications from institutions in low- and middle-income countries (LMICs), as defined by the World Bank, to support junior faculty investigators involved in aging and Alzheimer's Disease (AD) and AD-related dementias (ADRD) from these institutions. The goals of this NOFO are the following:: To support the aging and/or AD/ADRD research conducted by junior faculty investigators from institutions in LMICs; and To support the career development of junior faculty investigators from institutions in LMICs as future leaders in aging and AD/ ADRD. In support of the program's goals, this NOFO invites applications that will yield pilot data, resources, and experience for subsequent aging and AD/ADRD research projects. In addition, candidates are encouraged to seek out a supportive research environment that will achieve the goal of fostering the career development of junior investigators.</p>				
127792	RFA-AG-25-032--Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-25-032	14-Feb-2025	2,000,000 USD
	<p>Contact Name Maryam Ghaleh, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email maryam.ghaleh@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to promote collaborative research programs by inviting applications to support innovative and sustainable Alzheimer's disease (AD) and AD-related dementias (ADRD) (including frontotemporal dementia (FTD), Lewy body dementia (LBD), vascular cognitive impairment/dementia (VCID), and mixed etiology dementias (MEDs)) neuroscience research for experienced investigators in low- and middle-income countries (LMICs). These collaborative research programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience capacity and research, ultimately leading to prevention and mitigation strategies for AD/ADRD in LMICs. This NOFO supports applications submitted from LMIC institutions as defined by the World Bank. LMIC scientists are expected to collaborate with scientists from the United States.</p>				
114469	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-23-057	05-Feb-2025	Not Specified
	<p>Contact Name Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone 301-435-3047</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email romashks@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				
128615	NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-321	12-Feb-2025	Not Specified
	<p>Contact Name Maria Carranza, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIATraining@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRD research. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).</p>				
114120	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25-198	05-Feb-2025	Not Specified
	Contact Name Amanda DiBattista, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-9350 amanda.dibattista@nih.gov Link to program URL 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This NOFO is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 NOFO, which is identified above under the "Companion Funding Opportunity" heading.
--	---

120970	Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-25-226	21-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	--	--------------------------------------	------------	-------------------------------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Akanni Clarke 301-496-9350 akanni.clarke@nih.gov Link to program URL 21-Jan-2025 [Optional][LOI/Pre-App], 21-Feb-2025 , 23-Jun-2025 , 20-Oct-2025 , 20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026 The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117878	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-25-246	16-Feb-2025	200,000 USD
	<p>Contact Name Luci Roberts, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email roberlu@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p>				
122532	Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-130	16-Feb-2025	Not Specified
	<p>Contact Name Jamie Lahvic, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email NIATraining@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within NIA's strategic priorities.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120716	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-250	05-Feb-2025	2,500,000 USD
	<p>Contact Name Brett T. Hagman, Ph.D.</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.</p>				
120720	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-251	05-Feb-2025	Not Specified
	<p>Contact Name Laura E. Kwako, Ph.D.</p> <p>Contact Telephone 301-451-8507</p> <p>Contact Email laura.kwako@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.</p>				
120718	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-249	16-Feb-2025	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Brett T. Hagman, Ph.D.
Contact Telephone	301-443-0638
Contact Email	brett.hagman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

120721	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-252	16-Feb-2025	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Laura E. Kwako, Ph.D.
Contact Telephone	301-451-8507
Contact Email	laura.kwako@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

122636	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-068	17-Feb-2025	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	William Dunty, PhD
--------------	--------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-24-067, the R34 option).</p>				
124492	<p>RFA-AA-24-006--Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required)</p>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-24-006	20-Jan-2025 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Deidra Roach, M.D.</p> <p>Contact Telephone 301-443-5820</p> <p>Contact Email droach@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025</p> <p>Synopsis The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest dissemination and implementation science approaches to significantly reduce the prevalence and impact of multi-morbidity among racial/ethnic minority women and girls of reproductive age at risk and living with mental health disorders, substance</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>use disorders, chronic stress, cardiopulmonary diseases, common metabolic disorders (e.g., diabetes), cancer, and HIV/AIDS. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being of racial and ethnic minority and other underserved women and girls. While MCCI is not a maternal health initiative, women and girls ages 15-44 yrs. are centered because it is during the early reproductive period, i.e., adolescence, that multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Special emphasis will be placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high quality health care (e.g., racial/ethnic minority women and girls living in low resource settings). Applications that include a partnership between Research Centers in Minority Institutions and other institutions with extensive programs in women's health research are strongly encouraged. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
122632	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-067	16-Feb-2025	450,000 USD
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			
	Contact Email	duntyw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).</p>			
116584	Notice of Special Interest (NOSI): Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-23-003	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA’s interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term “domestic violence” will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).</p>				
107782	<p>Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College</p>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	05-Jan-2025	Not Specified

	<p>Contact Name Bradley Kerridge, Ph.D.</p> <p>Contact Telephone 301-827-7493</p> <p>Contact Email bradley.kerridge@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.				
122439	RFA-DC-24-004 -- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-004	03-Feb-2025	2,499,995 USD
	<p>Contact Name Amy Poremba, Ph.D.</p> <p>Contact Telephone 301-997-3152</p> <p>Contact Email amy.poremba@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to the development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in mammalian animal models may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This notice of funding opportunity announcement (NOFO) also supports investigator initiated low-risk clinical trials addressing the development or improvement of human in vivo structural and functional imaging technologies. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not be an NIH-defined Phase III Clinical Trial, have low risks to subjects, and intend to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low-risk trials determined to be Basic Experimental Studies with Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

application. High-risk clinical trials not meeting all the criteria above are referred to the companion U01 Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (Clinical Trial required) NOFO RFA-DC-24-005.

122441	RFA-DC-24-005 -- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-005	03-Feb-2025	2,499,995 USD
--------	--	---	---------------	-------------	---------------

Contact Name Amy Poremba, Ph.D.
 Contact Telephone 301-997-3152
 Contact Email amy.poremba@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 03-Feb-2025

Synopsis This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop, advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 - Clinical Trial Optional) RFA-DC-24-004. Investigators are strongly encouraged to contact the scientific/research contact, prior to submission, to ensure this is the correct NOFO for their proposed research.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
122021	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-051	07-Jan-2025	2,499,995 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Trinh T. Ly, M.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-4085</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">trinh.ly@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</td> </tr> </table>					Contact Name	Trinh T. Ly, M.D.	Contact Telephone	301-435-4085	Contact Email	trinh.ly@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027	Synopsis	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.
Contact Name	Trinh T. Ly, M.D.																		
Contact Telephone	301-435-4085																		
Contact Email	trinh.ly@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027																		
Synopsis	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.																		
123925	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-142	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Alberto L. Rivera-Rentas, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-1804</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">riverara@nidcd.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-</td> </tr> </table>					Contact Name	Alberto L. Rivera-Rentas, Ph.D.	Contact Telephone	301-496-1804	Contact Email	riverara@nidcd.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-		
Contact Name	Alberto L. Rivera-Rentas, Ph.D.																		
Contact Telephone	301-496-1804																		
Contact Email	riverara@nidcd.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-140 and PAR-24-143</p>			
123928	<p>NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</p>	<p>National Institute on Deafness and Other Communication Disorders/NIH/DHHS</p>	<p>PAR-24-143</p>	<p>07-Jan-2025</p>	<p>Not Specified</p>
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p>riverara@nidcd.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).

123922	NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-140	07-Jan-2025	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-142 and PAR-24-143.

124298	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-150	07-Jan-2025	315,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).</p>				
124297	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-149	07-Jan-2025	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..</p>				
124299	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D.	National Institute on Deafness	PAR-24-	07-Jan-2025	315,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Audiologists (K01 Independent Clinical Trial Not Allowed)	and Other Communication Disorders/NIH/DHHS	159		USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).</p>				
106846	NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22-025	06-Feb-2025	7,500,000 USD
	<p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email shekiml@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Feb-2025</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a low risk clinical trial but are not required to (optional).			
117406	Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-009	05-Jan-2025	Not Specified
	Contact Name	Holly L. Storkel, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	holly.storkel@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.			
117259	Notice of Special Interest (NOSI): Encouraging Women’s Health Research within the NIDCD Mission Areas	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-006	07-Jan-2025	Not Specified
	Contact Name	Christopher Myers			
	Contact Telephone	301-435-0713			
	Contact Email	myersc@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 25-Feb-2026 , 07-May-2026			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD’s mission. NIDCD's mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural, hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's quality of life.</p>			
122020	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-050	27-Feb-2025	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<p>Trinh T. Ly, M.D. 301-435-4085 trinh.ly@nih.gov Link to program URL 27-Feb-2025 , 27-Jun-2025 , 28-Oct-2025 , 27-Feb-2026 , 29-Jun-2026 , 27-Oct-2026</p>			
	Synopsis	<p>The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-24-051. Investigators are strongly encouraged to contact Dr. Trinh Ly, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>			
124315	NIDCD Early Career Research (ECR) Award (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25-120	19-Feb-2025	375,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Bracie Watson, Jr.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025 , 17-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026 , 17-Feb-2027 , 17-Jun-2027 , 15-Oct-2027</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
114999	Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-001	07-Jan-2025	Not Specified
	<p>Contact Name Merav Sabri, Ph.D.</p> <p>Contact Telephone 301-827-0908</p> <p>Contact Email merav.sabri@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities from its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, balance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	cutting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical imaging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are expected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical sciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studies and comparative, cross-species projects are highly encouraged.																		
123134	RFA-DC-24-007 -- NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-007	06-Feb-2025	2,495,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Kelly King, Au.D., Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-402-3458</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>kingke@nidcd.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>06-Feb-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.</td> </tr> </table>					Contact Name	Kelly King, Au.D., Ph.D.	Contact Telephone	301-402-3458	Contact Email	kingke@nidcd.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	06-Feb-2025	Synopsis	This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.
Contact Name	Kelly King, Au.D., Ph.D.																		
Contact Telephone	301-402-3458																		
Contact Email	kingke@nidcd.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	06-Feb-2025																		
Synopsis	This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.																		
122887	RFA-DA-25-023 -- Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-023	21-Jan-2025 [Optional][LOI/Pre-App]	700,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Olivier Berton, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-7771</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>olivier.berton@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>21-Jan-2025 [Optional][LOI/Pre-App], 20-Feb-2025 , 24-Jan-2026 [Optional][LOI/Pre-App], 23-Feb-2026</td> </tr> </table>					Contact Name	Olivier Berton, PhD	Contact Telephone	301-827-7771	Contact Email	olivier.berton@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	21-Jan-2025 [Optional][LOI/Pre-App], 20-Feb-2025 , 24-Jan-2026 [Optional][LOI/Pre-App], 23-Feb-2026		
Contact Name	Olivier Berton, PhD																		
Contact Telephone	301-827-7771																		
Contact Email	olivier.berton@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	21-Jan-2025 [Optional][LOI/Pre-App], 20-Feb-2025 , 24-Jan-2026 [Optional][LOI/Pre-App], 23-Feb-2026																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This notice of funding opportunity (NOFO) aims to support research programs that adopt innovative scalable technologies to inventory, register and molecularly profile distributed cell ensembles encoding the effects of addictive substances, across various stages of exposure (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches capable of integrating data generated through population-scale measurements of cellular activity dynamics in behaving rodents, with other granular data modalities, collected from the same cells at single-cell resolution, such as transcriptomic class, epigenetic state, connectivity and spatial localization. The overarching goal is to inform new models for the mechanisms whereby cells are recruited into neuronal ensembles to encode addiction-associated neurobehavioral states.</p>				
127413	NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-24-269	11-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Amy C. Lossie, PhD Contact Telephone 301-827-6092 Contact Email lossieac@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 11-Jan-2025 [Optional][LOI/Pre-App], 11-Feb-2025 , 23-Jul-2025 , 11-Feb-2026 , 23-Jul-2026 , 11-Feb-2027</p> <p>Synopsis The purpose of the National Institute on Drug Abuse (NIDA) Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie neural and behavioral processes and phenotypes relevant to SUD risk, the SUD trajectory and SUD comorbidities. This opportunity supports research that links genetic, genomic and molecular mechanisms to neural circuit function and behavior. Applications may seek to identify any type of genomic and/or epigenomic variants that contribute to the genetic architecture of addiction, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, data-based, and/or artificial intelligence/machine learning approaches that integrate multi-level ‘omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include variant identification at the circuit level and the application of neuroscience to variant identification studies in tissues and cells. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
110056	RFA-DA-23-021 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-021	15-Jan-2025 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(R43/R44 - Clinical Trial Optional)			App]	
	<p>Contact Name Leonardo Angelone, PhD</p> <p>Contact Telephone 301-827-5946</p> <p>Contact Email leonardo.angelone@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.</p>				
117771	<p>RFA-DA-24-038 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)</p> <p>(R43/R44 - Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-038	15-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Leonardo Angelone, PhD</p> <p>Contact Telephone 301-827-5946</p> <p>Contact Email leonardo.angelone@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.</p>				
107619	Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002	12-Feb-2025	Not Specified
	<p>Contact Name Kiran Vemuri, Ph.D. Contact Telephone 301-435-4446 Contact Email kiran.vemuri@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.</p>				
111673	Notice of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058	07-Jan-2025	Not Specified
	<p>Contact Name Olivier Berton, Ph.D. Contact Telephone 301-827-7771 Contact Email Olivier.bernton@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation.</p>				
114003	Notice of Special Interest (NOSI): Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	08-Dec-2024	Not Specified
	<p>Contact Name Sam Ananthan, Ph.D.</p> <p>Contact Telephone 301-435-2199</p> <p>Contact Email sam.ananthan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.</p>				
113995	Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-012	07-Jan-2025	Not Specified
	<p>Contact Name Tisha Wiley, Ph.D.</p> <p>Contact Telephone 301-594-4381</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email tisha.wiley@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026

Synopsis The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.

114048	Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	08-Dec-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name Sam Ananthan, Ph.D.

Contact Telephone 301-435-2199

Contact Email sam.ananthan@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026

Synopsis The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

127577	Notice of Special Interest (NOSI): Research on Illicit Drugs	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-26-008	12-Feb-2025	Not Specified
--------	--	---	---------------	-------------	---------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Elyse R. Grossman, Ph.D., JD, MPP</p> <p>Contact Telephone </p> <p>Contact Email elyse.grossman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research that examines illicit drug markets and informs prevention, intervention, treatment, and harm reduction efforts.</p>				
119295	Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-194	07-Jan-2025	100,000 USD
	<p>Contact Name Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email marsha.lopez@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
109484	Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Janet Kuramoto-Crawford, PhD			
	Contact Telephone	301-443-8856			
	Contact Email	janet.kuramoto-crawford@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	<p>This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).</p>			

109268	Notice of Special Interest (NOSI): Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	07-Jan-2025	Not Specified
--------	---	---	---------------	-------------	---------------

	Contact Name	Marsha Lopez, PhD, MHS			
	Contact Telephone	301-443-6504			
	Contact Email	Marsha.Lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	<p>The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	interactions.				
114150	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Jan-2025	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	240-281-0569			
	Contact Email	mandlerr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
114151	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Jan-2025	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	240-281-0569			
	Contact Email	mandlerr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
115450	Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A Jump Into Precision Medicine.	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-001	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Guifang Lao, Ph.D.</p> <p>Contact Telephone 301-827-5931</p> <p>Contact Email laog@nih.gov</p> <p>Sponsor Website </p> <p>Program URL </p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse..</p>				
117405	Notice of Special Interest (NOSI): Liveraging Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-006	07-Jan-2025	Not Specified
	<p>Contact Name Shang-Yi Anne Tsai, Ph.D.</p> <p>Contact Telephone 301-827-5842</p> <p>Contact Email stsai@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 [LOI/Pre-App], 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments.</p>				
127980	Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-24-299	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Will M. Aklin, Ph.D.</p> <p>Contact Telephone 301-827-5909</p> <p>Contact Email aklinwm@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 07-May-2025				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.			

127982	Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-24-300	17-Jan-2025 [Optional][LOI/Pre-App]	450,000 USD
--------	--	---	------------	-------------------------------------	-------------

Contact Name	Will M. Aklin, Ph.D.
Contact Telephone	301-827-5909
Contact Email	aklinwm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 17-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.</p>				
127451	<p>RFA-DA-26-008 -- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-008	12-Feb-2025 [Optional][LOI/Pre-App]	200,000 USD
	<p>Contact Name Sam Ananthan, PhD</p> <p>Contact Telephone 301-435-2199</p> <p>Contact Email sam.ananthan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mechanisms as potential therapeutic targets to address HIV-substance use disorder (SUD) comorbidity. This NOFO uses the R21 grant mechanism, while RFA-DA-26-007 uses the R01 mechanism. High risk high reward projects that lack preliminary data may be most appropriate for this NOFO. Applicants with preliminary data may wish to apply for the companion R01 NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

128091	RFA-DA-26-009 -- Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-009	10-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Kathleen Borgmann, Ph.D.
Contact Telephone	301-594-6561
Contact Email	Kahtleen.Borgmann@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Feb-2025 [Optional][LOI/Pre-App], 10-Mar-2025 , 10-Mar-2026
Synopsis	The purpose of this funding opportunity is to promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

128093	RFA-DA-26-010 --Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-010	10-Feb-2025 [Optional][LOI/Pre-App]	400,000 USD
--------	--	---	---------------	-------------------------------------	-------------

Contact Name	Kathleen Borgmann, Ph.D.
Contact Telephone	301-594-6561
Contact Email	Kahtleen.Borgmann@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Feb-2025 [Optional][LOI/Pre-App], 10-Mar-2025 , 10-Mar-2026
Synopsis	This notice of funding opportunity (NOFO) invites applications to investigate protective and pathogenic mechanisms at the

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>nexus of mitochondrial function and aging in the context of HIV infection, antiretroviral therapy (ART) and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use, and addiction. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
127436	RFA-DA-26-001 -- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional (R01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-001	19-Feb-2025 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name John Satterlee, Ph.D. Contact Telephone 301-435-1020 Contact Email satterleej@nida.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 19-Feb-2025 [Optional][LOI/Pre-App], 19-Mar-2025 , 19-Mar-2026 Synopsis The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
127437	RFA-DA-26-002 -- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-002	19-Feb-2025 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name John Satterlee, Ph.D. Contact Telephone 301-435-1020 Contact Email satterleej@nida.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 19-Feb-2025 [Optional][LOI/Pre-App], 19-Mar-2025 , 19-Mar-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
127285	<p>RFA-DA-25-024 -- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-024	12-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Richard A. Jenkins, Ph.D.</p> <p>301-443-1923</p> <p>jenkinsri@nida.nih.gov</p> <p></p> <p>Link to program URL</p> <p>12-Jan-2025 [Optional][LOI/Pre-App], 11-Feb-2025 , 14-Jul-2025 [Optional][LOI/Pre-App], 13-Aug-2025 , 12-Jan-2026 [Optional][LOI/Pre-App], 11-Feb-2026 , 14-Jul-2026 [Optional][LOI/Pre-App], 13-Aug-2026 , 12-Jan-2027 [Optional][LOI/Pre-App], 11-Feb-2027</p> <p>The purpose of this notice of funding opportunity (NOFO) is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. Applications submitted under this NOFO are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This initiative is open to both individual researchers and research teams. It addresses basic science, epidemiologic, clinical, intervention, and implementation research related to HIV in people with substance use and substance use disorders (SUDs). The proposed research areas must align with the NIH's HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			
123537	<p>RFA-DA-25-060 -- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-060	11-Feb-2025	7,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Vasundhara Varthakavi, DVM, PhD</p> <p>301-443-2146</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email vasundhara.varthakavi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025 , 15-Aug-2025 , 11-Feb-2026 , 14-Feb-2026 , 11-Feb-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of basic and clinical HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. This initiative is open only to research teams of three to six PD/PIs proposing to pursue challenging research questions at the intersection of HIV and substance use. Teams are encouraged to consider far-reaching objectives that will produce major advances in high priority HIV research areas for the institute and the NIH (NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding). This NOFO addresses basic science, epidemiologic, clinical, intervention, and implementation research related to HIV in people with substance use and substance use disorders (SUDs). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
127450	<p>RFA-DA-26-007 -- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-007	12-Feb-2025 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Sam Ananthan, PhD</p> <p>Contact Telephone 301-435-2199</p> <p>Contact Email sam.ananthan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorder (SUD) comorbidity. This NOFO uses the R01 grant mechanism, while RFA-DA-26-008 uses the R21 mechanism. Applicants with preliminary data may wish to apply to this R01 NOFO. High risk high reward projects that lack preliminary data may be most appropriate for the companion R21</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

127894	Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-24-297	16-Feb-2025	150,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Hoang Le, Ph.D.
Contact Telephone	301-451-8849
Contact Email	hoang.le@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028
Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.

121950	RFA-DA-25-068 --Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-068	13-Feb-2025 [Optional][LOI/Pre-App]	275,000 USD
--------	---	---	---------------	-------------------------------------	-------------

Contact Name	Shang-Yi Anne Tsai, PhD
Contact Telephone	301-827-5842
Contact Email	stsai@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	13-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025
Synopsis	The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This notice of funding opportunity (NOFO) addresses a crucial research gap regarding approaches to understanding and enhancing relationships individuals with a substance use disorder (SUD) have with their loved ones. Family, loved ones, and support persons play a critical role in the recovery process and are a critical element of the recovery capital of an individual with a SUD. This NOFO seeks phased (R61/R33) studies that address the role of support persons and loved ones in six focal areas: (1) developing interventions to enhance the well-being and coping skills among support persons; (2) enhancing knowledge of effective interventions for SUDs and reducing stigma, negative attitudes, and misconceptions among support persons; (3) testing enhancements to existing evidence-based interventions and practices to include engagement of support persons; (4) developing new interventions or adapting existing interventions to leverage support persons as lay interventionists; (5) developing and testing care navigation interventions and resources, particularly during care transitions; and (6) dyadic approaches to support engagement in evidence-based care when both parties have experienced or are experiencing a SUD. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128585	RFA-DA-26-019 -- Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods R41/R42 - Clinical Trials Optional	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-019	19-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Yordan Kostov, Ph.D. Contact Telephone 301-435-5650 Contact Email yordan.kostov@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 19-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage applications from Small Business Concerns (SBCs) to pursue the translation of target-agnostic technologies with sensitivity and selectivity similar to liquid chromatography-mass spectrometry (LC-MS). Applications received in response to this NOFO are expected to address development of such devices with significantly lower initial cost and low cost of operation compared with state of the art. Proposed research should be directed toward devices that require minimum training and consumables, allowing use at the point-of-need to detect and quantify existing and emergent drugs.</p>				
128584	RFA-DA-26-018 -- Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-018	19-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Yordan Kostov, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-5650</p> <p>Contact Email yordan.kostov@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage applications from Small Business Concerns (SBCs) to pursue the translation of target-agnostic technologies with sensitivity and selectivity similar to liquid chromatography-mass spectrometry (LC-MS). Applications received in response to this NOFO are expected to address development of such devices with significantly lower initial cost and low cost of operation compared with state of the art. Proposed research should be directed toward devices that require minimum training and consumables, allowing use at the point-of-need to detect and quantify existing and emergent drugs.</p>				
128881	RFA-DA-26-016 - Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-016	25-Jan-2025 [LOI/Pre-App]	400,000 USD
	<p>Contact Name Leonardo Angelone, PhD</p> <p>Contact Telephone 301-827-5946</p> <p>Contact Email leonardo.angelone@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2025 [LOI/Pre-App], 26-Feb-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the Food and Drug Administration (FDA) Center for Devices and Radiological Health) affected by substance use and addiction.</p>				
128882	RFA-DA-26-017 - Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-017	25-Jan-2025 [LOI/Pre-App]	400,000 USD
	<p>Contact Name Leonardo Angelone, PhD</p> <p>Contact Telephone 301-827-5946</p> <p>Contact Email leonardo.angelone@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2025 [LOI/Pre-App], 26-Feb-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) invites Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0–21 years old, as defined by the FDA Center for Devices and Radiological Health) affected by substance use and addiction.</p>				
125421	Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-110	07-Jan-2025	Not Specified
	<p>Contact Name Arielle S. Gillman, PhD, MPH</p> <p>Contact Telephone 301-435-0060</p> <p>Contact Email arielle.gillman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of this initiative is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce disparities for other health outcomes among populations that experience health disparities.</p>				
115679	NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23-111	07-Jan-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-402-1366</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.</p>				
127614	Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-273	05-Feb-2025	Not Specified
	<p>Contact Name Yewande Oladeinde, PhD</p> <p>Contact Telephone 301-402-4307</p> <p>Contact Email yewande.oladeinde@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.</p>				
120775	NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-229	06-Feb-2025	Not Specified
	<p>Contact Name Kimberly LeBlanc, Ph.D</p> <p>Contact Telephone 301-827-4102</p> <p>Contact Email kimberly.leblanc@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 06-Feb-2025 , 05-May-2025 , 07-Oct-2025 , 06-Feb-2026 , 05-May-2026</p> <p>Synopsis The Adolescent Brain Cognitive DevelopmentSM (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows investigators to apply for access to biological samples from the ABCD Study®. More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.</p>				
112756	<p>RFA-DA-23-054 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	RFA-DA-23-054	19-Feb-2025 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name Carrie Mulford, Ph.D.</p> <p>Contact Telephone 301827-6473</p> <p>Contact Email carrie.mulford@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025</p> <p>Synopsis The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This Funding Opportunity Announcement (FOA) solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of moving evidence-based and promising treatments into routine use. This FOA invites projects for which preliminary or feasibility data is available. This FOA is a companion to RFA-DA-23-053, which solicits applications for which pilot data is unavailable.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
112755	RFA-DA-23-053 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-23-053	19-Feb-2025 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Carrie Mulford, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301827-6473</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">carrie.mulford@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054 , which solicits applications for which pilot data is available.</p> </td> </tr> </table>					Contact Name	Carrie Mulford, Ph.D.	Contact Telephone	301827-6473	Contact Email	carrie.mulford@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025	Synopsis	<p>The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054 , which solicits applications for which pilot data is available.</p>
Contact Name	Carrie Mulford, Ph.D.																		
Contact Telephone	301827-6473																		
Contact Email	carrie.mulford@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	19-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025																		
Synopsis	<p>The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054 , which solicits applications for which pilot data is available.</p>																		
114369	Notice of Special Interest (NOSI): Administrative Supplements to Prepare Data Assets for Infectious and Immune-mediated Diseases for Inclusion into the NIAID Data Ecosystem	National Institutes of Health/DHHS	NOT-AI-23-009	13-Feb-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-761-7328</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">datascience-FOA@niaid.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">13-Feb-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for</p> </td> </tr> </table>					Contact Name		Contact Telephone	301-761-7328	Contact Email	datascience-FOA@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	13-Feb-2025	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for</p>
Contact Name																			
Contact Telephone	301-761-7328																		
Contact Email	datascience-FOA@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	13-Feb-2025																		
Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for</p>																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>infectious- and immune-mediated disease research for inclusion in the NIAID Data Ecosystem. Research may include studies that strive to generate a better understanding of mechanisms for the prevention, diagnosis, and treatment of infectious- and immune mediated diseases. Relevant data must already have been collected and applicants must demonstrate that the data assets have value to other researchers for studies of infectious- and immune-mediated disease. The supplemental funding will enable applicants to prepare their data assets for meeting technical specifications for inclusion in the NIAID Data Ecosystem. The proposed supplemental activities must be within the scope of the approved aims of the parent award.</p>				
121638	RFA-DA-25-047 -- Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-25-047	12-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Morris Flood, DHSc Contact Telephone 301-496-6144 Contact Email morris.flood@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025 , 12-Feb-2026 [Optional][LOI/Pre-App], 13-Mar-2026 Synopsis The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBCs) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder.</p>				
121634	RFA-DA-25-048 -- Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-25-048	12-Feb-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Morris Flood, DHSc Contact Telephone 301-496-6144 Contact Email morris.flood@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025 , 12-Feb-2026 [Optional][LOI/Pre-App], 13-Mar-2026 Synopsis The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder
112441	Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-210	05-Feb-2025	2,500,000 USD
	Contact Name	Liam O’Fallon			
	Contact Telephone	984-287-3298			
	Contact Email	ofallon@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS’ and NIMHD’s commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) “Partnerships for Environmental Public Health” (PEPH) network (https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm).</p>			
121565	Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-23-309	05-Feb-2025	Not Specified
	Contact Name	Sundania J. W. Wonnum, PhD, LCSW			
	Contact Telephone				
	Contact Email	sundania.wonnum@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.</p>				
122024	Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-059	05-Feb-2025	Not Specified
	<p>Contact Name Rada K. Dagher, PhD, MPH Contact Telephone 301-451-2187 Contact Email rada.dagher@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 Synopsis </p>				
114596	Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-23-067	16-Feb-2025	275,000 USD
	<p>Contact Name Sige Zou, PhD Contact Telephone 301-435-0749 Contact Email zous@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 Synopsis The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114700	RFA-NS-22-022 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-022	11-Feb-2025	Not Specified
	<p>Contact Name DP Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-023).</p>				
112444	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-207	12-Feb-2025	Not Specified
	<p>Contact Name Lori Ducharme, Ph.D.</p> <p>Contact Telephone 301-827-6331</p> <p>Contact Email Lori.Ducharme@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025</p> <p>Synopsis The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled clinician researchers with expertise in implementation science, who can help move these interventions into routine clinical practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world clinical settings, and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent clinician researchers with dual expertise in substance use and implementation science, limiting the field’s capacity to address persistent gaps in this area. There is a pressing need for a deeper bench of clinician researchers who can be called upon to meet ongoing and emerging implementation challenges in the substance use field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational clinical training in substance use prevention or treatment and/or co-occurring mental illness, and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to patient-oriented research in one or more of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.

112443	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-206	12-Feb-2025	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Lori Ducharme, Ph.D.
Contact Telephone	301-827-6331
Contact Email	Lori.Ducharme@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025
Synopsis	The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>Prevention and Treatment (K01) is to provide support and “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled researchers with expertise in implementation science, who can help move these interventions into routine practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world settings and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent researchers with dual expertise in addiction research and implementation science, constraining the field’s capacity to respond to continued calls for research in this area. There is a pressing need for a deeper bench of researchers who can be called upon to meet ongoing and emerging implementation challenges in the addiction field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to one of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>																		
112749	Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence	National Institutes of Health/DHHS	NOT-DA-23-007	12-Feb-2025	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%;">Contact Name</td> <td>Carrie Mulford</td> </tr> <tr> <td>Contact Telephone</td> <td>301-827-6473</td> </tr> <tr> <td>Contact Email</td> <td>Carrie.Mulford@nih.gov</td> </tr> <tr> <td>Sponsor Website</td> <td></td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>12-Feb-2025 , 12-Jun-2025</td> </tr> <tr> <td>Synopsis</td> <td>The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.</td> </tr> </table>					Contact Name	Carrie Mulford	Contact Telephone	301-827-6473	Contact Email	Carrie.Mulford@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025	Synopsis	The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.
Contact Name	Carrie Mulford																		
Contact Telephone	301-827-6473																		
Contact Email	Carrie.Mulford@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Feb-2025 , 12-Jun-2025																		
Synopsis	The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.																		
114710	RFA-NS-22-024 -- HEAL Initiative Advanced Postdoctoral-to-Independent	National Institutes of	RFA-NS-	11-Feb-2025	Not														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Basic Experimental Studies with Humans Required)	Health/DHHS	22-024		Specified
	<p>Contact Name DP Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
114711	RFA-NS-22-025 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-025	11-Feb-2025	Not Specified
	<p>Contact Name DP Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-024).</p>				
114707	<p>RFA-NS-22-023 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	RFA-NS-22-023	11-Feb-2025	Not Specified
	<p>Contact Name DP Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

117692	RFA-MH-23-331 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-23-331	13-Feb-2025	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>James Churchill, Ph.D.</p> <p>301-326-8800</p> <p>BRAINDIVERSITYK99R00@nih.gov</p> <p></p> <p>Link to program URL</p> <p>13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22-330).</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117690	RFA-MH-23-330 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-MH-23-330	13-Feb-2025	Not Specified
	<p>Contact Name James Churchill, Ph.D.</p> <p>Contact Telephone 301-326-8800</p> <p>Contact Email BRAINDIVERSITYK99R00@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).</p>				
107545	Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators	National Institutes of Health/DHHS	NOT-DC-22-001	07-Jan-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Bracie Watson, Jr., Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorder (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH https://grants.nih.gov/grants/new_investigators/index.htm#earlystage, to submit research applications that focus on OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.</p>				
107484	Notice of Special Interest (NOSI): The Functional Oral Microbiome	National Institutes of Health/DHHS	NOT-DE-21-015	07-Jan-2025	Not Specified
	<p>Contact Name Tamara McNealy, PhD.</p> <p>Contact Telephone 202-430-1474</p> <p>Contact Email tamara.mcnealy@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.</p>				
110034	Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings	National Institutes of Health/DHHS	NOT-MH-22-170	07-Jan-2025	Not Specified
	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.</p>				
111858	<p>Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities</p>	National Institutes of Health/DHHS	NOT-OD-22-154	07-Jan-2025	Not Specified
	<p>Contact Name Jennifer Alvidrez, PhD</p> <p>Contact Telephone 301-827-0071</p> <p>Contact Email Jennifer.alvidrez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.</p>				
114061	<p>Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior</p>	National Institutes of Health/DHHS	NOT-MH-23-110	07-Jan-2025	Not Specified
	<p>Contact Name Mauricio Rangel-Gomez, Ph.D.</p> <p>Contact Telephone 301-435-6908</p> <p>Contact Email mauricio.rangel-gomez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.

115289	Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services	National Institutes of Health/DHHS	NOT-MH-23-140	07-Jan-2025	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Stephen O'Connor, Ph.D. 301-480-8366 stephen.o'connor2@nih.gov Link to program URL 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women's Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.
--	---

115095	Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-073	07-Jan-2025	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	 AITraininghelpdesk@niaid.nih.gov Link to program URL 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
115062	Notice of Special Interest (NOSI): argeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases	National Institutes of Health/DHHS	NOT-DA-22-048	07-Jan-2025	Not Specified	
	Contact Name	Yu (Woody) Lin, PhD				
	Contact Telephone	301-435-1318				
	Contact Email	ylin1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 13-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 25-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026				
	Synopsis	<p>This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.</p>				
115307	Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research	National Institutes of Health/DHHS	NOT-HL-22-040	07-Jan-2025	Not Specified	
	Contact Name	Kristin M. Burns, MD				
	Contact Telephone	301-594-6859				
	Contact Email	kristin.burns@nih.gov				
	Sponsor Website					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere to the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.</p>				
121868	<p>Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	PAR-23-303	07-Jan-2025	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH, Director</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p>				
121869	<p>Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)</p>	National Institutes of Health/DHHS	PAR-23-304	07-Jan-2025	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH, Director</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p>				
122108	<p>RFA-AI-23-061 -- Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-AI-23-061	07-Jan-2025	5,450,000 USD
	<p>Contact Name Tania B. Lombo Rodriguez, Ph.D.</p> <p>Contact Telephone 301-761-7612</p> <p>Contact Email tania.lombo@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.</p>				
125230	<p>Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	PA-24-186	07-Jan-2025	Not Specified
	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email grantinfo@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
125228	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-185	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-184).				
125227	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-184	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-185).</p>				
127139	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-226	07-Jan-2025	Not Specified
	<p>Contact Name Lanay M. Mudd, Ph.D., FACS</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email lanay.mudd@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108898	<p>Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services</p>	National Institutes of Health/DHHS	NOT-MH-22-110	07-Jan-2025	Not Specified

Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH’s efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutions to apply to companion NOFO PAR-24-225.

Contact Name Stephen O'Connor, Ph.D.
Contact Telephone 301-480-8366
Contact Email stephen.o'connor2@nih.gov
Sponsor Website
Program URL [Link to program URL](#)
Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025

Synopsis The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.

108571	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	05-Feb-2025	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Anthony Agresti
Contact Telephone	301-827-8014
Contact Email	agrestia@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025
Synopsis	This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.

111616	Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project	National Institutes of Health/DHHS	NOT-OD-22-123	07-Jan-2025	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Charlene Schramm, PhD
Contact Telephone	301-402-3739
Contact Email	schrammc@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).					
116310	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	05-Feb-2025	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email agrestia@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
116616	Notice of Special Interest (NOSI): Research Project Grants in Valvular Heart Disease (CAROL Act)	National Institutes of Health/DHHS	NOT-HL-23-079	07-Jan-2025	Not Specified
	<p>Contact Name Frank Evans, PhD</p> <p>Contact Telephone 301-435-0510</p> <p>Contact Email evansf@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.</p>				
120821	RFA-HD-24-007 -- Understanding and Mitigating Health Disparities	National Institutes of	RFA-HD-	07-Jan-2025	2,499,995

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	Experienced by People with Disabilities Caused by Ableism (R01 Clinical Trial Optional)	Health/DHHS	24-007		USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Toyin Ajisafe, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-9242</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>toyin.ajisafe@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.</td> </tr> </table>					Contact Name	Toyin Ajisafe, PhD	Contact Telephone	301-827-9242	Contact Email	toyin.ajisafe@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.
Contact Name	Toyin Ajisafe, PhD																		
Contact Telephone	301-827-9242																		
Contact Email	toyin.ajisafe@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.																		
122946	Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-092	07-Jan-2025	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ann Namkung, MPH</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-6838</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ann.namkung@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR) as described in NOT-OD-20-018.</td> </tr> </table>					Contact Name	Ann Namkung, MPH	Contact Telephone	301-496-6838	Contact Email	ann.namkung@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027	Synopsis	This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR) as described in NOT-OD-20-018.
Contact Name	Ann Namkung, MPH																		
Contact Telephone	301-496-6838																		
Contact Email	ann.namkung@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027																		
Synopsis	This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR) as described in NOT-OD-20-018.																		
122945	Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-091	07-Jan-2025	Not Specified														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122756	Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-24-077	07-Jan-2025	2,500,000 USD

Contact Name	Ann Namkung, MPH
Contact Telephone	301-496-6838
Contact Email	ann.namkung@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027
Synopsis	This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR), as described in NOT-OD-20-018.

Contact Name	Rada K. Dagher, Ph.D., M.P.H.
Contact Telephone	301-451-2187
Contact Email	ada.dagher@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and intervention-based research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accept nonclinical trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH’s Approach to Mental Health Disparities Research. Clinical trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involving

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| human research participants will collect a minimum set of Common Data Elements.

123347	Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-060	07-Jan-2025	450,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Amy B. Goldstein, PhD
Contact Telephone	301-827-4124
Contact Email	amy.goldstein@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this NOFO include a reduction in negative sequelae of use, such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.

125485	Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-192	07-Jan-2025	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125482	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-190	07-Jan-2025	Not Specified

Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-191).				
125483	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-191	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-192).</p>				
125516	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-183	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125512	Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-181	07-Jan-2025	Not Specified

Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Contact Name

Contact Telephone 301-496-8580

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125527	Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-177	07-Jan-2025	Not Specified

Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-182).

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>					
125513	Mentored Clinical Scientist Research Career Development Award (Parent K08 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-182	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-181).</p>				
125524	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-175	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-176).</p>				
125526	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-176	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-175).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
106925	Notice of Special Interest (NOSI): Promoting Research To Understand Vascular Contributions to Cognitive Impairment and Dementia (VCID)	National Institutes of Health/DHHS	NOT-HL-23-002	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Jue Chen, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-0550</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">jue.chen@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.</td> </tr> </table>					Contact Name	Jue Chen, Ph.D.	Contact Telephone	301-435-0550	Contact Email	jue.chen@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.
Contact Name	Jue Chen, Ph.D.																		
Contact Telephone	301-435-0550																		
Contact Email	jue.chen@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.																		
107841	Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-358	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Deborah E. Linares, PhD, MA</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-402-2516</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">Deborah.Linares@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.</td> </tr> </table>					Contact Name	Deborah E. Linares, PhD, MA	Contact Telephone	301-402-2516	Contact Email	Deborah.Linares@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.
Contact Name	Deborah E. Linares, PhD, MA																		
Contact Telephone	301-402-2516																		
Contact Email	Deborah.Linares@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.																		
108065	Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection	National Institutes of Health/DHHS	NOT-HL-22-004	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"></td> </tr> </table>					Contact Name		Contact Telephone		Contact Email									
Contact Name																			
Contact Telephone																			
Contact Email																			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.</p>				
109181	Notice of Special Interest (NOSI): Public Health Research on Cannabis	National Institutes of Health/DHHS	NOT-DA-22-003	07-Jan-2025	Not Specified
	<p>Contact Name Marsha Lopez, PhD</p> <p>Contact Telephone (301) 402-1846</p> <p>Contact Email (301) 402-1846</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.</p>				
110112	Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-145	07-Jan-2025	Not Specified
	<p>Contact Name Yewande A. Oladeinde, Ph.D.</p> <p>Contact Telephone 301-402-4307</p> <p>Contact Email beda.jean-francois@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110996	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-160	07-Jan-2025	100,000 USD
	<p>Contact Name Gila Neta, PhD</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email Gila.Neta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
110794	Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)	National Institutes of Health/DHHS	NOT-AI-22-042	07-Jan-2025	Not Specified
	<p>Contact Name Marina Protopopova, Ph.D.</p> <p>Contact Telephone 301-761-7653</p> <p>Contact Email marina.protopopova@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110513	Notice of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior	National Institutes of Health/DHHS	NOT-DA-23-004	07-Jan-2025	Not Specified
	<p>Contact Name Jonathan D. Pollock, Ph.D.</p> <p>Contact Telephone 301-435-1309</p> <p>Contact Email jpollock@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).</p>				
110813	Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection	National Institutes of Health/DHHS	NOT-AI-22-043	05-Jan-2025	Not Specified
	<p>Contact Name Chris Lambros, PhD</p> <p>Contact Telephone 240-627-3093</p> <p>Contact Email clambros@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025</p> <p>Synopsis The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics.</p>				
112346	Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM)	National Institutes of Health/DHHS	NOT-MD-22-012	07-Jan-2025	Not Specified
	<p>Contact Name Crystal L. Barksdale, PhD MPH</p> <p>Contact Telephone 301-827-4228</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email crystal.barksdale@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025</p> <p>Synopsis This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.</p>				
112420	Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan	National Institutes of Health/DHHS	NOT-OD-22-178	07-Jan-2025	Not Specified
	<p>Contact Name Melissa C. Green Parker, PhD</p> <p>Contact Telephone 301-480-1161</p> <p>Contact Email melissa.greenparker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.</p>				
112421	Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening	National Institutes of Health/DHHS	NOT-OD-22-179	07-Jan-2025	Not Specified
	<p>Contact Name Melissa C. Green Parker, PhD</p> <p>Contact Telephone 301-480-1161</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email melissa.greenparker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.</p>				
112791	<p>Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	NOT-OD-22-142	07-Jan-2025	Not Specified
	<p>Contact Name Sujata Bardhan, Ph.D.</p> <p>Contact Telephone 301-435-0471</p> <p>Contact Email sujata.bardhan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 16-Feb-2025</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project.</p>				
112471	<p>Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis</p>	National Institutes of Health/DHHS	NOT-DE-22-003	07-Jan-2025	Not Specified
	<p>Contact Name Kathryn Stein, PhD</p> <p>Contact Telephone 301-827-4653</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput 'omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo.</p>				
112267	Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss	National Institutes of Health/DHHS	NOT-HD-22-026	07-Jan-2025	Not Specified
	<p>Contact Name Clara Cheng, PhD</p> <p>Contact Telephone 301-435-6992</p> <p>Contact Email clara.cheng@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic EPL and recurrent pregnancy loss.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
114402	Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-037	07-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Robert Tamburro, MD, MSc</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-480-2619</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>NICHD-Network-ClinicalResearch@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.</td> </tr> </table>					Contact Name	Robert Tamburro, MD, MSc	Contact Telephone	301-480-2619	Contact Email	NICHD-Network-ClinicalResearch@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026	Synopsis	The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.
Contact Name	Robert Tamburro, MD, MSc																		
Contact Telephone	301-480-2619																		
Contact Email	NICHD-Network-ClinicalResearch@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.																		
114367	Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics	National Institutes of Health/DHHS	NOT-AI-23-001	05-Jan-2025	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Julie Dyall, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-631-7296</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>dyallj@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-</td> </tr> </table>					Contact Name	Julie Dyall, PhD	Contact Telephone	301-631-7296	Contact Email	dyallj@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-		
Contact Name	Julie Dyall, PhD																		
Contact Telephone	301-631-7296																		
Contact Email	dyallj@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis	<p>2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections.</p>
----------	---

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

121337	NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-275	07-Jan-2025	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Diane Adger-Johnson, MPH
Contact Telephone	240-669-2924
Contact Email	Altraininghelpdesk@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025

Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.</p>
----------	---

124219	Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-109	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	------------	--	---------------

Contact Name	Carolina Solis-Sanabria, MD, MPH, FACS
Contact Telephone	301-827-3460
Contact Email	carolina.solissanabria@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 06-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027 , 05-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on healthcare systems serving populations that experience health disparities living in the U.S. and its territories.</p>				
125538	NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-195	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.				
125534	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-193	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-194).</p>				
125537	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-194	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-193).</p>			
125559	<p>Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	PA-24-189	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>grantinfo@nih.gov</p> <p>Link to program URL</p> <p>07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125557	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-187	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-188).</p>				
125583	Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-180	07-Jan-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125530	<p>Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)</p>	National Institutes of Health/DHHS	PA-24-178	07-Jan-2025	Not Specified

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Contact Name

Contact Telephone

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>				

125558	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-188	07-Jan-2025	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>grantinfo@nih.gov</p> <p>Link to program URL</p> <p>07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or</p>
---	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-187).

125532	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-179	07-Jan-2025	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p>	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by another investigator. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-178). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>
--	---

122410	Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-24-062	13-Dec-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Amy B. Goldstein, PhD</p> <p>301-827-4124</p> <p>amy.goldstein@nih.gov</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Dec-2024 , 14-Feb-2025 , 17-Mar-2025 , 13-Jun-2025 , 14-Aug-2025 , 10-Oct-2025 , 15-Dec-2025 , 13-Feb-2026 , 16-Mar-2026 , 15-Jun-2026 , 14-Aug-2026 , 14-Oct-2026 , 14-Dec-2026</p> <p>Synopsis The purpose of this notice of this funding opportunity (NOFO) is to support translational research across epidemiology, addiction services, and prevention to, ultimately, reduce the burden of substance use on public health. This NOFO encourages research that facilitates rapid translation from one discipline to another (e.g., epidemiology to prevention); supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study. The goal is to support translational research improving our ability to 1) identify and characterize malleable individual, familial, behavioral, developmental, and socio-cultural/environmental factors (within the population or precise subgroups) with the potential for multi-directional transfer of knowledge; 2) prevent initiation of substance use or progression to misuse or use disorder; and 3) maximize the efficient delivery of high-quality, personalized addiction treatment and related services to ultimately inform and facilitate real world responses designed to reduce the burden of substance use, misuse and/or addiction on the health of the population. This NOFO invites projects for which preliminary feasibility or pilot data are not available. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				

117793	Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities (R01, Clinical Trial Required)	National Institutes of Health/DHHS	PAR-25-098	05-Feb-2025	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	Contact Name	JoyAnn Courtney, Ph.D.			
	Contact Telephone	301-402-3911			
	Contact Email	joyann.courtney@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027			
	Synopsis	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>(ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.</p>				
111545	FCO -- AMENDMENT -- Research Opportunity Announcement (ROA): NIH All of Us Engagement, Communications, and Enrollment Partnerships	National Institutes of Health/DHHS	OTA-22-006	29-Nov-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	All of Us ROA Inquiries AOU-ROA@nih.gov Link to program URL 29-Nov-2024 , 28-Feb-2025 , 23-May-2025			
	Synopsis	Research Opportunity Announcement (ROA) Title: All of Us Engagement, Communications, and Enrollment Partnerships ROA Number: OTA-22-006 ROA Open Period: May 26, 2022 to May 23, 2025 (Note: open period includes multiple white paper deadlines) Overview: The All of Us Research Program, within the Office of the Director (OD) at the National Institutes of Health (NIH), has issued a research opportunity announcement to solicit white papers supporting various Areas of Interest (AOIs). A ROA is a method of solicitation that announces the anticipated availability of Other Transactions (OT) awards, a special type of legal instrument other than contracts, grants, or cooperative agreements. Purpose: The All of Us Research Program is a historic effort to gather data from at least 1 million people, with the goal of accelerating health research and medical breakthroughs, and enabling individualized prevention, treatment, and care. The program is creating a national research resource to inform thousands of studies, covering a wide variety of health conditions. Researchers will use data from the program to learn more about how individual differences in lifestyle, environment, and biological makeup can influence health and disease. The purpose of this announcement is to fund organizations who can help All of Us build its cohort of volunteers who reflect the rich diversity of the United States and are actively engaged as partners. These funded organizations will help design and implement strategies to raise awareness of the program through community and health care provider organizations, drive increased enrollment of participants, foster regular communication with participants, and			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

engage the research community to use the data being gathered. Award Project Duration: Award periods are anticipated to be up to five (5) years but may be shortened or extended as needed. Pre-Submission Webinar: A webinar will be conducted on June 27, 2022 at [Time TBD]. Registration information will be posted here once it is available. White Paper Deadlines: This ROA will remain open for three (3) years from its issue date, unless otherwise updated via an amendment, and includes multiple white paper (WP) submission deadlines. All WP deadline times are 3:00 PM Eastern Time: Calendar Year 2022 WP Deadlines August 31, 2022 November 30, 2022 Calendar Year 2023 WP Deadlines February 28, 2023 May 31, 2023 August 31, 2023 November 30, 2023 Calendar Year 2024 WP Deadlines February 29, 2024 May 31, 2024 August 30, 2024 November 29, 2024 Calendar Year 2025 WP Deadlines February 28, 2025 May 23, 2025 Documents and Related Links: The full ROA package is attached in the 'Attachments/Links' section. Potential offerors are encouraged to carefully review the announcement before submitting questions and/or preparing a white paper submission. A link to the All of Us Research Program webpage has been provided for additional information about our program.

127967	RFA-MH-25-200 -- Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MH-25-200	03-Jan-2025 [Optional][LOI/Pre-App]	4,000,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	03-Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025

Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit Program Project (P01) applications from scientific hubs to support learning health care research in clinics offering evidence-based Coordinated Specialty Care (CSC) to persons in the early stages of psychotic illness. For this NOFO, "early psychosis" is defined as the period spanning the onset of an affective or non-affective psychotic disorder and up to 5 years following the first episode of psychosis. Each scientific hub will link multiple early psychosis service programs through (1) the EPINET Core Assessment Battery (CAB) of early psychosis clinical features, CSC services, and treatment outcomes; (2) informatics tools to collect de-identified, person-level data across sites; and (3) a unified approach for analyzing pooled data and disseminating promising findings rapidly across the network. In this re-issued NOFO, the National Institute of Mental Health (NIMH) encourages applications from new and existing scientific hubs, including those that partner with state mental health authorities on the implementation, sustainment, and continuous improvement of CSC programs in state-supported health systems. The P01 activity code supports research that has multiple distinct but complementary and/or synergistic projects built around a clearly defined unifying central theme or well-defined

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	overall objective.				
110969	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-144	24-Feb-2025	Not Specified
	<p>Contact Name Linda Brady, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email lbrady@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2025</p> <p>Synopsis </p>	<p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-143). This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>			
110968	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical	National Institutes of Health/DHHS	PAR-22-143	24-Feb-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Trial Optional)					
	<p>Contact Name Linda Brady, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email lbrady@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2025</p> <p>Synopsis </p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-144) This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
122207	Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-293	20-Feb-2025	Not Specified
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026

Synopsis

This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

122256	Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-294	20-Feb-2025	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name Dave Kaufman

Contact Telephone 301-402-4997

Contact Email dave.kaufman@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>				
122258	Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-295	20-Feb-2025	100,000 USD
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>				
114675	Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA)	National Institutes of Health/DHHS	NOT-GM-23-015	08-Dec-2024	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 05-Apr-2025 , 12-Apr-2025 , 07-May-2025 , 16-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 08-Aug-2025 , 05-Sep-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 08-Dec-2025 Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.				
128338	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-059	18-Feb-2025	750,000 USD
	Contact Name Becky Roof, PhD Contact Telephone 301-496-1779 Contact Email rebecca.roof@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 18-Feb-2025 , 18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027 Synopsis This Notice of Funding Opportunity (NOFO) encourages research grant applications to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE). This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				
114377	Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)	National Institutes of Health/DHHS	NOT-AI-23-013	05-Jan-2025	Not Specified
	Contact Name Samuel Perdue, Ph.D. Contact Telephone 240-627-3341 Contact Email sperdue@nih.gov				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines, vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.</p>				
113804	<p>Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest</p>	National Institutes of Health/DHHS	NOT-HD-22-038	07-Jan-2025	Not Specified
	<p>Contact Name Elyse R. Grossman</p> <p>Contact Telephone 240-551-3628</p> <p>Contact Email elyse.grossman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see https://nida.nih.gov/about-nida/strategic-plan/nidas-mission.</p>				
112904	Notice of Special Interest (NOSI): Research on the Health of Bisexual and Bisexual+ People	National Institutes of Health/DHHS	NOT-OD-22-166	07-Jan-2025	Not Specified
	<p>Contact Name Christopher Barnhart, PhD Contact Telephone 301-594-8983 Contact Email christopher.barnhart@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 Synopsis This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.</p>				
112325	Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes	National Institutes of Health/DHHS	NOT-OD-22-167	07-Jan-2025	Not Specified
	<p>Contact Name Dara R. Blachman, Ph.D. Contact Telephone 301-496-8522 Contact Email Dara.blachman-demner@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.</p>				
126793	<p>NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH) Required)</p>	National Institutes of Health/DHHS	PAR-24-218	12-Feb-2025	Not Specified
	<p>Contact Name Laura D. Wandner</p> <p>Contact Telephone</p> <p>Contact Email Laura.Wandner@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p> <p>Synopsis The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial basic experimental study with humans led by another investigator, must apply to the Independent Clinical Trial Not Allowed companion NOFO.

128589	FCO--2026 NIAID DMID Omnibus Broad Agency Announcement	National Institutes of Health/DHHS	HHS-NIH-NIAID-BAA2025-1	21-Feb-2025	Not Specified
--------	--	------------------------------------	-------------------------	-------------	---------------

Contact Name | Swee L. Teo
 Contact Telephone | 2406695173
 Contact Email | teosl@niaid.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 21-Feb-2025

Synopsis

Introduction: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the National Institutes of Health, an agency within the Department of Health and Human Services (DHHS), conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical countermeasures (MCMs) against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. The Research Areas included in this NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2025-1, as well as the projected amounts of available funding, are discussed below. Dates for receipt of proposals will be identified separately for EACH Research Area within the solicitation. Description: Research Area 001 – Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for Antimicrobial-Resistant (AMR) Bacterial or Fungal Pathogens For Research Area 001, there are three (3) separate Topics – A, B, and C. Offerors may submit a proposal in response to Topics A, B, and/or C. If proposing to multiple Topics, Offerors must submit separate technical and business proposals for each Topic. Topic A: Therapeutics for AMR Bacterial or Fungal Pathogens The objective of Topic A is to develop new therapeutic products against severe infections and/or drug-resistant strains of the following bacterial and fungal pathogens: a. Pseudomonas aeruginosa, and/or Acinetobacter baumannii; OR b. Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales. For the purpose of this Topic, “therapeutic” activity refers to the cure of disease, by elimination or substantial reduction of infective pathogens, by

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	administration of a pharmaceutical agent after symptoms of disease are clinically observable. An antimicrobial therapeutic candidate refers to an advanced lead series, optimized leads, or product candidate, that is a new chemical entity and either a small molecule (e.g., natural products, nucleosides, or peptides of				
128630	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-227	06-Jan-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Melissa Parisi, MD, PhD</p> <p>Contact Telephone 301-435-6880</p> <p>Contact Email parisima@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jan-2025 [Optional][LOI/Pre-App], 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 06-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages applications that will expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening. Characterization of the sequence and timing of symptom development provides information crucial for developing targeted, age-appropriate treatments and for establishing a baseline against which to assess novel interventions. In addition, for some conditions, establishment of genotype-phenotype correlations may facilitate prediction of the clinical course; for others, identification of modifying genetic, epigenetic, or environmental factors may enhance understanding of clinical outcomes. Comprehensive data on the natural history of a condition will facilitate the field's ability to: 1) identify the underlying biological mechanisms; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the condition; 3) improve diagnostic accuracy; 4) facilitate clinical trials by providing comprehensive natural history data; 5) prevent, manage, and treat symptoms and complications of the condition; 6) furnish physicians and families with needed support and predictive information about the condition; and 7) establish data collection systems or patient registries to collect longitudinal data (e.g., child/family outcomes following newborn screening).</p>				
120817	Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-221	05-Feb-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David Berrigan</p> <p>Contact Telephone 240-276-6752</p> <p>Contact Email berrigad@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.</p>				
114765	Notice of Special Interest (NOSI): Firearm Injury and Mortality Prevention Research	National Institutes of Health/DHHS	NOT-OD-23-039	07-Jan-2025	Not Specified
	<p>Contact Name Dara R. Blachman, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email Dara.blachman-demner@nih.gov</p> <p>Sponsor Website </p> <p>Program URL </p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</p> <p>Synopsis The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.</p>				
117360	Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and	National Institutes of	NOT-MD-23-	05-Feb-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Implementation among Populations Experiencing Health Disparities	Health/DHHS	008		Specified
	<p>Contact Name Deborah E. Linares, Ph.D., M.A.</p> <p>Contact Telephone 301-402-2516</p> <p>Contact Email deborah.linares@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.</p>				
128846	Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-220	03-Feb-2025	275,000 USD
	<p>Contact Name Holly Storkel, PhD, CCC-SLP</p> <p>Contact Telephone 301-451-6842</p> <p>Contact Email holly.storkel@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025 , 02-Jun-2025 , 02-Oct-2025</p> <p>Synopsis The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

better understand early language learning and delay. NIH TALK invites applications for research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequelae. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones, for any reason. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

111641	Notice of Special Interest (NOSI): Climate Change and Health	National Institutes of Health/DHHS	NOT-ES-22-006	08-Dec-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Claudia L. Thompson 984-287-3330 thompso1@niehs.nih.gov Link to program URL 08-Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 19-Feb-2025 , 08-Apr-2025 , 07-May-2025 The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.
--	--

110353	Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-186	28-Feb-2025	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone	Tram Kim Lam, Ph.D., MPH 240-276-6970
-----------------------------------	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email lamt@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p> <p>Synopsis Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts” PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement.</p>				
114589	<p>Notice of Special Interest (NOSI): Research to Address ‘Ending the HIV Epidemic’ Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV</p>	National Institutes of Health/DHHS	NOT-DA-23-013	07-Jan-2025	Not Specified
	<p>Contact Name Vasundhara Varthakavi, PhD</p> <p>Contact Telephone 301-443-2146</p> <p>Contact Email vasundhara.varthakavi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 21-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Oct-2027</p> <p>Synopsis The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the ‘Ending the HIV Epidemic in the U.S. (EHE)’ initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.</p>				
120102	<p>Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-25-066	16-Feb-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Jovier Evans, Ph.D.</p> <p>Contact Telephone 301-443-6328</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion announcement PAR-25-067 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism.</p>				
120101	Social Disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-067	02-Feb-2025	Not Specified
	<p>Contact Name Jovier Evans, Ph.D.</p> <p>Contact Telephone 301-443-6328</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-25-066 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.</p>				
121564	Developing Novel Theory and Methods for Understanding the Genetic	National Institutes of	PAR-25-256	16-Feb-2025	275,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)	Health/DHHS			USD
	<p>Contact Name Alexander Arguello, Ph.D.</p> <p>Contact Telephone 240-731-3753</p> <p>Contact Email alexander.arguello@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.</p>				
120393	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-25-096	16-Feb-2025	400,000 USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128847	Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-217	03-Feb-2025	275,000 USD
	<p>Contact Name Holly Storkel, PhD, CCC-SLP</p> <p>Contact Telephone 301-451-6842</p> <p>Contact Email holly.storkel@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025 , 02-Jun-2025 , 02-Oct-2025</p> <p>Synopsis The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones, for any reason. Community engaged research combined with rigorous qualitative research and diverse research teams are needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children. This Notice of Funding Opportunity (NOFO) requires a Community Engagement Plan (CEP).</p>				
116476	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-110	05-Feb-2025	Not Specified
	<p>Contact Name Katie M. Vance, Ph.D.</p> <p>Contact Telephone 301-435-6640</p> <p>Contact Email Katie.Vance@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.
116487	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-111	16-Feb-2025	275,000 USD
	Contact Name	Katie M. Vance, Ph.D.			
	Contact Telephone	301-435-6640			
	Contact Email	Katie.Vance@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.			
128814	Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-229	16-Feb-2025	275,000 USD
	Contact Name	Daniel Gilchrist, Ph.D.			
	Contact Telephone				
	Contact Email	daniel.gilchrist@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2025 , 16-Jun-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Feb-2027 , 16-Jun-2027			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.			
128812	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-228	05-Feb-2025	2,500,000 USD
	Contact Name	Jean Gao, Ph.D.			
	Contact Telephone				
	Contact Email	jean.gao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2025 , 05-Jun-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Feb-2027 , 05-Jun-2027			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.			
122379	RFA-HG-25-003 -- Advancing Genomic Medicine Research (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-HG-25-003	11-Feb-2025	750,000 USD
	Contact Name	Christine Chang, MPH			
	Contact Telephone	240-552-1208			
	Contact Email	changcq@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Feb-2025			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This NOFO solicits proposals that stimulate innovation and advance understanding of when, where, and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons irrespective of racial/ethnic background or socioeconomic status.			
114250	Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-022	07-Jan-2025	400,000 USD
	Contact Name	Randy King, Ph.D.			
	Contact Telephone	301-451-0707			
	Contact Email	Randy.King@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-2025 , 07-Jan-2026			
	Synopsis	This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.			
120387	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-095	05-Feb-2025	1,750,000 USD
	Contact Name	Melissa Rotunno, Ph.D.			
	Contact Telephone	240-276-7245			
	Contact Email	rotunnom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
120869	<p>Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations That Experience Health Disparities (R01, Clinical Trial Required)</p>	National Institutes of Health/DHHS	PAR-26-001	05-Feb-2025	Not Specified
	<p>Contact Name Denise Stredrick, Ph.D.</p> <p>Contact Telephone 301-402-9749</p> <p>Contact Email denise.stredrick@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within.</p>				
118583	<p>NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)</p>	National Library of Medicine/NIH/DHHS	PAR-23-183	26-Feb-2025	160,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Yanli Wang, Ph.D.</p> <p>Contact Telephone 301-827-7092</p> <p>Contact Email yanli.wang@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2025 , 26-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.</p>				
113609	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-23-034	07-Jan-2025	1,000,000 USD
	<p>Contact Name Meryl Sufian, PhD</p> <p>Contact Telephone 301-496-4671</p> <p>Contact Email sufianm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.</p>				
115310	Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data	National Library of Medicine/NIH/DHHS	NOT-LM-23-001	07-Jan-2025	Not Specified
	<p>Contact Name Meryl Sufian, PhD</p> <p>Contact Telephone 301-496-4671</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sufianm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets.</p>				
120715	<p>Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)</p>	National Library of Medicine/NIH/DHHS	PAR-25-235	05-Feb-2025	1,000,000 USD
	<p>Contact Name Allison Dennis, PhD</p> <p>Contact Telephone 301-827-9721</p> <p>Contact Email allison.dennis@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.</p>				
113926	<p>Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)</p>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-076	05-Feb-2025	Not Specified
	<p>Contact Name Sige Zou, Ph.D.</p> <p>Contact Telephone 301-435-0749</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email zous@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP's NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.</p>				
128808	<p>Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed)</p>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-176	16-Feb-2025	150,000 USD
	<p>Contact Name Stephanie Murphy, VMD, PhD</p> <p>Contact Telephone 301-451-7818</p> <p>Contact Email stephanie.murphy@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The Office of Research Infrastructure Programs (ORIP) within the Division of Program Coordination, Planning, and Strategic Initiatives announces an opportunity to apply for small grant support for ORIP-supported Special Emphasis Research Career Award (SERCA) K01 recipients who have completed the first two years (24 months) of the SERCA K01 award. ORIP seeks to enhance the ability of ORIP SERCA K01 recipients to conduct research as they transition to fully independent investigator status. The R03 mechanism supports projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support research projects that can realistically be completed in two years and that require limited levels of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| funding. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

128780	Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-273	16-Feb-2025	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Sige Zou, Ph.D.
Contact Telephone	301-435-0749
Contact Email	sige.zou@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028
Synopsis	This notice of funding opportunity (NOFO) encourages innovative research to develop, improve, characterize, and preserve animal models as well as animal model related biological materials, technologies, and new approach methodologies (NAMs) for studies relevant to human health and disease. This NOFO also seeks projects aimed at improving the diagnosis and control of diseases that could confound or interfere with animal use in biomedical research. The proposed project must have broad applicability to multiple NIH Institutes or Centers (ICs) to align with the NIH-wide mission of the Office of Research Infrastructure Programs (ORIP). The proposed studies must include animal models and explore multiple body systems or multiple categories of diseases. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this NOFO and will be withdrawn.

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128671	Designing Materials to Revolutionize and Engineer our Future	National Science Foundation	25-508	04-Feb-2025	2,000,000 USD
	<p>Contact Name John Schlueter</p> <p>Contact Telephone 703-292-7766</p> <p>Contact Email jschluet@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2025</p> <p>Synopsis DMREF seeks to foster the design, discovery, and development of materials to accelerate their path to deployment by harnessing the power of data and computational tools in concert with experiment and theory. DMREF emphasizes a deep integration of experiments, computation, and theory; the use of accessible digital data across the materials development continuum; and strengthening connections among theorists, computational scientists, data scientists, mathematicians, statisticians, and experimentalists as well as those from academia, industry, and government. DMREF is committed to the education and training of a next-generation materials research and development (R&D) workforce; well-equipped for successful careers as educators and innovators; and able to take full advantage of the materials development continuum and innovation infrastructures that NSF is creating through partnership with other federal and international agencies.</p>				
124484	Artificial Intelligence, Formal Methods, and Mathematical Reasoning	National Science Foundation	24-554	05-Feb-2025	1,200,000 USD
	<p>Contact Name Tomek Bartoszynski</p> <p>Contact Telephone 703-292-4885</p> <p>Contact Email tbartosz@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Feb-2026</p> <p>Synopsis The Artificial Intelligence, Formal Methods, and Mathematical Reasoning (AIMing) program seeks to support research at the interface of innovative computational and artificial intelligence (AI) technologies and new strategies/technologies in mathematical reasoning to automate knowledge discovery. Mathematical reasoning is a central ability of human intelligence that plays an important role in knowledge discovery. In the last decades, both the mathematics and computer science</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>communities have contributed to research in machine-assisted mathematical reasoning, encompassing conjecture, proof, and verification. This has been in the form of both formal methods and interactive theorem provers, as well as using techniques from artificial intelligence. Recent technological advances have led to a surge of interest in machine-assisted mathematical reasoning from the mathematical sciences, formal methods, and AI communities. In turn, advances in this field have potential impact on research in AI.</p>			
127609	Quantum Leap Challenge Institutes	National Science Foundation	24-599	07-Feb-2025 [LOI/Pre-App]	45,000,000 USD
	Contact Name	Peter S. Atherton			
	Contact Telephone	703-292-8772			
	Contact Email	patherto@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2025 [LOI/Pre-App], 07-Mar-2025 [LOI/Pre-App], 17-Sep-2025			
	Synopsis	<p>Quantum Leap Challenge Institutes are large-scale interdisciplinary research projects motivated by major challenges at the frontiers of quantum information science and technology (QIST). Institutes are expected to catalyze breakthroughs on important problems underpinning QIST, for example in the focus areas of quantum computation, quantum communication, quantum simulation and/or quantum sensing. Successful institutes will coordinate a variety of approaches to specific scientific, technological, and educational goals in these fields, including multiple institutions and building upon multiple disciplines, as motivated by the science and engineering challenges. In so doing, Institutes will nurture a culture of discovery, provide education, training, and workforce development opportunities in the context of cutting-edge research, and demonstrate value-added from synergistic coordination within the institute and with the broader community. Partnerships, infrastructure, industry engagement, outreach, international collaboration, and new applications for QIST should be fostered by Institutes in support of their research, education, and coordination goals. The QLCI program can support awards to continue existing Quantum Leap Challenge Institutes or to establish and operate new Quantum Leap Challenge Institutes. In either case, proposers should follow the same guidance for Challenge Institute proposal preparation described in this solicitation. While this is a crosscutting program, proposals responding to this solicitation must be submitted to the Office of Strategic Initiatives (OSI) in the Directorate of Mathematical and Physical Sciences (MPS). They will subsequently be managed by a cross-disciplinary team of NSF Program Directors.</p>			
123809	Civic Innovation Challenge	National Science Foundation	24-534	10-Feb-2025	Not Specified

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David Corman</p> <p>Contact Telephone 703-292-8754</p> <p>Contact Email dcorman@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025</p> <p>Synopsis The Civic Innovation Challenge (CIVIC) is a research and action competition that accelerates the transition to practice of foundational research and emerging technologies into communities through civic-engaged research. By addressing priorities at the local scale that are relevant across the US, CIVIC is laying the foundation for a broader and more fluid exchange of research and technology capabilities and civic priorities through joint partnerships involving civic partners and the research community. CIVIC funds projects that pilot state-of-the-art solutions to community challenges over 12 months, following a six-month planning phase, and have the potential for lasting impact in the partnering community as well as the potential to be scaled and implemented in other communities. Additionally, the foundation for CIVIC projects should be rooted in maturing and transitioning state-of-the-art research in disciplines, including but not limited to computer science, engineering, geosciences, biological sciences, and social sciences.</p>				
123546	Growing Convergence Research (GCR)	National Science Foundation	24-527	10-Feb-2025	1,200,000 USD
	<p>Contact Name Dragana Brzakovic</p> <p>Contact Telephone 703-292-5033</p> <p>Contact Email dbrzakov@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025</p> <p>Synopsis This GCR solicitation targets multidisciplinary teams who are embracing convergence research as a means of developing highly innovative solutions to complex research problems. GCR proposals are expected to be bold and address scientific or technical challenges and bottlenecks which if resolved have the potential to transform scientific understanding and solve vexing problems. Successful GCR projects are anticipated to lead to paradigm shifting approaches within disciplines, establishment of new scientific communities, or development of transformative technologies that have the potential for broad scientific or societal impact. The aim of GCR is to cultivate and grow the earliest foundations of convergent approaches</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

for addressing a specific and compelling problem. As such, proposals submitted to this solicitation are expected to explore novel avenues not previously investigated that are at the forefront of advancing science through deep integration. Proposers must make a convincing case that the research to be conducted is within NSF's purview, integrates across NSF directorate or division boundaries, and is currently not supported by other NSF programs or solicitations. The proposers must outline a five-year research plan delineated in two phases, Phase I: years 1-2, and Phase II: years 3-5. The total budget for Phase I may not exceed \$1,200,000, and the total for Phase II may not exceed \$2,400,000. Successful proposals will be funded initially for two years. Each team's progress will be evaluated at a reverse site visit near the end of year 2; this will involve preparing a progress report and making a team presentation to a panel of reviewers/site visitors.

124285	Dear Colleague Letter: Science of Science Approach to Analyzing and Innovating the Biomedical Research Enterprise (SoS:Bio)	National Science Foundation	NSF 24-061	10-Feb-2025	Not Specified
--------	---	-----------------------------	------------	-------------	---------------

Contact Name	Mary K. Feeney
Contact Telephone	
Contact Email	mfeeney@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	10-Feb-2025
Synopsis	With this Dear Colleague Letter (DCL) the U.S. National Science Foundation (NSF) and the National Institutes of Health (NIH) wish to notify the research community of a joint NSF and National Institute of General Medical Sciences (NIGMS) research program called the Science of Science Approach to Analyzing and Innovating the Biomedical Research Enterprise (SoS:Bio). This DCL encourages proposals that broaden participation from diverse talent pools to advance the science of science on biomedical sciences.

124523	Computer Science for All	National Science Foundation	24-555	12-Feb-2025	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	Allyson Kennedy
Contact Telephone	703-292-8950
Contact Email	aykenned@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Feb-2025</p> <p>Synopsis This program aims to provide all U.S. students with the opportunity to participate in computer science (CS) and computational thinking (CT) education in their schools at the preK-12 levels. With this solicitation, the National Science Foundation (NSF) focuses on both research and research-practice partnerships (RPPs) that foster the research and development needed to bring CS and CT to all schools. Specifically, this solicitation aims to provide (1) high school teachers with the preparation, professional development (PD) and ongoing support they need to teach rigorous computer science courses; (2) preK-8 teachers with the instructional materials and preparation they need to integrate CS and CT into their teaching; and (3) schools and districts with the resources needed to define and evaluate multi-grade pathways in CS and CT.</p>				
123451	Algorithms for Threat Detection	National Science Foundation	24-526	19-Feb-2025	3,000,000 USD
	<p>Contact Name Tomek Bartoszynski</p> <p>Contact Telephone 703-292-4885</p> <p>Contact Email tbartosz@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2025</p> <p>Synopsis The Algorithms for Threat Detection (ATD) program will support research projects to develop the next generation of mathematical and statistical algorithms for analysis of large spatiotemporal datasets with application to quantitative models of human dynamics. The program is a partnership between the Division of Mathematical Sciences (DMS) at the National Science Foundation (NSF) and the National Geospatial Intelligence Agency (NGA).</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128857	Pediatric Pulmonary Centers Program	Maternal and Child Health Bureau/HRSA/DHHS	HRSA-25-026	18-Feb-2025	1,700,000 USD
	Contact Name	Nikki West			
	Contact Telephone	240-638-7518			
	Contact Email	NWest@hrsa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	18-Feb-2025			
	Synopsis	The purpose of the Pediatric Pulmonary Centers (PPC) program is to provide interdisciplinary training to improve the health of infants, children, and adolescents with chronic respiratory conditions, sleep issues, and other related special health care needs. The PPCs strive to improve systems of care and increase access to pediatric pulmonary care for children with complex health care needs.			
128127	FCO--FY2025-2034 DTRA Chemical and Biological Technologies Fundamental Research Broad Agency Announcement	Defense Threat Reduction Agency/Department of Defense	HDTRA125S0001	14-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	dtra.belvoir.rd.mbx.rd-cb-frbaa25-34-ta1@mail.mil			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Feb-2025			
	Synopsis	This is the initial announcement of this funding opportunity. This BAA is in effect from October 1, 2024 through September 30, 2034. It is anticipated that a majority of the actions funded from this announcement will be in the form of grants; however, other instruments such as cooperative agreements (CAs) or other transactions (OTs) for research may also be awarded from this announcement. No contracts will be awarded from this announcement. Submissions for this BAA may occur in two ways: 1) in response to the published topics detailed in Attachment 1 or 2) to a general thrust area as described in Section 1.5. In general, all topic-specific and general thrust area submissions require pre-coordination in accordance with the guidelines in Section 1.5 and Section 4.2.1. DTRA reserves the right to waive the pre-coordination requirement for topics on a case-by-case basis; and will state the waiver applies within the individual topic description. If a pre-application white paper is received without prior coordination, DTRA may not review it. From the date of the disposition email the applicant			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

has 63 days to submit the pre-application white paper. If the submission is not feasible within this 63-day window, the abstract must be coordinated again to ensure the interest in the white paper remains. The evaluation of all submissions will be conducted in two phases. Phase I is for receipt and evaluation of pre-application white papers in direct response to a published topic or by invitation based on the assessment of the idea by the Technical POC. Phase II is for receipt and evaluation of invited proposal applications. Invitation to the Phase II, invited proposal submission, will be based on the evaluation results of the Phase I pre-application white paper. Catalog of Federal Domestic Assistance (CFDA) Number: 12.351 This BAA is open continuously from October 1, 2024 through September 30, 2034. Published topics will include instructions on any topic-specific opening and closing dates as well as any topic-specific limitations on award types, dollar values, and eligibility. Submissions to a general thrust area may occur at any time this BAA is in effect. Applicants should take care to note requirements for pre-coordination of an abstract. DTRA safeguards America and its allies from weapons of mass destruction (WMD) and provides capabilities to reduce, eliminate, and counter the threat and effects from chemical, biological, radiological, nuclear, and high yield explosives. DTRA seeks to identify, adopt, and adapt emerging, existing, and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. This BAA is an extramural endeavor that combines the fundamental research, educational program, or other effort needs appropriate for basic or applied research funding of DTRA and other DoD interests. This announcement solicits ideas and topic-based pre-application white papers for long-term challenges that offer a significant contribution: to the current body of knowledge, to the understanding of phenomena and observable facts, to significantly advance revolutionary technology, to new concepts for technology application, or that may have impact on future C-WMD threat reduction, expertise, or capabilities. A portion of this effort is expected to be devoted to awards for science, technology, engineering and mathematics education programs with a C-WMD focus, such as, but not limited to postdoctoral fellowships, stipends, degrees, visiting scientist programs, student exchange programs, and development of accredited C-WMD curricula. Fundamental research means basic and applied research in science and engineering, the results of which ordinarily are published and shared broadly within the scientific community, as distinguished from proprietary research and from industrial development, design, production, and product utilization, the results of which ordinarily are restricted for proprietary or national security reasons. Fundamental Research includes research performed under grants, CAs, or OTs that are (a) funded by budget Category 6.1 (Basic Research), whether performed by universities or industry or (b) funded by budget Category 6.2 (Applied Research) performed on-campus at a university. Fundamental research provides for science and technology (S&T) research and early applied development. It seeks to lower performance risk to a manageable level and facilitate transition and funding to capability end-state programs. Technology Readiness Levels (TRLs) provide a systematic metric/measurement system that supports assessments of the maturity of a particular technology and the consistent comparison of maturity between different types of technology. Fundamental research may be defined within the first four (4) TRLs. This BAA seeks optimum approaches to meet DTRA fundamental research objectives. The Government encourages pre-application white papers and proposals that span a wide spectrum of research to expand fundamental scientific knowledge in response to

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>specific topics and to the more general thrust area. The Government reserves the right to award any combination of approaches which offer the best overall value to the Government and to oversee any and all processes and approaches once ongoing. Thrust Area 1 is described below. When a specific set of topics has been identified, these detailed needs will be described in Attachment 1 along with any topic-specific submission instructions, deadlines, anticipated award structure, and funding requirements. Otherwise, pre-application white papers and proposals may be written against one of the general thrust area descriptions. Thrust Area 1— Fundamental Science for Chemical and Biological Defense: Fundamental science for chemical and biological (CB) defense includes science and technology research that advances knowledge in physical and life sciences to defend and counter chemical and biological WMD that could be used against our Nation’s warfighters. Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration.</p>				
107009	Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Feb-2025	2,500,000 USD
	<p>Contact Name James Cleeman, MD Contact Telephone 301-427-1330 Contact Email james.cleeman@ahrq.hhs.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 Synopsis Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R01 Research Project Grant award mechanism.</p>				
114270	Special Emphasis Notice (SEN): Interest in Healthcare Associated Infections and Combating Antibiotic Resistant Bacteria Research	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-003	25-Jan-2025	Not Specified
	<p>Contact Name Leyi Lin, MD Contact Telephone 301-427-1333</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email levi.lin@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2025 , 05-Feb-2025 , 25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.</p>				
123849	AHRQ Health Services Research Projects (R01)	Agency for Healthcare Research and Quality/DHHS	PA-24-154	05-Feb-2025	2,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-427-1025</p> <p>Contact Email kathryn.woolridge@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 , 05-Feb-2028 , 05-Jun-2028 , 05-Oct-2028 , 05-Feb-2029 , 05-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				
123850	AHRQ Small Health Services Research Grant Program (R03)	Agency for Healthcare Research and	PA-24-155	16-Feb-	100,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Quality/DHHS			2025		
	<p>Contact Name</p> <p>Contact Telephone 301-427-1025</p> <p>Contact Email kathryn.woolridge@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027 , 16-Feb-2028 , 16-Jun-2028 , 16-Oct-2028 , 16-Feb-2029 , 16-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				
109186	Notice of Special Interest (NOSI): Health Services Research on Health System and Healthcare Professional Responsiveness to COVID-19	Agency for Healthcare Research and Quality/DHHS	NOT-HS-22-010	25-Jan-2025	Not Specified
	<p>Contact Name Leeann Comfort, PhD, MPP</p> <p>Contact Telephone</p> <p>Contact Email Leeann.Comfort@ahrq.hhs.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2025 , 05-Feb-2025</p> <p>Synopsis This Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to develop models of care that improve access, quality, and outcomes of care related to COVID-19 and post-acute sequelae from COVID-19 (PASC).</p>				
115139	Special Emphasis Notice (SEN):Research on Climate Change and Healthcare	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	08-Dec-2024	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Brent Sandmeyer, MPH
Contact Telephone	301-427-1441
Contact Email	Brent.sandmeyer@ahrq.hhs.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Dec-2024 , 12-Dec-2024 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 26-Feb-2025 , 08-Apr-2025 , 12-Apr-2025 , 25-May-2025 , 12-Jun-2025 , 08-Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2025 , 12-Oct-2025 , 12-Dec-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027
Synopsis	This Special Emphasis Notice (SEN) announces AHRQ’s interest in receiving health services research grant applications that address the intersection of climate change and healthcare.

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
024492	Vegetarian Nutrition Dietetic Practice Group Research Grant	Academy of Nutrition and Dietetics Foundation		24-Feb-2025	10,000 USD
	Contact Name	Elisha Reichling, MS, RDN, LDN, Foundation Program Manager			
	Contact Telephone				
	Contact Email	scholarship@eatright.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Feb-2025			
	Synopsis	The Vegetarian Nutrition Dietetic Practice Group Research Grant consists of \$10,000 and is given for innovative research relating to vegetarian nutrition to an individual who is an RDN, DTR or Dietetic Student member of the Academy.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
123140	Request for Proposals: Single Ventricle Research Fund	Additional Ventures		12-Feb-2025	600,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	grants@additionalventures.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2025			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Single Ventricle Research Fund (SVRF) is an annual research award program that supports foundational research to improve our mechanistic understanding of single ventricle congenital heart disease through multi-year, high-impact grants. This year, the SVRF will consider applications to both the Independent Investigator and Career Development Tracks, providing up to \$600,000 and \$300,000, respectively, to support direct costs over a three-year award period. In its fifth cycle, the SVRF is hosting an open call, and welcomes any research with relevance to single ventricle.			
	Applicant Types				
	Funding Limit	600,000.00 maximum			
	Limited Submission	No			
126242	John W. Walsh Career Development Grant	Alpha-1 Foundation		07-Feb-2025	300,000 USD
	Contact Name				
	Contact Telephone	1-877-228-7321,ext.242			
	Contact Email	vvalencia@alpha1.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2025			
	Synopsis	The Alpha-1 Foundation offers the John W. Walsh Career Development Grant of up to \$100,000 for a three-year period to encourage the development/testing of new hypotheses/new methods in AATD relevant research.			
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			
067833	Postdoctoral Research Fellowship Grant	Alpha-1 Foundation		07-Feb-2025	150,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Vanessa Valencia</p> <p>Contact Telephone 305-567-9888 ext. 242</p> <p>Contact Email vvalencia@alpha1.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2025</p> <p>Synopsis Alpha-1 Foundation offers Postdoctoral Research Fellowship Grants to provide support for postdoctoral research fellows who are starting their research careers and are working in the laboratories of established researchers or conducting research with the mentorship of established researchers. A maximum of \$75,000 per year may be requested. Up to 2 years of support is available.</p> <p>Applicant Types </p> <p>Funding Limit 75,000.00 per year</p> <p>Limited Submission No</p>				
067831	Research Grants	Alpha-1 Foundation		07-Feb-2025	200,000 USD
	<p>Contact Name Vanessa Valencia</p> <p>Contact Telephone 305-567-9888 ext. 242</p> <p>Contact Email vvalencia@alpha1.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2025</p> <p>Synopsis Alpha-1 Foundation offers Research Grants to provide funds to encourage the development of new information that contributes to the understanding of the basic biology of alpha-1 antitrypsin expression, and the</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	pathogenesis/management of AAT Deficiency. A maximum of \$100,000 per year may be requested. Up to 2 years of support is available.				
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			
126290	Clinical Pilot Grants	Alpha-1 Foundation		07-Feb-2025	75,000 USD
	Contact Name	Vanessa Valencia, Grants Administration Manager			
	Contact Telephone	877-228-7321, ext. 242			
	Contact Email	vvalencia@alpha1.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2025			
	Synopsis	Alpha-1 Foundation offers Clinical Pilot grants to support projects involving human subjects that will develop and test new hypotheses and/or new methods (or those being applied to the problems of Alpha-1 for the first time), and to support promising new investigators as they establish themselves in research areas relevant to Alpha-1.			
	Applicant Types				
	Funding Limit	75,000.00 maximum			
	Limited Submission	No			
067828	Pilot and Feasibility Grants	Alpha-1 Foundation		07-Feb-2025	75,000 USD
	Contact Name	Vanessa Valencia, Grants Administration Manager			
	Contact Telephone	877-228-7321, ext. 242			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email vvalencia@alpha1.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2025</p> <p>Synopsis Alpha-1 Foundation offers Pilot and Feasibility Grants to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to AAT Deficiency. Proposed work must be hypothesis generating or hypothesis testing, reflecting innovative approaches to important questions in AAT research or development of novel methods, and providing sufficient preliminary data to justify the Foundation's support. A maximum of \$75,000 may be requested.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
110441	Hoffman ALS Clinical Trial Awards Program	ALS Association		26-Nov-2024 [LOI/Pre-App]	1,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email researchgrants@alsa-national.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Nov-2024 [LOI/Pre-App], 11-Feb-2025</p> <p>Synopsis This program supports early- to mid-stage (phase 1 or 2a) clinical trials of novel or repositioned therapeutics for ALS (either disease-modifying or symptomatic) or early trials testing imaging tracers in people living with ALS. This year, the sponsor is particularly interested in funding programs targeting TDP-43 and/or protein aggregation.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">1,000,000.00 maximum</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Applicant Types						Funding Limit	1,000,000.00 maximum					Limited Submission	No																																														
Applicant Types																																																																	
Funding Limit	1,000,000.00 maximum																																																																
Limited Submission	No																																																																
010661	Resident Research Preceptorship	American College of Rheumatology		01-Feb-2025	15,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">404-365-1373</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">foundation@rheumatology.org</td> </tr> <tr> <td>Sponsor Website</td> <td colspan="5">Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td colspan="5">Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="5">01-Feb-2025</td> </tr> <tr> <td>Synopsis</td> <td colspan="5">The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The award is worth \$15,000 for a three-month research preceptorship, to be completed in reasonable portions within 12 months of the award's start date.</td> </tr> <tr> <td>Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">15,000.00 maximum</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Contact Name						Contact Telephone	404-365-1373					Contact Email	foundation@rheumatology.org					Sponsor Website	Link to sponsor website					Program URL	Link to program URL					Deadline Dates (ALL)	01-Feb-2025					Synopsis	The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The award is worth \$15,000 for a three-month research preceptorship, to be completed in reasonable portions within 12 months of the award's start date.					Applicant Types						Funding Limit	15,000.00 maximum					Limited Submission	No				
Contact Name																																																																	
Contact Telephone	404-365-1373																																																																
Contact Email	foundation@rheumatology.org																																																																
Sponsor Website	Link to sponsor website																																																																
Program URL	Link to program URL																																																																
Deadline Dates (ALL)	01-Feb-2025																																																																
Synopsis	The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The award is worth \$15,000 for a three-month research preceptorship, to be completed in reasonable portions within 12 months of the award's start date.																																																																
Applicant Types																																																																	
Funding Limit	15,000.00 maximum																																																																
Limited Submission	No																																																																
114585	Glenn Foundation Discovery Award	American Federation for Aging Research		18-Feb-2025 [LOI/Pre-App]	525,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">212-703-9977</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">grants@afar.org</td> </tr> </table>						Contact Name						Contact Telephone	212-703-9977					Contact Email	grants@afar.org																																														
Contact Name																																																																	
Contact Telephone	212-703-9977																																																																
Contact Email	grants@afar.org																																																																

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2025 [LOI/Pre-App]</p> <p>Synopsis This funding program specifically seeks to include principal investigators who may not have previously worked in the area of aging, but whose research and expertise are applicable to understanding the biological mechanisms of normal aging and its relevance to age-associated health decline. Up to two three-year awards will be made in 2025. Each award is for \$525,000.</p> <p>Applicant Types</p> <p>Funding Limit 525,000.00 maximum</p> <p>Limited Submission No</p>				
089669	Student Abstract Award	American Gastroenterological Association		20-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-654-2055</p> <p>Contact Email awards@gastro.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Feb-2025</p> <p>Synopsis This \$500 travel award supports recipients who are graduate students, medical students or medical residents (residents up to postgraduate year three) giving abstract-based oral or poster presentations at Digestive Disease Week® (DDW). The top scoring abstract will be designated the Student Abstract of the Year and receive a \$1,000 award. Four recipients will receive the AGA–Eric Esrailian Student Abstract Prize and four recipients will receive the AGA–Radhika Srinivasan Student Abstract Prize.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission Yes				
110787	AGA Abstract Award for Health Disparities Research	American Gastroenterological Association		20-Feb-2025	500 USD
	Contact Name Contact Telephone 301-654-2055 Contact Email awards@gastro.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 20-Feb-2025 Synopsis This \$500 travel award supports recipients who are graduate students, medical students, medical residents (residents up to postgraduate year three), clinical fellows or postdoctoral fellows giving abstract-based oral or poster presentations at Digestive Disease Week (DDW) that communicate research into health or health care disparities. Applicant Types Funding Limit 500.00 maximum Limited Submission No				
126091	Global Cardiovascular Research Funders Forum Data Challenge	American Heart Association		21-Feb-2025	Not Specified
	Contact Name Contact Telephone Contact Email pmp@heart.org				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Feb-2025			
	Synopsis	The Global Cardiovascular Research Funders Forum (GCRFF) invites scientific researchers to compete in a data challenge to better understand how to improve acceleration of science through funding. The winning project is eligible to receive a \$20,000 USD cash prize. The GCRFF is a coalition of major international cardiovascular research funders whose aim is to improve cardiovascular health worldwide by catalyzing, supporting, and promoting transformational international research efforts in heart, stroke, and circulatory diseases. The GCRFF works to identify research gaps, coordinate multinational clinical trials, share data, and oversee the international research funding portfolio.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
062089	Transformational Project Award	American Heart Association		13-Feb-2025	300,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	apply@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Feb-2025			
	Synopsis	The American Heart Association's Transformational Project Award supports highly innovative, high-impact projects that build on work in progress that could ultimately lead to critical discoveries or major advancements that will accelerate the field of cardiovascular and/or cerebrovascular research. The candidate must hold a post-baccalaureate			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Applicant Types Funding Limit Limited Submission	Ph.D. degree or equivalent, or a doctoral-level clinical degree, such as MD, DO, DVM, PharmD, or PhD in nursing, public health, or other clinical health science. Funding is \$100,000 per year for three years. 100,000.00 per year No				
113264	Research Supplement to Promote Diversity in Science	American Heart Association		06-Feb-2025	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	 apply@heart.org Link to sponsor website Link to program URL 06-Feb-2025 The American Heart Association offers the Research Supplement to Promote Diversity in Science to enable current AHA awardees to identify and serve as mentors for predoctoral and postdoctoral fellows from underrepresented racial and ethnic groups in science and medicine (Black/African American, Hispanic/Latino, American Indian/Alaskan Native, or Native Hawaiian/Pacific Islander). 0.00 see detail Yes				
106409	AMS Congressional Fellowship	American Mathematical Society		01-Feb-2025	105,812 USD	
	Contact Name					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 401-455-4000 Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2025 Synopsis The American Mathematical Society (AMS), in conjunction with the American Association for the Advancement of Science (AAAS), sponsors this fellowship. It includes an orientation on congressional and executive branch operations, and a year-long seminar series on issues involving science, technology and public policy. The AMS Congressional Fellow spends a year working on the staff of either a member of Congress or a congressional committee, working in legislative and policy areas requiring scientific and technical input. Applicant Types Funding Limit 105,812.00 minimum Limited Submission No				
021147	Excellence in Medicine Awards - Pride in the Profession Award	American Medical Association Foundation		07-Feb-2025	Not Specified
	Contact Name Contact Telephone 312-464-4200 Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-Feb-2025 Synopsis The Pride in the Profession Awards honors physicians who aid underserved populations in the United States.				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">0.00 see detail</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Applicant Types						Funding Limit	0.00 see detail					Limited Submission	No																																														
Applicant Types																																																																	
Funding Limit	0.00 see detail																																																																
Limited Submission	No																																																																
121075	AMSSM Minority Research Grant	American Medical Society for Sports Medicine		14-Feb-2025	10,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5">Sarah Sund</td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">913-327-1415</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">ssund@amssm.org</td> </tr> <tr> <td>Sponsor Website</td> <td colspan="5">Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td colspan="5">Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="5">14-Feb-2025</td> </tr> <tr> <td>Synopsis</td> <td colspan="5">The purpose of the AMSSM minority research grant is to provide research opportunities specifically for historically underrepresented minorities in biomedical research to advance representation across diverse backgrounds and promote health equity in sports medicine research.</td> </tr> <tr> <td>Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">10,000.00 maximum</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Contact Name	Sarah Sund					Contact Telephone	913-327-1415					Contact Email	ssund@amssm.org					Sponsor Website	Link to sponsor website					Program URL	Link to program URL					Deadline Dates (ALL)	14-Feb-2025					Synopsis	The purpose of the AMSSM minority research grant is to provide research opportunities specifically for historically underrepresented minorities in biomedical research to advance representation across diverse backgrounds and promote health equity in sports medicine research.					Applicant Types						Funding Limit	10,000.00 maximum					Limited Submission	No				
Contact Name	Sarah Sund																																																																
Contact Telephone	913-327-1415																																																																
Contact Email	ssund@amssm.org																																																																
Sponsor Website	Link to sponsor website																																																																
Program URL	Link to program URL																																																																
Deadline Dates (ALL)	14-Feb-2025																																																																
Synopsis	The purpose of the AMSSM minority research grant is to provide research opportunities specifically for historically underrepresented minorities in biomedical research to advance representation across diverse backgrounds and promote health equity in sports medicine research.																																																																
Applicant Types																																																																	
Funding Limit	10,000.00 maximum																																																																
Limited Submission	No																																																																
071243	Development Grants	American Neuromuscular Foundation		10-Jan-2025 [LOI/Pre-App]	50,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">507-538-1037</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">foundation@neuromuscularfoundation.org</td> </tr> </table>						Contact Name						Contact Telephone	507-538-1037					Contact Email	foundation@neuromuscularfoundation.org																																														
Contact Name																																																																	
Contact Telephone	507-538-1037																																																																
Contact Email	foundation@neuromuscularfoundation.org																																																																

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Jan-2025 [LOI/Pre-App], 21-Feb-2025			
	Synopsis	The American Neuromuscular Foundation offers development grants intended as seed money to help launch research into muscle and nerve disorders by promising new researchers. Research that addresses quality issues is encouraged. Applications should directly relate to a muscle and nerve disorder covered by the AANEM.			
	Applicant Types				
	Funding Limit	50,000.00 see detail			
	Limited Submission	No			
043086	Student Educational Scholarship	American Phytopathological Society		28-Feb-2025	500 USD
	Contact Name				
	Contact Telephone	651-454-7250			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2025			
	Synopsis	This award is to be used for furthering education outside the APS Annual Meeting to develop skills and/or to network with other scientists. Currently, there is one \$500 Student Education Award being provided.			
	Applicant Types				
	Funding Limit	500.00 maximum			
	Limited Submission	No			
004636	Raymond J. Tarleton Student Fellowship	American Phytopathological Society		28-Feb-2025	1,500 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 651-454-7250</p> <p>Contact Email apshq@scisoc.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p> <p>Synopsis The fund supports APS graduate student members in plant pathology to encourage them to further their careers in plant pathology. The fellowship is given to an APS Graduate Student Member majoring in plant pathology at a university in the United States. The purpose is to support graduate education in plant pathology and may be used as a stipend for research expenses, books, research, summer internships (industry, other research labs, etc.) and/or for equipment necessary to the recipient's thesis research. The sponsor anticipates making one award of \$1,500.</p> <p>Applicant Types</p> <p>Funding Limit 1,500.00 maximum</p> <p>Limited Submission No</p>				
043878	Books for the World Award	American Phytopathological Society		28-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 651-454-7250</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Books for the World program helps scientists, educators, extension personnel and other agriculturalists in developing countries acquire educational materials from APS PRESS, and promotes the international distribution of books, CDs, and other APS resources.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
123241	Henry P. David Grant for International Travel in Human Reproductive Behavior and Population Studies	American Psychological Foundation		14-Feb-2025	1,000 USD
	Contact Name				
	Contact Telephone	202-336-5843			
	Contact Email	programs@ampsychfdn.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Feb-2025			
	Synopsis	The American Psychological Foundation's Henry David Fund was established to support young psychologists with a demonstrated interest in the behavioral aspects of human reproductive behavior or an area related to population concerns. This is a one-time, \$1,000 grant, intended to cover expenses associated with travel to, during, and from the 2025 Population Association of America (PAA) Psychosocial Workshop.			
	Applicant Types				
	Funding Limit	1,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
018550	Robert G. Quinn Award	American Society for Engineering Education (ASEE)		14-Feb-2025	5,000 USD
	Contact Name				
	Contact Telephone	202-331-3516			
	Contact Email	awards@asee.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Feb-2025			
	Synopsis	The American Society for Engineering Education presents the Robert G. Quinn Award to recognize outstanding contributions in providing and promoting excellence in experimentation and laboratory instruction. The award consists of a \$5,000 honorarium, a medal, and an inscribed plaque.			
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			
013847	Biomedical Engineering Division (BED) - Theo C. Pilkington Outstanding Educator Award	American Society for Engineering Education (ASEE)		15-Feb-2025	350 USD
	Contact Name	Yanfen Li, BED Awards Chair			
	Contact Telephone	978-934-3299			
	Contact Email	Yanfen_Li@uml.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2025			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Biomedical Engineering Division (BED) of ASEE annually awards the Theo Pilkington Outstanding Educator Award for significant contributions to biomedical engineering education as evidenced by the development of successful undergraduate or graduate level programs, curricula, publications as well as by membership and activities in ASEE/BED and other biomedical engineering organizations. The award consists of a commemorative plaque and a check for \$350.			
	Applicant Types				
	Funding Limit	350.00 see detail			
	Limited Submission	No			
071563	ASIP Experimental Pathologist-in-Training Award (EPIT)	American Society for Investigative Pathology		28-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	awards@asip.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2025			
	Synopsis	The Experimental Pathologist-in Training (EPIT) Award is a prestigious award presented to an ASIP Post-Doctoral Trainee member (research and clinical fellows) who has excelled in investigative efforts in studying the mechanisms of disease.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
084785	Research Institute Grants -- Discovery & Innovation (D&I) Grants	American Society for Reproductive Medicine (ASRM)		14-Feb-2025	750,000 USD
	<p>Contact Name</p> <p>Contact Telephone 205-978-5000</p> <p>Contact Email research@asrm.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025</p> <p>Synopsis The ASRM Research Institute Discovery & Innovation Grant (\$50,000 per year or greater) are to develop research projects addressing fundamental questions of major clinical significance to reproductive medicine. Preference for funding will be given to projects that attempt to answer timely, basic, and clinically relevant questions of potential high impact to the practice of reproductive medicine and which are currently not fundable (either because of applicable existing federal law or because of relatively lower prioritization) by federal funding agencies.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 per year</p> <p>Limited Submission No</p>				
116862	Hematology Inclusion Pathway (HIP) - Resident Award	American Society of Hematology		14-Feb-2025	7,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-776-0544</p> <p>Contact Email awards@hematology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-Feb-2025</p> <p>Synopsis The American Society of Hematology (ASH) offers the Hematology Inclusion Pathway (HIP) Resident Award to first- and second-year medical residents from communities underserved and underrepresented in hematology across the U.S. and Canada. Each HIP Resident Award applicant must have a research mentor who is an ASH member in good standing. This program includes the ASH-Roland B. Scott Award which recognizes the highest-scoring HIP Resident award recipient whose research project is focused on Sickle Cell Disease.</p> <p>Applicant Types</p> <p>Funding Limit 7,000.00 see detail</p> <p>Limited Submission No</p>				
021033	Hematology Inclusion Pathway (HIP) Medical Student Award	American Society of Hematology		14-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email diversity@hematology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Feb-2025</p> <p>Synopsis The ASH Hematology Inclusion Pathway (HIP) Medical Student Award provides medical students from communities underrepresented in hematology in the US and Canada with a stipend to conduct hematologic research under the mentorship of an ASH member. Recipients of this award will also receive a stipend to attend the ASH annual meeting to present their research. As part of the ASH Hematology Inclusion Pathway program, the Medical Student Award aims to create inclusivity and expand the program’s reach to the next generation of hematologists.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
020086	Research Starter Grants	American Society of Pharmacognosy		15-Feb-2025	5,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	afc@pharmacognosy.us			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2025			
	Synopsis	The Research Starter Grants are small research grants from \$2000 to \$5000 available for active members in the first eight years after earning their Ph.D. and in the first five years of their first independent career position. These are one-time awards and do not provide indirect costs. They are awarded preferentially to applicants who have not yet received major external funding.			
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			
128274	Hoffman ALS Clinical Trial Awards Program	Amyotrophic Lateral Sclerosis Association		26-Nov-2024 [LOI/Pre-App]	1,000,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	researchgrants@als.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Nov-2024 [LOI/Pre-App], 11-Feb-2025</p> <p>Synopsis The Amyotrophic Lateral Sclerosis Association's Hoffman ALS Clinical Trial Awards Program helps develop new and improved ALS therapies by supporting early-stage clinical trials. These trials generally produce data on safety, dosing, and biomarkers that are essential for moving an investigational therapy one step closer to being evaluated by the FDA. Positive results at this stage “de-risk” the next stage of drug development, typically large clinical trials, and help attract the follow-on funding necessary to complete this work. The Hoffman ALS Clinical Trial Awards Program also supports early trials of imaging tracers in people living with ALS. This year, the ALS is particularly interested in funding programs targeting TDP-43 and/or protein aggregation. Budgets for total costs up to \$1,000,000 (inclusive of direct and indirect costs) may be requested.</p> <p>Applicant Types</p> <p>Funding Limit 1,000,000.00 maximum</p> <p>Limited Submission No</p>				
086519	AAV Student and House Officer Manuscript Competitions	Association of Avian Veterinarians		01-Feb-2025	500 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email office@aav.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2025</p> <p>Synopsis The Association of Avian Veterinarians offers awards for manuscripts on avian medicine.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	500.00 see detail			
	Limited Submission	No			
020143	Awards for Excellence in Health Care Journalism	Association of Health Care Journalists		24-Jan-2025	500 USD
	Contact Name				
	Contact Telephone				
	Contact Email	info@healthjournalism.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jan-2025 , 28-Feb-2025			
	Synopsis	The Awards for Excellence in Health Care Journalism recognize the best health reporting in print, broadcast, and online media.			
	Applicant Types				
	Funding Limit	500.00 see detail			
	Limited Submission	No			
021853	Plant Genome Research Program (PGRP) Research Experience for Undergrads (REU)	Boyce Thompson Institute for Plant Research		01-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone	607-254-1234			
	Contact Email	internships@btiscience.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	<p>The Boyce Thompson Institute for Plant Research - Plant Genome Research Program (PGRP) summer internship program offers an opportunity for undergraduate students to learn how basic plant research can be applied to protect the environment, enhance human health, and improve agriculture. PGRP undergraduate researchers gain knowledge of plant genomics and scientific research by working closely with their mentors, postdoctoral fellows, and graduate students in a laboratory setting. Undergraduate researchers will learn the latest molecular biology techniques and bioinformatics tools while working on a supervised, independent research project within the framework of the assigned laboratory's research program. The program offers a variety of projects spanning plant science, plant molecular biology, plant biotic interactions, bioinformatics, and biological engineering of plant systems. To learn more about each area please visit https://btiscience.org/education-outreach/research-internships/</p>			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
107387	Programmable Plant Systems Research Experience for Undergrads (REU)	Boyce Thompson Institute for Plant Research		02-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone	607-254-1234			
	Contact Email	internships@btiscience.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Feb-2025			
	Synopsis	<p>The NSF-funded Programmable Plant Systems Research Experiences for Undergraduates is funded through CROPPS, the Center for Research on Programmable Plant Systems, and involves trans-disciplinary research that connects</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>engineering and plant science. This program involves labs and faculty members at both the Boyce Thompson Institute and Cornell University, as well as at the University of Illinois, Urbana-Champaign, IL campus.</p> <p>0.00 see detail</p> <p>No</p>			
128734	Request for Applications: Advancing Technologies to Enhance Engraftment in Cell Therapy for T1D	Breakthrough T1D		10-Jan-2025 [LOI/Pre-App]	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Madhu Prakash</p> <p>800-533-2873</p> <p>mprakash@breakthrough1d.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>10-Jan-2025 [LOI/Pre-App], 21-Feb-2025</p> <p>Breakthrough T1D requests applications seeking support for preclinical and clinical research projects aiming to accelerate the development of technologies and/or strategies focused on enhancing the survival, engraftment, and function of insulin-producing cells following transplantation at extrahepatic sites. Breakthrough T1D will award grants up to \$300,000 per year for 2 years. Awards of increased scope may be considered following discussion with the Breakthrough T1D scientific lead.</p> <p></p> <p>300,000.00 see detail</p> <p>No</p>			
058765	Innovation in Regulatory Science Award	Burroughs Wellcome Fund		07-Feb-2025	500,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email irsa@bwfund.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2025</p> <p>Synopsis The Burroughs Wellcome Fund's Innovation in Regulatory Science Awards provides up to \$500,000 over five years to academic investigators developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions the Food and Drug Administration (FDA) and others make. The BWF especially encourages applications from those who are seeking to advance regulatory science approaches that will expedite the realization of equitable clinical outcomes. Innovation in Regulatory Science Awards provides up to \$500,000 over five years.</p> <p>Applicant Types</p> <p>Funding Limit 500,000.00 maximum</p> <p>Limited Submission No</p>				
045538	Partnering Opportunity For Clinical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine		29-Nov-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 510-340-9101</p> <p>Contact Email Clinical@cirm.ca.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	29-Nov-2024 , 30-Dec-2024 , 31-Jan-2025 , 28-Feb-2025 , 31-Mar-2025 , 30-Apr-2025 , 30-May-2025 , 30-Jun-2025			
	Synopsis	The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this funding opportunity is to support completion of a clinical trial for a regenerative medicine-based therapy (stem cell-based or genetic therapy) that addresses an unmet medical need. Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
045367	Partnering Opportunity for Late Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine		29-Nov-2024	6,000,000 USD
	Contact Name				
	Contact Telephone	510-340-9101			
	Contact Email	clinical@cirm.ca.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Nov-2024 , 30-Dec-2024 , 31-Jan-2025 , 28-Feb-2025 , 31-Mar-2025 , 30-Apr-2025 , 30-May-2025 , 30-Jun-2025			
	Synopsis	The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this program announcement is to support late-stage preclinical studies necessary to file and attain an active IND with the Food and Drug Administration (FDA) and initiate start-up activities to prepare for a clinical trial for			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>a regenerative medicine therapy (stem cell-based or genetic therapy). Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p> <p>6,000,000.00 maximum</p> <p>No</p>			
065639	Amgen Scholars	California Institute of Technology		01-Feb-2025	6,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>626-395-2885</p> <p>sfp@caltech.edu</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Feb-2025</p> <p>The Amgen Scholars Program is a national program aimed at increasing research opportunities for students committed to pursuing careers in the sciences. At Caltech, visiting students are provided the opportunity to conduct research in biology, chemistry, and bio-technical related fields under the guidance of some of the world's leading academic scientists. Research projects, along with scientific seminars, workshops, and networking events, prepare participants to pursue a Ph.D. or the joint M.D./Ph.D. degree and research careers in the sciences and biotechnology.</p> <p></p> <p>6,000.00 see detail</p> <p>No</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
030571	CART Grants Program	Coins for Alzheimer's Research Trust Fund (CART)		06-Dec-2024 [LOI/Pre-App]	500,000 USD
	Contact Name	Dr. Gary Goforth, MD, Vice President of Grants			
	Contact Telephone	828-243-5870			
	Contact Email	gagoforth@earthlink.net			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Dec-2024 [LOI/Pre-App], 14-Feb-2025			
	Synopsis	The goal of CART is to encourage exploratory and developmental AD research projects within the United States by providing support for the early and conceptual plans of those projects that may not yet be supported by extensive preliminary data, but have the potential to substantially advance biomedical research.			
	Applicant Types				
	Funding Limit	500,000.00 maximum			
	Limited Submission	No			
059521	Grants Program	Conservation, Food and Health Foundation		01-Jan-2025 [LOI/Pre-App]	Not Specified
	Contact Name	Prentice Zinn			
	Contact Telephone	617-391-3091			
	Contact Email	pzinn@gmafoundations.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jan-2025 [LOI/Pre-App], 15-Feb-2025 , 15-Jun-2025 [LOI/Pre-App], 15-Aug-2025			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Conservation, Food and Health Foundation seeks to protect the environment, improve food production, and promote public health in Africa, Asia, the Caribbean, Latin America, and the Middle East. The Foundation supports projects and applied research that generate local or regional solutions to problems affecting the quality of the environment and human life; advance local leadership and promote professional development in the conservation, agricultural, and health sciences; develop the capacity of local organizations and coalitions; and address challenges in the field. The Foundation prefers to support projects that address under-funded issues and geographic areas. The Foundation funds applied research, pilot projects, new initiatives, training, and technical assistance, rather than ongoing support for programs that are already well underway. An important goal for the Foundation is to provide seed money to help promising projects, organizations, and individuals develop the track record they need to attract major foundation funding in the future.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	Yes			

019497	Support for Ongoing Clinical Research in Thalassemia	Cooley's Anemia Foundation, Inc.		16-Dec-2024 [LOI/Pre-App]	100,000 USD
--------	--	----------------------------------	--	------------------------------	-------------

Contact Name	
Contact Telephone	212-279-8090
Contact Email	grants@thalassemia.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	16-Dec-2024 [LOI/Pre-App], 03-Feb-2025
Synopsis	The Cooley's Anemia Foundation invites national and international applicants to apply for grants to support Ongoing Clinical Research projects in thalassemia.

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 50,000.00 per year Limited Submission No				
001955	Research Fellowship	Cooley's Anemia Foundation, Inc.		03-Feb-2025	50,000 USD
	Contact Name Contact Telephone 212-279-8090 Contact Email grants@thalassemia.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-Feb-2025 Synopsis The Cooley's Anemia Foundation invites national and international clinical and basic science investigators (postdoctoral or junior faculty) to apply for its prestigious fellowship program. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. The areas of interest include, but are not limited to, studies of globin gene regulation, globin gene transfer and expression, fetal hemoglobin production, hematopoietic stem cell research, bone marrow transplantation, iron chelation and iron overload, endocrine and cardiac disorders in thalassemia, and transfusion therapy and its complications. Applicant Types Funding Limit 50,000.00 per year Limited Submission No				
019493	Support for Trials in Thalassemia Cell and Gene Therapy Grant	Cooley's Anemia Foundation, Inc.		16-Dec-2024 [LOI/Pre-App]	75,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 212-279-8090</p> <p>Contact Email grants@thalassemia.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Dec-2024 [LOI/Pre-App], 03-Feb-2025</p> <p>Synopsis The Cooley's Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for thalassemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support. The research may not be conducted at a for-profit laboratory.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 per year</p> <p>Limited Submission No</p>				
033065	Clinical Pilot and Feasibility Awards	Cystic Fibrosis Foundation		18-Feb-2025	Not Specified
	<p>Contact Name Dara Riva, Program Officer</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email driva@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2025 , 03-Apr-2025 [LOI/Pre-App], 18-Aug-2025</p> <p>Synopsis The Clinical Pilot and Feasibility Award is intended to support a project involving human subjects or samples that will develop and test new hypotheses and/or new methods in research areas relevant to cystic fibrosis.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	Yes			
066130	Damon Runyon Clinical Investigator Award	Damon Runyon Cancer Research Foundation		03-Feb-2025	600,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	awards@damonrunyon.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Feb-2025			
	Synopsis	<p>The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to \$100,000 of any medical school debt still owed by the awardee. For the purpose of this award, clinical research is defined as: a) Patient-oriented research: Research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: patient-based studies of mechanisms of human disease, diagnostic and therapeutic interventions, clinical trials and development of new technologies for the detection, treatment and prevention of human cancers. b) Epidemiologic and behavioral studies. c) Outcomes research and health services research.</p>			
	Applicant Types				
	Funding Limit	600,000.00 see detail			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes			
089130	Request for Applications: Ruth K. Broad Biomedical Research Foundation Extramural Grant	Duke University		01-Feb-2025	250,000 USD
	Contact Name	Cathleen Durgin			
	Contact Telephone				
	Contact Email	cathleen.durgin@duke.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	<p>The Ruth K. Broad Biomedical Research Foundation, Inc. is a support corporation of Duke University, that believes that effective treatment(s) for Alzheimer’s disease is attainable, and the hope that a cure will be found. In addition to its grant-making within Duke University, the foundation operates an extramural program that supports high-priority, high-potential, basic, or translational research toward the prevention or treatment of neurodegenerative diseases outside of Duke University. The Foundation will award a two-year grant, effective July 1, 2025, for \$125,000 each year for non-Duke Faculty. Applications will be evaluated on their potential for advancing the understanding of neurodegenerative disorders, with particular interest in the potential relationship to Alzheimer’s disease.</p>			
	Applicant Types				
	Funding Limit	125,000.00 per year			
	Limited Submission	No			
125986	Climate, Energy and Mobility -- PV-Integrated Electric Mobility Applications	European Commission	HORIZON-CL5-2024-D3-02-05	04-Feb-2025	7,280,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone Contact Email See notes Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 04-Feb-2025 Synopsis Proposals are invited against the following topic: HORIZON-CL5-2024-D3-02-05 - PV-Integrated Electric Mobility Applications This topic is under the call: Sustainable, secure and competitive energy supply Applicant Types Funding Limit 7,000,000.00 on average Limited Submission No				
028276	Postdoctoral Fellowships	European Molecular Biology Organisation (EMBO)		14-Feb-2025	Not Specified
	Contact Name Contact Telephone + 49 6221 8891 112 Contact Email fellowships@embo.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 14-Feb-2025 Synopsis EMBO Postdoctoral Fellowships support excellent postdoctoral researchers throughout Europe and the world for a period of up to two years. International mobility is a key requirement. Research proposals must be within EMBO's scientific scope. Applicant Types				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
000277	Mentored Research Training Grants (MRTG)	Foundation for Anesthesia Education & Research		15-Feb-2025	250,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			
	Contact Email	FAER@faer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2025			
	Synopsis	Mentored Research Training Grants (MRTG) help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators. The MRTG is a two-year, \$250,000 primary investigator award (no co-investigators) that provides funding to faculty members who have completed their core anesthesiology training within the past 10 years. Year one is funded at \$125,000, and year two is funded at \$125,000. The MRTG requires 75 percent protected nonclinical time for research.			
	Applicant Types				
	Funding Limit	125,000.00 per year			
	Limited Submission	No			
000512	Research Fellowship Grant (RFG)	Foundation for Anesthesia Education & Research		15-Feb-2025	75,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email FAER@faer.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2025</p> <p>Synopsis Research Fellowship Grants are intended to provide anesthesiology residents and fellows with the opportunity to obtain significant training in research techniques and scientific methods. The RFG is a one-year (12-month), \$75,000 primary investigator (no co-investigators) award for anesthesiology trainees after the CA-1 year. The RFG is awarded in conjunction with clinical training in an anesthesiology residency or fellowship program. The RFG requires 80 percent research time.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
113771	Postdoctoral Research Award	Friedreich's Ataxia Research Alliance		15-Feb-2025 [LOI/Pre-App]	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone 484-879-6160</p> <p>Contact Email grants@curefa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2025 [LOI/Pre-App], 15-Apr-2025 , 15-Aug-2025 [LOI/Pre-App], 15-Oct-2025</p> <p>Synopsis The Friedreich's Ataxia Research Alliance (FARA) offers a Postdoctoral Research Award as a mechanism to expand and retain young investigators in the Friedreich's Ataxia (FA) biomedical research space. The maximum budget is \$100,000 per year for one or two years.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">100,000.00 per year</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Applicant Types						Funding Limit	100,000.00 per year					Limited Submission	No																																														
Applicant Types																																																																	
Funding Limit	100,000.00 per year																																																																
Limited Submission	No																																																																
036254	Keith Michael Andrus Cardiac Award	Friedreich's Ataxia Research Alliance		01-Feb-2025	300,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">484-879-6160</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">grants@curefa.org</td> </tr> <tr> <td>Sponsor Website</td> <td colspan="5">Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td colspan="5">Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="5">01-Feb-2025</td> </tr> <tr> <td>Synopsis</td> <td colspan="5">The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA. The applicant may request a budget of up to \$150,000 per year for one or two years.</td> </tr> <tr> <td>Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">150,000.00 per year</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Contact Name						Contact Telephone	484-879-6160					Contact Email	grants@curefa.org					Sponsor Website	Link to sponsor website					Program URL	Link to program URL					Deadline Dates (ALL)	01-Feb-2025					Synopsis	The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA. The applicant may request a budget of up to \$150,000 per year for one or two years.					Applicant Types						Funding Limit	150,000.00 per year					Limited Submission	No				
Contact Name																																																																	
Contact Telephone	484-879-6160																																																																
Contact Email	grants@curefa.org																																																																
Sponsor Website	Link to sponsor website																																																																
Program URL	Link to program URL																																																																
Deadline Dates (ALL)	01-Feb-2025																																																																
Synopsis	The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA. The applicant may request a budget of up to \$150,000 per year for one or two years.																																																																
Applicant Types																																																																	
Funding Limit	150,000.00 per year																																																																
Limited Submission	No																																																																
036255	Kyle Bryant Translational Research Award	Friedreich's Ataxia Research Alliance		01-Feb-2025	500,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">484-879-6160</td> </tr> <tr> <td>Contact Email</td> <td colspan="5">grants@curefa.org</td> </tr> </table>						Contact Name						Contact Telephone	484-879-6160					Contact Email	grants@curefa.org																																														
Contact Name																																																																	
Contact Telephone	484-879-6160																																																																
Contact Email	grants@curefa.org																																																																

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	The Kyle Bryant Translational Research Award is given to proposals focused on pre-clinical and clinical investigations that will advance treatments for Friedreich's Ataxia. The applicant may request a budget of up to \$250,000 per year for one or two years.			
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	No			
006873	Bronya J. Keats Research Collaboration Award	Friedreich's Ataxia Research Alliance		01-Feb-2025	400,000 USD
	Contact Name				
	Contact Telephone	484-879-6160			
	Contact Email	grants@curefa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	The Bronya J. Keats Research Collaboration Award supports proposals that focus on Friedreich's ataxia (FA) research that relies on collaboration among investigators from at least two different Institutions.			
	Applicant Types				
	Funding Limit	200,000.00 per year			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
128637	Postdoctoral Fellowship	Friedreich's Ataxia Research Alliance		15-Feb-2025 [LOI/Pre-App]	Not Specified																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>484-879-6160</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@curefa.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>15-Feb-2025 [LOI/Pre-App], 15-Apr-2025 , 15-Aug-2025 [LOI/Pre-App], 15-Oct-2025</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Friedreich's Ataxia Research Alliance (FARA) offers a Postdoctoral Fellowship to support young investigators in the FA biomedical research space. For this application type, the PI of the grant proposal may be either the trainee or the trainee's faculty advisor; however, both the trainee and advisor must be named in the application. The fellowship provides up to two years of support.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>					Contact Name		Contact Telephone	484-879-6160	Contact Email	grants@curefa.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Feb-2025 [LOI/Pre-App], 15-Apr-2025 , 15-Aug-2025 [LOI/Pre-App], 15-Oct-2025	Synopsis	The Friedreich's Ataxia Research Alliance (FARA) offers a Postdoctoral Fellowship to support young investigators in the FA biomedical research space. For this application type, the PI of the grant proposal may be either the trainee or the trainee's faculty advisor; however, both the trainee and advisor must be named in the application. The fellowship provides up to two years of support.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No
Contact Name																									
Contact Telephone	484-879-6160																								
Contact Email	grants@curefa.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Feb-2025 [LOI/Pre-App], 15-Apr-2025 , 15-Aug-2025 [LOI/Pre-App], 15-Oct-2025																								
Synopsis	The Friedreich's Ataxia Research Alliance (FARA) offers a Postdoctoral Fellowship to support young investigators in the FA biomedical research space. For this application type, the PI of the grant proposal may be either the trainee or the trainee's faculty advisor; however, both the trainee and advisor must be named in the application. The fellowship provides up to two years of support.																								
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
073959	Research Grants	Gerber Foundation		15-Feb-2025	Not Specified																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>231-924-3175</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>tgf@gerberfoundation.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name		Contact Telephone	231-924-3175	Contact Email	tgf@gerberfoundation.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone	231-924-3175																								
Contact Email	tgf@gerberfoundation.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	15-Feb-2025			
	Synopsis	The Gerber Foundation provides support for studies to improve the nutrition and/or health of infants and toddlers. The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
073728	Summer Student Pre-Med and Research Program	Hartford Hospital		20-Feb-2025	4,000 USD
	Contact Name	Angely D. Martinez, MBA, C-TAGME Program Director, Summer Student Pre-Med & Research Program			
	Contact Telephone	860-972-4096			
	Contact Email	Angely.Martinez@hhchealth.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Feb-2025			
	Synopsis	The Summer Student Pre-Med & Research Program at Hartford Hospital offers a unique clinical research opportunity for third year college students pursuing careers in medicine. The program offers the student with an introduction to research methodology, patient care, and medical ethics as well as exposure to a broad spectrum of healthcare providers within a large community teaching hospital.			
	Applicant Types				
	Funding Limit	4,000.00 see detail			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
003585	Hippocrates Prize for Poetry and Medicine	Hippocrates Society for Poetry and Medicine		14-Feb-2025	1,250 USD
	Contact Name Contact Telephone Contact Email hippocrates.poetry@gmail.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 14-Feb-2025 Synopsis The Hippocrates Prize for Poetry and Medicine is an annual international award for an unpublished poem on a medical subject. Poems must be no more than 50 lines in length and not have previously been published in any form. They must be by a living poet, written in English and should not be translations of another writer's work. There is no limit to the number of entries. Results will be announced via an online Prize Ceremony in May 2025. Winning poems will be published in an anthology of winning poems. Applicant Types Funding Limit 1,000.00 see detail Limited Submission No				
012624	International Travel and Subsistence Grants	Houghton Trust		15-Feb-2025	Not Specified
	Contact Name Dr. S. J. Baigent Contact Telephone Contact Email sue.baigent@outlook.com Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2025 , 15-Jun-2025 , 15-Oct-2025 Synopsis Grants of up to £1500 are awarded for the furtherance of study or research in avian diseases by attending/participating in relevant scientific conferences, visiting appropriate laboratories for discussions, and learning specific techniques, or attending training courses. Applicant Types Funding Limit 0.00 see detail Limited Submission Yes				
069446	Addressing Evidence-Based Health Benefits of Human-Animal Interaction	Human Animal Bond Research Institute		13-Feb-2025	49,000 USD
	Contact Name Matt Cryer Contact Telephone Contact Email MCryer@HABRI.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 13-Feb-2025 Synopsis The Human-Animal Bond Research Institute (HABRI) is calling for research proposals to investigate the health outcomes of pet ownership and/or animal-assisted activity or therapy, both for the people and the animals involved. Applicant Types Funding Limit 49,000.00 on average Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
027071	Maurice Weber Laboratorian Award	International Association for Food Protection		11-Feb-2025	2,500 USD
	Contact Name				
	Contact Telephone	515-276-3344			
	Contact Email	awards@foodprotection.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Feb-2025			
	Synopsis	The Maurice Weber Laboratorian Award is presented to an individual for outstanding contributions in the laboratory, recognizing a commitment to the development of innovative and practical analytical approaches in support of food safety. The recipient of the Maurice Weber Laboratorian Award will receive a personalized plaque and \$2,500 Honorarium at the IAFP Annual Meeting.			
	Applicant Types				
	Funding Limit	2,500.00 maximum			
	Limited Submission	No			
122501	Travel Award for Health or Agricultural Department Employees in North America	International Association for Food Protection		11-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone	+1 515-276-3344			
	Contact Email	travel@foodprotection.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 11-Feb-2025</p> <p>Synopsis The International Association for Food Protection (IAFP) will support the travel of up to five qualified health or agricultural department employees in North America to attend IAFP 2025, to be held July 27-30, 2025, in Cleveland, Ohio. This award is sponsored by the IAFP Foundation.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
026756	Research Grant	International Pain & Spine Intervention Society		01-Feb-2025 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 630-203-2252</p> <p>Contact Email grants@ipsismed.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2025 [LOI/Pre-App], 01-May-2025</p> <p>Synopsis The International Pain & Spine Intervention Society (IPIS) is proud to provide funding for high quality research to help generate definitive evidence and support the interventional pain medicine field. IPIS has supported research in the field since 1990, yet much more needs to be accomplished in order to sustain our specialty.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
019864	Richard J. Bing Award for Young Investigators	International Society for Heart Research (ISHR)		01-Feb-2025	Not Specified
	Contact Name	Dr. Leslie Anderson Lobaugh, ISHR Executive Secretary			
	Contact Telephone				
	Contact Email	llobaugh@ishrworld.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	The Richard J. Bing Award for Young Investigators is given at each World Congress of the International Society for Heart Research. The purpose of this Award is to recognize outstanding endeavors by new investigators in research activities, and to encourage continued biomedical research careers broadly related to cardiovascular biology.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
018976	ISSLS Clinical Travelling Fellowship	International Society for the Study of the Lumbar Spine		28-Feb-2025	5,000 USD
	Contact Name				
	Contact Telephone	+61 3 8692 2036			
	Contact Email	ISSLS@asnevents.net.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2025			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The ISSLS Clinical Travelling Fellowship is open to junior faculty members (in practice for fewer than 10 years) from any country or part of the world. It is judged by the ISSLS Fellowship Committee, who review each application and make a decision, which is based on merit and qualifications, with an emphasis on scholarly activities and clinical experience. The winner will be announced during the Fellowship Ceremony at the ISSLS Annual Meeting.</p> <p>5,000.00 maximum</p> <p>No</p>			
050852	IWMF-LLS Strategic Research Roadmap Initiative	International Waldenstrom's Macroglobulinemia Foundation		26-Feb-2025	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Robin Tucker</p> <p>rtucker@iwmf.com</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>26-Feb-2025</p> <p>The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and the Leukemia & Lymphoma Society (LLS) announce the eighth IWMF-LLS Strategic Research Roadmap Initiative – a Request for Proposals (RFP) to help further knowledge in five key domains of Waldenstrom’s macroglobulinemia (WM) research. Each project shall be two (2) years in length, at a cost of up to \$200,000 per year per project plus up to an additional 20% for indirect costs.</p> <p>200,000.00 per year</p> <p>No</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
001692	Grant Programs - Science and Engineering Research	Keck (W. M.) Foundation		15-Feb-2025	5,000,000 USD
	Contact Name				
	Contact Telephone	213-612-2000			
	Contact Email	research@wmkeck.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2025 , 01-May-2025 [LOI/Pre-App], 15-Aug-2025			
	Synopsis	The W. M. Keck Research Program seeks to benefit humanity by supporting Medical Research and Science & Engineering projects that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. Grants range from \$1 million to \$5 million and are typically \$2 million or less.			
	Applicant Types				
	Funding Limit	5,000,000.00 maximum			
	Limited Submission	No			
010942	Lasker-DeBakey Clinical Medical Research Award	Lasker Foundation		03-Feb-2025	Not Specified
	Contact Name	David Keegan			
	Contact Telephone	212-286-0222			
	Contact Email	dkeegan@laskerfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Lasker Awards program was created to shine a spotlight on fundamental biological discoveries and clinical advances that improve human health, and to draw attention to the importance of public support of science. Each Award consists of an honorarium, a citation and an inscribed statuette of the Winged Victory of Samothrace, symbolizing victory over death and disease.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
071136	Albert Lasker Basic Medical Research Award	Lasker Foundation		03-Feb-2025	Not Specified
	<p>Contact Name David Keegan</p> <p>Contact Telephone 212-286-0222</p> <p>Contact Email dkeegan@laskerfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Albert Lasker Basic Medical Research Award honors individuals who have made a fundamental discovery that opens up a new area of biomedical science.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
034069	Lasker-Koshland Special Achievement Award in Medical Science	Lasker Foundation		03-Feb-2025	Not Specified
	<p>Contact Name David Keegan</p> <p>Contact Telephone 212-286-0222</p> <p>Contact Email dkeegan@laskerfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis Since 1945, Lasker Awards have recognized the contributions of scientists, physicians, and public citizens who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of disease. The Lasker-Koshland Special Achievement Award in Medical Science is presented for research accomplishments and scientific statesmanship that engender the deepest feelings of awe and respect.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
055958	New Investigator Research Grant Program	Leukemia Research Foundation		14-Feb-2025 [LOI/Pre-App]	150,000 USD
	<p>Contact Name </p> <p>Contact Telephone 847-424-0600</p> <p>Contact Email grants@leukemiarf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 14-Feb-2025 [LOI/Pre-App], 25-Apr-2025 Synopsis The New Investigator Research Grant Program supports early-career investigators of exceptional creativity who propose highly innovative research projects with the potential to impact broad, essential areas of leukemia research. For the program to support the best and brightest minds, applications are sought from investigators who reflect the full diversity of the research workforce and represent diverse backgrounds, institutions, and geographic locations. Applicant Types Funding Limit 150,000.00 maximum Limited Submission No				
011987	College Student Summer Internship Program	Magee-Womens Research Institute (MWRI)		02-Feb-2025	Not Specified
	Contact Name Ashley Hnatow Contact Telephone 412-641-2440 Contact Email mwrcollegeprogram@mwri.magee.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 02-Feb-2025 Synopsis The College Summer Internship Program at Magee-Womens Research Institute provides students with the opportunity to participate in basic, translational, or clinical scientific research with the goal of interesting students in biomedical research as a potential career. Applicant Types Funding Limit 0.00 see detail Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091548	Summer Research Fellowship	Mayo Clinic College of Medicine and Science		15-Feb-2025	7,000 USD
	Contact Name	Luis Lujan, Ph.D.			
	Contact Telephone	507-293-9010			
	Contact Email	officeforeducationdiversity@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2025			
	Synopsis	The Summer Research Fellowship was created to address the need for clinical investigators from diverse backgrounds. The health needs of U.S. minority populations have been studied inadequately, due in part to the shortage of clinical investigators belonging to underrepresented groups. The Summer Research Fellowship award is \$7,000 for eight weeks, plus flights to and from Rochester, Minnesota.			
	Applicant Types				
	Funding Limit	7,000.00 maximum			
	Limited Submission	No			
013312	Surgery - Abdominal Transplant Surgery Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		12-Feb-2025	Not Specified
	Contact Name	Stephanie L. Putzier, Education Coordinator			
	Contact Telephone	507-266-8731			
	Contact Email	rsttransplantcenter@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	12-Feb-2025			
	Synopsis	The Abdominal Transplant Surgery Fellowship at Mayo Clinic's campus in Rochester, Minnesota, provides fellows with the best possible foundation for a career in transplantation surgery. The American Society of Transplant Surgeons (ASTS) has accredited Mayo Clinic for training in liver and kidney transplantation.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
013122	Neurosurgical Oncology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		01-Feb-2025	Not Specified
	Contact Name	Daks Marquart, Education Program Coordinator			
	Contact Telephone	507-538-5851			
	Contact Email	rstnseduc@mayo.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	The Department of Neurological Surgery at Mayo Clinic in Rochester, Minnesota one-year enfolded or external Neurosurgical Oncology Fellowship offers training in all aspects of neurosurgical care for adult patients with primary and secondary intra-axial brain tumors.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
121116	Resident/Fellow Research Grants	Melanoma Research Foundation		03-Feb-2025	10,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 800-673-1290</p> <p>Contact Email research@melanoma.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Melanoma Research Foundation offers a Resident/Fellow Research Grants program which provides \$10,000 over one year to promote research opportunities to resident/fellows early in their careers by funding clinical or laboratory-based research projects focused on better understanding the prevention, early detection, behaviors that impact melanoma risk, biology and treatment of melanoma, including cutaneous, ocular, mucosal, pediatric, etc.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
037398	Research Associateship Program (RAP)	National Academies		01-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email RAP@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2025 , 01-May-2025 , 01-Aug-2025 , 01-Nov-2025</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
071361	Revolutionary Aerospace Systems Concepts – Academic Linkage (RASC-AL) Competition	National Institute of Aerospace		24-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone	757-218-8313			
	Contact Email	rascal@nianet.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Feb-2025			
	Synopsis	RASC-AL competitions fuel innovation for aerospace systems concepts, analogs, and technology prototyping by bridging gaps through university engagement. RASC-AL is open to undergraduate and graduate university-level students studying fields with applications to human space exploration (i.e., aerospace, bio-medical, electrical, and mechanical engineering; and life, physical, and computer sciences). RASC-AL projects allow students to incorporate their coursework into real aerospace design concepts and work together in a team environment. Interdisciplinary teams are encouraged. Teams selected to present their work at the RASC-AL Forum will receive a \$6,500 stipend to facilitate full participation in the RASC-AL Forum. The top two overall winning teams at the 2025 RASC-AL Forum will be awarded with a travel stipend to present their concept at an aerospace conference, such as AIAA ASCEND.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission No				
001547	Young Investigator Research Grants	National Kidney Foundation		10-Feb-2025	35,000 USD
	Contact Name Contact Telephone 800-622-9010 Contact Email info@kidney.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 10-Feb-2025 Synopsis NKF established a Young Investigator Research Grant program to support clinical research studies addressing important issues for patients with kidney disease. Projects must be patient-oriented. Elements of patient-oriented research activities may include, but are not limited to, development of new technologies, mechanisms of human disease, educational or therapeutic interventions, epidemiological studies, health policy studies, and clinical trials. Individuals who have completed fellowship training in an ACGME-accredited training program and who hold junior faculty positions (Instructor or Assistant Professor) at university-affiliated medical centers in the United States are eligible to apply. (Francisco 'Frank' M. Gonzalez Memorial Research Fund projects will accept Basic Science applications). Applicant Types Funding Limit 35,000.00 maximum Limited Submission No				
114047	Edmund J.Y. Pajarillo Health Informatics and Innovation Collaborative Research Award	National League for Nursing		04-Feb-2025	2,500 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 800-669-1656</p> <p>Contact Email research@nlm.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2025</p> <p>Synopsis The Edmund J.Y. Pajarillo Health Informatics and Innovation Collaborative Research Award opens a new avenue of research money to support the National League for Nursing and its members. Multiple real-world applications of research evidence focused on health informatics and innovation are urgently needed. This is a \$2,500 award offered annually to support a PhD doctoral dissertation, DNP research or capstone, or a Master of Science in Nursing student focusing on health informatics and innovation in research in nursing education.</p> <p>Applicant Types</p> <p>Funding Limit 2,500.00 maximum</p> <p>Limited Submission No</p>				
071600	Research Grants	National Pancreas Foundation		15-Feb-2025	50,000 USD
	<p>Contact Name Carrie Anderson, National Program Manager</p> <p>Contact Telephone</p> <p>Contact Email carrie@pancreasfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2025</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis Applicant Types Funding Limit Limited Submission	The National Pancreas Foundation (NPF) provides support for the funding of research related to pancreatic diseases. Grants will be made for one year only (project will start September 1, 2025). The maximum award will be \$50,000, depending on the availability of funds. 50,000.00 maximum No				
070292	Research Associateship Programs -- Environmental Protection Agency Faculty Fellowship Program (EPA/FFP)	National Research Council		01-Feb-2025	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	202-334-2760 rap@nas.edu Link to sponsor website Link to program URL 01-Feb-2025 , 01-May-2025 , 01-Aug-2025 , 01-Nov-2025 The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the Environmental Protection Agency Faculty Fellowship Program (EPA/FFP). 0.00 see detail No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114353	NTSAD Research Initiative Program	National Tay-Sachs & Allied Diseases Association, Inc.		02-Dec-2024 [LOI/Pre-App]	25,000 USD
	Contact Name	Valerie Greger			
	Contact Telephone	617-277-4463			
	Contact Email	vgreger@ntsad.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Dec-2024 [LOI/Pre-App], 18-Feb-2025			
	Synopsis	The National Tay-Sachs & Allied Diseases Association (NTSAD) is requesting proposals to their Research Initiative Program for research focused on Canavan Disease. NTSAD is interested in all aspects of therapeutic discovery. Basic research and translational studies are strongly encouraged to generate strong preliminary data to enable major funding by other third parties in the future.			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
058854	National Energy Technology Laboratory Postgraduate Research Program (PGRP)	Oak Ridge Institute for Science and Education		15-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	NETLinfo@ornl.gov			
	Sponsor Website				
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Feb-2025</p> <p>Synopsis The NETL Postgraduate Research Program (PGRP) is a high-intensity program designed to identify recent Master’s and Doctoral graduates of high promise and to foster advanced skill development. It allows the postgraduate to systematically outline career goals and helps provide the means of achieving these goals. NETL principal investigators and leads serve as mentors to PGRP participants during the program. This interaction affords the postgraduate a unique opportunity to develop critical skills needed to become an independent professional. NETL typically hosts participants at its Pittsburgh, Pennsylvania; Morgantown, West Virginia; and Albany, Oregon locations.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
001901	Graduate Research Grant Program	Organization for Autism Research		03-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 571-977-5391</p> <p>Contact Email programs@researchautism.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Graduate Research Grant Competition offers grant awards of \$1,000 for students conducting autism research as a requirement in pursuit of a master’s degree and \$2,000 for students who are doctoral candidates or post-doctoral students. The Organization for Autism Research (OAR) funds studies that will likely produce practical and clearly objective results that may aid parents, families, professionals, and people with autism to make more fully informed choices that will lead to healthier and happier lives. Note that these grants are for independent research studies only.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No														
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
016273	OREF/MTF Biologics Research Grant	Orthopaedic Research & Education Foundation (OREF)		13-Feb-2025	100,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>847-698-9980</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@oref.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>13-Feb-2025</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>This Funding Opportunity Announcement solicits investigator-initiated research proposals focusing on research in the science of biologic – reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation. New investigators who have demonstrated a sustained interest in research and excellence in their training are encouraged to apply. The maximum funding will be a total of \$100,000 over a two-year grant period, conditional upon periodic progress reports and annual review.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>100,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	847-698-9980	Contact Email	grants@oref.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	13-Feb-2025	Synopsis	This Funding Opportunity Announcement solicits investigator-initiated research proposals focusing on research in the science of biologic – reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation. New investigators who have demonstrated a sustained interest in research and excellence in their training are encouraged to apply. The maximum funding will be a total of \$100,000 over a two-year grant period, conditional upon periodic progress reports and annual review.	Applicant Types		Funding Limit	100,000.00 maximum	Limited Submission	No
Contact Name																									
Contact Telephone	847-698-9980																								
Contact Email	grants@oref.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	13-Feb-2025																								
Synopsis	This Funding Opportunity Announcement solicits investigator-initiated research proposals focusing on research in the science of biologic – reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation. New investigators who have demonstrated a sustained interest in research and excellence in their training are encouraged to apply. The maximum funding will be a total of \$100,000 over a two-year grant period, conditional upon periodic progress reports and annual review.																								
Applicant Types																									
Funding Limit	100,000.00 maximum																								
Limited Submission	No																								
074693	Visiting Scholar Award	Parkinson's Foundation		03-Feb-2025	4,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td></td> </tr> </table>						Contact Name		Contact Telephone																	
Contact Name																									
Contact Telephone																									

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grants@parkinson.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Parkinson's Foundation Visiting Scholar Award provides a stipend to support the travel and housing of scholar while visiting a host laboratory to learn new techniques that will benefit their Parkinson's research.</p> <p>Applicant Types</p> <p>Funding Limit 4,000.00 see detail</p> <p>Limited Submission No</p>				
002181	Summer Student Fellowships	Parkinson's Foundation		03-Feb-2025	4,000 USD
	<p>Contact Name</p> <p>Contact Telephone 1-800-473-4636</p> <p>Contact Email grants@parkinson.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Summer Student Fellowships Program supports students, specifically advanced undergraduates and medical students, in their pursuit of Parkinson's-related summer research projects. The goal of the Parkinson's Foundation Summer Student Fellowships is to cultivate students' early interest in helping to solve, treat and end Parkinson's and providing the tools they need to transition into leaders in the field. Fellows work under the close supervision of a sponsor who is an expert in the Parkinson's community and oversees the project. The sponsor offers summer fellowships for 10 weeks of clinical or laboratory work with a \$4,000 award. They invite fellows to apply for up to \$1,000 in travel funds to attend a related scientific conference to present their research upon project completion.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The award supports the student's summer research, defraying tuition costs of research credits or supplementing living or housing costs.</p> <p>4,000.00 see detail</p> <p>No</p>			
087892	Impact Awards	Parkinson's Foundation		28-Feb-2025	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>grants@parkinson.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>28-Feb-2025</p> <p>The Parkinson's Foundation supports innovative projects from their inception, providing the necessary resources to maximize their impact on the Parkinson's community.</p> <p>150,000.00 maximum</p> <p>No</p>			
052906	Research Project Grants	Project Apis m.		01-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email grants@projectapism.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2025 , 01-Jun-2025 Synopsis PAm funds practical research supporting beekeeper priorities focused on actionable outcomes leading to practical tools and solutions supporting bee health and pollination security. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
022929	Research Medical Student Grant	Radiological Society of North America		07-Feb-2025	3,000 USD
	Contact Name Keshia Osley, Assistant Director, Grant Administration Contact Telephone 630-571-7816 Contact Email grants@rsna.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-Feb-2025 Synopsis The Medical Student Research Grant gives medical students the opportunity to gain research experience in medical imaging while they're still in school. Applicant Types Funding Limit 3,000.00 see detail Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

113719	Medical Student Research Grant	Radiological Society of North America		07-Feb-2025	6,000 USD
	Contact Name				
	Contact Telephone	630-590-7789			
	Contact Email	grants@rsna.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2025			
	Synopsis	Medical Student Research Grants provide medical students the opportunity to gain research experience in medical imaging while they're still in school. Recipients will define objectives, develop research skills and test hypotheses, all before even choosing a residency program. Ultimately, this experience gives students a chance to consider academic radiology as a future career option.			
	Applicant Types				
	Funding Limit	6,000.00 see detail			
	Limited Submission	No			

001884	Innovator Awards	Rainin (Kenneth) Foundation		03-Feb-2025	300,000 USD
	Contact Name				
	Contact Telephone	510-625-5200			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Kenneth Rainin Foundation offers Innovator Awards in the field of Inflammatory Bowel Disease (IBD) to support individual research projects with grants of up to \$150,000 and collaborative projects involving multiple investigators with grants of up to \$300,000. Grantees who demonstrate significant progress are eligible for up to two years of additional support.</p> <p>Applicant Types</p> <p>Funding Limit 300,000.00 see detail</p> <p>Limited Submission No</p>				
071713	Medical and Graduate Student Preceptorship	Rheumatology Research Foundation		01-Feb-2025	4,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email Foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2025</p> <p>Synopsis The Medical and Graduate Student Preceptorship program introduces medical and graduate students to rheumatology-related health care by supporting a 4-Week or 8-Week, full-time clinical or research experience in the broad area of rheumatic disease.</p> <p>Applicant Types</p> <p>Funding Limit 4,000.00 see detail</p> <p>Limited Submission No</p>				
128114	Resident Research Preceptorship	Rheumatology Research Foundation		01-Feb-2025	15,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email Foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2025</p> <p>Synopsis The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases. The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physicians to develop an investigative career in the field of rheumatology.</p> <p>Applicant Types</p> <p>Funding Limit 15,000.00 see detail</p> <p>Limited Submission No</p>				
104673	Health Professional Online Education Grant	Rheumatology Research Foundation		03-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email Foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2025</p> <p>Synopsis The Rheumatology Research Foundation offers a Health Professional Online Education Grant for non-physician rheumatology health professionals to complete the Advanced Rheumatology Course or the Fundamentals of</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	Rheumatology Course. The award amount is equal to the registration cost of the course awardee decides to take and will be paid directly to the awardee.			
	Funding Limit	0.00 see detail			
	Limited Submission	No			
127941	Faraday Discovery Fellowships	Royal Society		06-Feb-2025	10,000,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	faraday@royalsociety.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Feb-2025			
	Synopsis	The Faraday Discovery Fellowships are large, investigator-led grants awarded to a single Principal Investigator (PI) to enable them to establish an outstanding team of researchers to address challenging research questions. The programme is aimed at outstanding mid-career STEM researchers and will provide grants of up to £8m over a ten-year period to support the development of world-leading research groups in UK Universities and Research Institutes.			
	Applicant Types				
	Funding Limit	8,000,000.00 maximum			
	Limited Submission	No			
085972	Public Awareness Grant	Society for the Advancement of Behavior Analysis		05-Feb-2025	5,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 269-492-9310</p> <p>Contact Email saba@abainternational.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2025</p> <p>Synopsis The Society for the Advancement of Behavioral Analysis (SABA) will award grants of up to US\$5,000 to support projects designed to deliver messaging focused on behavior science and behavior analytic solutions to important problems.</p> <p>Applicant Types</p> <p>Funding Limit 5,000.00 maximum</p> <p>Limited Submission No</p>				
020728	Alan N. Epstein Research Award	Society for the Study of Ingestive Behavior		28-Feb-2025	750 USD
	<p>Contact Name</p> <p>Contact Telephone 847-807-4924</p> <p>Contact Email info@ssib.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p> <p>Synopsis This award honors an individual for a specific research discovery that has advanced the understanding of ingestive behavior.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	750.00 see detail			
	Limited Submission	No			
020497	Distinguished Career Award	Society for the Study of Ingestive Behavior		28-Feb-2025	1,500 USD
	Contact Name				
	Contact Telephone	847-807-4924			
	Contact Email	info@ssib.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2025			
	Synopsis	The award honors an individual for his or her accomplishments in and contributions to the understanding of ingestive behavior.			
	Applicant Types				
	Funding Limit	1,500.00 see detail			
	Limited Submission	No			
020729	New Investigator Travel Award	Society for the Study of Ingestive Behavior		28-Feb-2025	Not Specified
	Contact Name				
	Contact Telephone	847-807-4924			
	Contact Email	info@ssib.org			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2025			
	Synopsis	Travel awards are available for students and postdoctoral fellows (until five years after receiving doctoral degree). These awards are competitive, and are made based on scientific merit and abstract quality, as assessed by the NITA selection committee.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
020236	Student Research Fellowship	Society for Vascular Surgery		01-Feb-2025	3,000 USD
	Contact Name				
	Contact Telephone	800-258-7188			
	Contact Email	svsfoundation@vascularsociety.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2025			
	Synopsis	The SVS Foundation Student Research Fellowship stimulates laboratory and clinical vascular research by undergraduate college students and medical school students registered at universities in the United States and Canada. The intent of the fellowship award is to further the student's education and introduce the student to the application of rigorous scientific methods to clinical problems and underlying biologic processes important to patients with vascular disease. Each fellowship consists of a \$3,000 award and a two-year complimentary subscription to the Journal of Vascular Surgery.			
	Applicant Types				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	3,000.00 see detail			
	Limited Submission	No			
008108	Kathryn D. Sullivan Earth and Marine Science Fellowship	South Carolina Space Grant Consortium		27-Jan-2025	16,000 USD
	Contact Name	Tara B. Scozzaro			
	Contact Telephone	843-953-5463			
	Contact Email	scozzarot@cofc.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Jan-2025 , 03-Feb-2025			
	Synopsis	The Kathryn D. Sullivan Earth and Marine Science Fellowship is designed to increase the number of highly trained earth and marine scientists and enable graduate students to conduct NASA-related Earth/marine science research. Indirect charges (IDCs) are not allowed on any SC Space Grant student awards. A fellowship of \$16,000 will be awarded, with each of the sponsoring programs contributing. SC Space Grant Consortium will contribute \$8,000 and SC Sea Grant Consortium will contribute \$8,000. No institutional match is required.			
	Applicant Types				
	Funding Limit	16,000.00 maximum			
	Limited Submission	No			
066765	Pilot Research Program	Southwest National Primate Research Center		06-Dec-2024 [LOI/Pre-App]	100,000 USD
	Contact Name	Dr. Angélica Olmo-Fontánez			
	Contact Telephone				
	Contact Email	aolmo@txbiomed.org			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Dec-2024 [LOI/Pre-App], 14-Feb-2025</p> <p>Synopsis The Southwest National Primate Research Center (SNPRC) Pilot Research program provides opportunities and support for investigators to use SNPRC nonhuman primate resources in highly focused, short-term studies with a high likelihood of enhancing the value, utility, feasibility, and attractiveness of nonhuman primates for biomedical research. High priority will be given to studies that propose to generate preliminary data for applications to the National Institutes of Health (NIH) for support of future research projects. Those proposing to develop new nonhuman primate models of disease, or develop and/or test new research methods, instrumentation, or approaches for biomedical research using nonhuman primates, also will be considered responsive to the goals of the program. Investigators at the Staff Scientist (Research Assistant Professor) through Full Scientist (Full Professor) or equivalent positions at institutions meeting the requirements to apply for, receive, and administer grants in aid of research from the NIH are eligible to apply. Proposal budgets will be capped at \$100,000.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
001413	Research Grants	St. Baldrick's Foundation		09-Dec-2024 [LOI/Pre-App]	200,000 USD
	<p>Contact Name Laura Chung</p> <p>Contact Telephone 626-792-8247 x236</p> <p>Contact Email Laura@StBaldricks.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 09-Dec-2024 [LOI/Pre-App], 28-Feb-2025 Synopsis Grants are for specific two-year research projects which are hypothesis driven and may be either laboratory, clinical, or epidemiological in nature. Grants will be \$100,000/year or less. Applicant Types Funding Limit 100,000.00 per year Limited Submission Yes				
001382	St. Baldrick's Scholars (Career Development Award)	St. Baldrick's Foundation		09-Dec-2024 [LOI/Pre-App]	330,000 USD
	Contact Name Contact Telephone 626-792-8247 Contact Email Grants@StBaldricks.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 09-Dec-2024 [LOI/Pre-App], 28-Feb-2025 Synopsis The three year Scholar (Career Development) Award, with an option for two additional years based on progress, is meant to help develop the independent research of highly qualified individuals still early in their careers. Recipients are called St. Baldrick's Scholars. The award provides up to \$110,000 per year, for a three year minimum. Applicant Types Funding Limit 110,000.00 per year Limited Submission Yes				
061081	Cancer Prevention Research Training Program (CP RTP) Postdoctoral Fellowships in Cancer Prevention	University of Texas M.D. Anderson Cancer Center - Science Park		10-Feb-2025	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email Apply@CancerPreventionTraining.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2025</p> <p>Synopsis The Cancer Prevention Research Training Program (CP RTP) at MD Anderson prepares health scientists and clinicians to assume leadership roles as cancer prevention and control research investigators. The CP RTP is currently offering one postdoctoral fellowship — the Janice Davis Gordon Memorial Postdoctoral Fellowship in Colorectal Cancer Prevention, awarded to a research fellow specializing in the prevention of colorectal cancer.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
117827	Virchow Prize for Global Health	Virchow Foundation for Global Health		28-Feb-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +49 30 2063 0613</p> <p>Contact Email nominations@virchow.foundation</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2025</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The Virchow Prize recognizes and celebrates groundbreaking research, major innovations and outstanding contributions with significant impact on the broad health challenges we face as a global community. With this award, stellar achievements “towards health for all” and hence for the planet’s liveability are honoured.</p> <p>0.00 see detail</p> <p>No</p>			
001018	Research Grants	Whitehall Foundation, Inc.		15-Jan-2025 [LOI/Pre-App]	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Catherine Thomas</p> <p>561-655-4474</p> <p>email@whitehall.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Jan-2025 [LOI/Pre-App], 17-Feb-2025 , 15-Apr-2025 [LOI/Pre-App], 02-Jun-2025 , 01-Sep-2025 , 01-Oct-2025 [LOI/Pre-App]</p> <p>The Whitehall Foundation is focused exclusively on assisting basic research in vertebrate (excluding clinical) and invertebrate neurobiology. They offer research grants to established scientists of all ages working at accredited institutions in the United States. Research grants of up to three years are available. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis.</p> <p>100,000.00 per year</p> <p>No</p>			